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Abstract 
 
CD28-costimulatory signals interact with antigen-specific TCR signals to 
enhance T cell activation, proliferation and differentiation. The regulation of 
CD28-costimulation is controlled by CTLA-4 through its shared affinity for the 
CD28-ligands CD80 and CD86. CTLA-4-ig (abatacept) has emerged as an 
effective treatment for rheumatoid arthritis. The aims of this study were to 
consider the factors that influence CD28-costimulation requirements during in 
vitro T cell stimulation in order to identify strategies that may predict or 
improve clinical responses to abatacept-treatment.  
 
The efficacy of abatacept during in vitro T cell stimulation inversely correlated 
with parameters that increased the strength of TCR-stimulation. The 
simultaneous inhibition of TCR- and CD28-signals by Cyclosporine A and 
abatacept respectively promoted the inhibition of T cell activation above the 
level seen by either agent alone. The active form of vitamin D3, 1,25(OH)2D3, 
acted in a comparable manner to CsA to increase CD28-costimulation 
requirements by specifically inhibiting TCR-driven activation.  
 
These findings suggest that clinical responses to abatacept treatment may be 
determined by the strength of TCR stimulus that underlies T cell activation. 
Furthermore, that vitamin D3 may represent a useful adjunct to enhance 
clinical responses to abatacept.  
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Chapter 1: Introduction 
 
Following activation, CD4+ effector T cell (Teff) populations coordinate the 
activities of the adaptive immune system (denHaan et al., 2014) and interact 
with various components of the innate immune system (Strutt et al., 2011). As 
such, appropriate T cell activation represents a crucial step in maintaining 
protection during immune challenge.  Accordingly, the requirement to regulate 
T cell activation signals is critical since inappropriate T cell activation leads to 
further activation of the wider immune system and its potentially destructive 
capacity. This is clearly demonstrated by a central role played by activated T 
cells in various autoimmune diseases (Xing and Hogquist, 2012). Therefore, 
the regulation of T cell activation is a crucial factor in maintaining immune 
tolerance. In this thesis I explore how the adjustment of T cell activation 
conditions influences immune function. 
 
1.1. T cell subsets 
T cells originate from hematopoietic progenitor cells that initially develop 
within the bone marrow. These T cell precursors subsequently traffic to the 
thymus where their development to a mature T cell is completed (Bhandoola 
et al., 2003). This transition includes the acquisition of a functional T cell 
receptor (TCR) following TCR gene rearrangement and subsequent positive 
selection (Vrisekoop et al., 2014) and CD4-CD8 lineage differentiation (Wang 
and Bosselut, 2009). Additionally, the process of negative selection shapes 
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the TCR repertoire to limit the egress of “self” reactive T cells from the 
thymus. Negative selection is influenced by the expression of an array of 
tissue specific antigens by epithelial cells within the thymic medulla that are 
expressed under the control of the transcription factor autoimmune regulator 
(AIRE) (Anderson and Su, 2011). Autoreactive T cells that display high affinity 
for antigen either undergo clonal deletion through the induction of apoptosis or 
are subjected to clonal diversion which entails their differentiation into 
regulatory T cells (Treg) (Xing and Hogquist, 2012). It is those T cells that 
survive both positive and negative selection that constitute our peripheral T 
cell repertoire. 
 
Treg differentiation and function is dependent upon the forkhead box P3 
(FoxP3) transcription factor (Benoist and Mathis, 2012). Mice deficient in 
FoxP3 display a lethal autoimmune phenotype (Fontenot et al., 2003). In 
humans, mutations within the FOXP3 gene result in immune dysregulation 
polyendocrinopathy X-linked syndrome (IPEX) (Wildin et al., 2001; Bennett et 
al., 2001). IPEX is characterized by Treg dysfunction and autoimmunity, clearly 
demonstrating the importance of Treg in the regulation of the immune system 
(Ziegler, 2006). In the periphery, Treg utilize an array of effector molecules to 
maintain tolerance. For example, Treg express various molecules that 
suppress the activation and function of other lymphocytes such as Cytotoxic T 
Lymphocyte Antigen (CTLA)-4 (Wing et al., 2008) and Programmed Death 
(PD)-1 and its ligands PD-L1 and PD-L2 (Gotot et al., 2012; Park et al., 2015). 
Additionally, Treg produce various anti-inflammatory cytokines including 
Transforming growth factor (TGF)-β, Interleukin (IL)-10 and IL-35 (Benoist 
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and Mathis, 2012). It has been suggested that Treg mediate granzyme/perforin 
dependent cytotoxicity of activated T cells and antigen presenting cells (APC) 
subsets to regulate the magnitude of T cell responses and delivery of T cell 
activation signals (Grossman et al., 2004; Zhao et al., 2006; Salti et al., 2011). 
Finally, several lines of evidence suggest that Treg suppress T cell activation 
indirectly by modulating the phenotype and stimulatory capacity of APCs 
(Shevach, 2009). 
 
Mature T cells that enter the periphery can be classified in terms of their 
mutually exclusive expression of the TCR co-receptors CD4 and CD8 (Wang 
and Bosselut, 2009). CD8 specifically interacts with major histocompatibility 
(MHC)- class I molecules, which are expressed on the surface of all nucleated 
cells and present endogenous peptides that are derived from transcription. 
This is central to the function of CD8+ cytotoxic T cells in mediating immunity 
against intracellular pathogens (Zhang and Bevan, 2011). In contrast, CD4 
specifically interacts with MHC-II that is expressed by professional APCs and 
presents exogenous peptides that are processed following internalization by 
endocytosis. 
 
CD4+ T cells recirculate between the bloodstream and secondary lymphoid 
organs via the lymphatic system. Lymphoid tissue architecture provides a 
platform for T cells to interact and scan the surface of APCs for cognate 
antigen (Itano and Jenkins, 2003). Upon activation CD4+ fulfill a “helper” 
function by enhancing the activities of other components of the immune 
system. In 1989, Mosmann and Coffman outlined a model of CD4+ T cell 
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differentiation based upon differential cytokine expression. For example, 
specific production of IL-2 and Interferon (IFN)-γ by T helper (Th) 1 cells and of 
IL-4 and IL-5 by Th2 cells. This differential cytokine production was proposed 
to underlie differential helper functions with Th1 cells primarily mediating 
cellular immunity via effects upon macrophages and CD8+ T cells and Th2 
cells mediating humoral immunity in association with effects upon B cells and 
antibody class switching (Mosmann and Coffman, 1989). To some extent, this 
model has been supported by the identification that the transcription factors T-
bet (Szabo et al., 2000) and GATA-3 (Zheng and Flavell, 1997) act as master-
regulators of Th1 and Th2 lineage differentiation respectively and that there 
are specific conditions optimal for the polarization of T cells during stimulation 
to Th1 or Th2 outcomes (Constant and Bottomly, 1997).  
 
Several observations suggest that a model of mutually exclusive Th1 vs. Th2 
differentiation is overly simplistic. For instance, human T cells frequently 
display either shared characteristics of, or plasticity between, Th1 and Th2 
lineage differentiation (Messi et al., 2003; Krawczyk et al., 2007; Hegazy et 
al., 2010; Peine et al., 2013; Tumes et al., 2013). Significantly, several 
additional Th lineages have been defined which play important roles in T cell 
mediated immunity and regulation including induced Treg (iTreg), Th17, Th9 and 
T follicular helper (Tfh) cells. For example, naïve T cell stimulation in the 
presence of TGF-β promotes the generation of iTreg that are characterized by 
FoxP3 expression (Chen et al., 2003; Fantini et al., 2004). These employ 
comparable suppressive mechanisms to “natural” Treg (nTreg) that are 
generated in the thymus. However, the activities of both Treg populations are 
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required to effectively maintain tolerance at least in part because nTreg and 
iTreg display a non-overlapping TCR repertoire (Haribhai et al., 2011). Thus 
iTreg, are induced by exposure to antigen in a non-inflammatory environment 
where TGF-β predominates and this serves as a mechanism of peripheral 
tolerance that reinforces centrally induced tolerance.  
 
TGFβ signaling in the presence of other immunomodulatory cytokines also 
determines T cell differentiation towards the Th9 or Th17 lineage. Th9 cells are 
generated in the presence of TGF-β and IL-4 (Veldhoen et al., 2008; 
Dardalhon et al., 2008) and express high IL-9 levels under the control of the 
control of the transcription factor PU.1 (Gerlach et al., 2014). These cells 
interact with other Th lineages to mediate inflammatory processes and 
autoimmunity in a variety of animal models (Kaplan et al., 2015). The 
development of the Th17 cell subset, characterized by the production of IL-17, 
is promoted by TGF-β, however, this occurs on a background of 
proinflammatory cytokines such IL-6, IL-21 and IL-23 (Aggarwal et al., 2003; 
Bettelli et al., 2006; Korn et al., 2007; Zhou et al., 2007). These 
proinflammatory cytokines positively enforce Th17 differentiation and 
negatively regulate iTreg expression by upregulating the transcription factor 
retinoic-acid receptor related orphan nuclear receptor (ROR)γt that acts as a 
master regulator of Th17 differentiation and function and simultaneously 
inhibiting FoxP3 expression (Korn et al., 2008). Th17 cells have been found to 
play a prominent role in chronic inflammation and autoimmune diseases. This 
is associated with the induction of a highly proinflammatory cytokine response 
following IL-17 signaling primarily among stromal and myeloid cells (Weaver 
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et al., 2007). Additionally Th17 cells produce several additional 
proinflammatory cytokines including the related cytokine IL-17F, IL-6, TNFα, 
IL-21 and IL-22 that act to reinforce Th17 differentiation and propagate 
inflammation (Damsker et al., 2010).  
 
Tfh differentiation is controlled by the transcription factor Bcl6 (Johnston et al., 
2009). Following activation, these cells migrate to B cell follicles in association 
with their characteristic expression of the chemokine receptor CXCR5 
(Breitfeld et al., 2000). Here, Tfh cells utilize various surface and effector 
molecules including CD40L, Inducible T cell Costimulator (ICOS), IL-4 and IL-
21 to promote B cell responses by initiating germinal center formation and 
directly interacting with B cells to facilitate affinity maturation (Crotty, 2014).  
 
1.2. A two-signal model for T cell activation 
Control over the initiation of CD4+ T cell responses is associated with a 
requirement for multiple signals that contribute towards T cell activation 
thresholds. This, in effect, generates a checkpoint that must be passed before 
T cell activation can ensue. In 1970, Bretscher and Cohn proposed a “two-
signal” model for antibody responses based upon differential responses 
towards antigen in the periphery (Bretscher and Cohn, 1970). This hypothesis 
was expanded upon by investigations into allograft responses by Lafferty and 
Woolnough who suggested that it was T cell activation that occurred as the 
result of an “inductive stimulus” in addition to antigen-stimulation (signal 1) 
(Lafferty and Woolnough, 1977). It was suggested that the absence of this 
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inductive stimulus promoted a state of “proliferative non-responsiveness to 
subsequent stimulation” (Quill and Schwartz, 1987). Several receptors have 
now been identified to display this costimulatory or accessory function by 
supporting antigen-stimulation via the T cell receptor (TCR) (Chen and Flies, 
2013). Probably the predominant source of initial costimulation is via CD28, a 
T cell surface protein that is constitutively expressed by resting CD4+ T cells 
which interacts with ligands (CD80 and CD86) expressed by APCs (Sansom, 
2000). Together, TCR- and CD28-driven signals determine the extent and 
efficiency of T cell activation and provide an opportunity for regulation of this 
process. 
 
1.3. Signal one: TCR signaling 
CD4+ TCR-signals are driven following the ligation of the TCR by cognate 
antigen presented in the context of major histocompatibility complex (MHC) II 
(pMHC). This recognition of pMHC complexes by the TCR is mediated by an 
extracellular polypeptide heterodimer comprising an association between a 
single TCRα and TCRβ chain (Wange and Samelson, 1996). Additionally, a 
small proportion of T cells express a TCR that comprises an association 
between a TCRγ chain and a TCRδ chain (Vantourout and Hayday, 2013). 
These γδ T cells do not require antigen processing and presentation by MHC 
for activation, however, in some cases they interact with non-classical MHC 
gamma delta (Luoma et al., 2014). Their function is not entirely understood 
but appears to contribute towards immunity at epithelial surfaces (Vantourout 
and Hayday, 2013). αβ TCRs are restricted to antigen binding in the context 
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of MHC possibly due to the coevolution of complementary structural motifs 
that mediate TCR-MHC interactions and which facilitate interactions between 
hypervariable regions of the TCR with antigen (Garcia et al., 2009). These 
hypervariable regions are generated by TCR gene rearrangement during T 
cell development and are expressed within complementarity determining 
regions (CDR) within the membrane distal variable domains of the TCRα and 
TCRβ chains. CDR3α and CDR3β play a particularly prominent role due to 
their placement over the MHC binding groove during TCR-MHC interactions 
(Wucherpfennig et al., 2010). The hypervariability within these CDRs is 
central to the function of T cells in recognizing and responding to a diverse 
group of epitopes. 
 
1.3.1. Balancing the sensitivity and specificity of T cell responses 
Even where the agonist peptide displays optimal affinity, interactions between 
the TCR and pMHC display an inherently low affinity and are short-lived 
(Valitutti et al., 1995). Nevertheless, TCR interactions with cognate peptide 
are extremely sensitive. For example, CD4+ T cells are activated when just 
0.03% surface MHC-II present cognate antigen (Demotz et al., 1990). 
Furthermore, CD4+ T cells display transient calcium flux in response to a 
single cognate pMHC-II complex (Irvine et al., 2002). However, this level 
sensitivity could be predicted to be detrimental to the requirement of T cells to 
display a functional specificity for specific pMHC interactions that ultimately 
determines the specificity of T cell activation. The requirement for T cell 
responses that are both sensitive and specific is partly achieved through the 
activities of positive and negative thymic selection which produces a diverse 
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and functional TCR repertoire that displays high affinity interactions with “non-
self” antigen and an inherently low affinity for “self” (Morris and Allen, 2012). 
Additionally, the serial triggering model for TCR activation predicts that the 
rapid off-rate of pMHC:TCR interactions balances this requirement for 
sensitive and specific T cell responses to antigen by rendering a requirement 
for serial triggering of TCRs (Valitutti and Lanzavecchia, 1997). As such, this 
model predicts that few cognate pMHC complexes can activate many TCRs in 
order to promote the sensitivity of TCR binding, similarly, that small reductions 
TCR affinities for pMHC potently inhibit this serial TCR triggering. 
Nonetheless, the problem of TCR triggering is still poorly understood and a 
number of models have been proposed (Davis and van der Merwe, 2006). 
 
1.3.2. TCR signaling pathways 
TCR triggering initiates a complex signaling cascade that is illustrated in fig. 
1.1. In simplistic terms, productive TCR signaling can be suggested to occur 
due the combined activation of Nuclear Factor of Activated T cells (NFAT), 
Activator Protein (AP)-1 and Nuclear Factor (NF) κB transcription factors and 
their subsequent regulation of genes such as IL-2 that mediate T cell 
activation, proliferation and differentiation (Crabtree and Clipstone, 1994).  
 
Signals are transmitted from the T cell surface upon antigen recognition by 
the TCRαβ heterodimer due to its association within the TCR/CD3 complex 
consisting of the CD3εδ, CD3εγ heterodimers and TCRζ homodimer (Wange 
and Samelson, 1996). This complex lacks intrinsic kinase activity, however, 
each CD3 chain comprises an immunoreceptor tyrosine-based activation 
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motif (ITAM), furthermore, each TCRζ chain comprises three ITAMs (Wange 
and Samelson, 1996). The Src family kinase member Lck, which physically 
associates with the TCR co-receptor and is brought into close proximity to the 
TCR/CD3 complex by antigen binding (Veillette et al., 1988), phosphorylates 
tyrosine residues within these ITAMs. Additionally, the Src kinase family 
member Fyn plays a role in the initiation of TCR signaling via its association 
with CD3 chains (Timson Gauen et al., 1992) but appears to have a more 
prominent role in thymocytes than peripheral T cells (Stein et al., 1992).  
 
Phosphorylation of ITAMs within the CD3 complex results in the recruitment of 
zeta chain associated protein kinase (ZAP)-70 to the signaling complex via its 
Src Homology 2 (SH2) domains and its subsequent activation by both 
autophosphorylation and the activity of Lck (Iwashima et al., 1994). Upon 
activation, ZAP-70 phosphorylates multiple tyrosine residues on the adaptor 
protein linker for the activation of T cells (LAT) and SH2 domain containing 
leukocyte protein (SLP)-76 (Wang et al., 2010a).  
 
LAT is localized at the cell membrane and its phosphorylation facilitates the 
recruitment of and interaction with SLP-76. These two scaffold proteins act as 
a platform for an elaborate signaling complex that mediates downstream TCR 
signals by recruiting various SH2 domain-containing proteins (Koretzky et al., 
2006). For example, LAT promotes the activation of the Ras-ERK mitogen-
activated protein (MAP)-kinase pathway. This occurs as the adaptor protein 
growth-factor-receptor-bound protein 2 (Grb2) binds to phosphorylated LAT; 
this subsequently recruits Son of Sevenless (SOS), which acts as a guanine-
11 
 
nuclear-exchange factor (GEF) for the small GTPase Ras (Balagopalan et al., 
2010). Additionally, phosphorylated SLP-76 recruits the adaptor protein Nck 
and the GEF Vav-1 that promotes subsequent Wiskott-Aldrich syndrome 
protein (WASp) recruitment and activation (Zeng et al., 2003). Activated 
WASp regulates T cell activation by effects upon the actin cytoskeleton which 
stabilize T cell-APC interactions (Sims et al., 2007). This regulation of the 
actin cytoskeleton during stimulation has emerged as a crucial aspect of T cell 
activation in that actin remodeling is necessary for the transduction of 
proximal TCR signaling events (e.g. Lck/ZAP-70 activation) to downstream 
TCR signaling (e.g. calcium flux and ERK phosphorylation) (Tan et al., 2014). 
 
Another important step in the TCR signaling cascade is the recruitment and 
activation of phospholipase Cγ1 (PLCγ1) to the LAT-SLP-76 complex 
promotes the generation of the second messengers inositol 1,4,5-
trisphosphate (IP3) and diacyglycerol (DAG) from phosphatidylinositol 4,5-
bisphosphate (PIP2). By recruiting RAS guanyl nucleotide releasing protein 
(RasGRP) to the plasma membrane, DAG promotes the activation of the MAP 
kinase pathway (Huse, 2009), which in turn promotes the transcription of the 
AP-1 subunit c-Fos (Huang and Wange, 2004). DAG also positively regulates 
NFκB and AP-1 mediated transcription through the activation of protein kinase 
C-θ (PKCθ) (Arendt et al., 2002). Whilst DAG predominantly regulates the AP-
1 transcription factor, IP3 promotes NFAT nuclear translocation. This is 
mediated via an elevation in intracellular Ca2+ initially from intracellular stores 
and secondarily via a Ca2+ dependent activation of calcium release activated 
channels (CRAC) that mediate an extracellular Ca2+ flux (Hogan et al., 2003). 
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Elevated intracellular Ca2+ subsequently activates the calcium-binding 
messenger protein Calmodulin that activates the phosphatase calcineurin. In 
turn, calcineurin dephosphorylates NFAT that facilitates its nuclear 
translocation (Macián, 2005). NFAT and AP-1 are known to cooperate and 
synergistically enhance cytokines such as IL-2 and IL-4 that regulate T cell 
activation, differentiation and effector function (Macián et al., 2001). 
 
1.3.3. The impact of TCR stimulus strength on the T cell response 
Signaling pathways can be activated in a ‘digital’ or ‘analog’ manner. In this 
context, digital activation represents ‘all-or-nothing’ signaling events and is 
therefore ‘switch-like’ upon reaching a specific activation threshold. In 
contrast, analog signals are graded where the magnitude of the output is 
determined by the strength of the input (i.e. strength of TCR stimulation). 
Several TCR signaling modules display a digital activation pattern which 
facilitates the requirement for T cells to respond with specificity towards 
particular antigen (Germain, 2010). Accordingly, highly sensitive T cell 
responses have been observed in which T cells respond to a single specific 
pMHC complex with Tumour Necrosis Factor (TNF)-α and IL-2 production. 
Under these conditions, increasing pMHC numbers augmented the proportion 
of responding T cells but not the magnitude of cytokine production by 
activated T cells on a per cell basis (Huang et al., 2013). These observations 
are implying a digital response to TCR stimulation. In association with this, 
TCR-induced NFκB activation (Kingeter et al., 2010), NFAT translocation 
(Podtschaske et al., 2007) and ERK signaling (Altan-Bonnet and Germain, 
2005) display a digital activation pattern in response to graded TCR stimuli.  
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Fig. 1.1. TCR ligation initiates a complex signaling cascade. CD4+ T cells interact 
with pMHC complexes presented upon the surface of professional APCs. TCR ligation 
brings Lck via its association with CD4 into close proximity to ITAMs within the CD3 
complex. Lck phosphorylates ITAMs which facilitates ZAP-70 association with the 
TCR/CD3 complex. ZAP-70 phosphorylates LAT and SLP-76 on multiple residues 
which subsequently act as scaffold proteins  that facilitate downstream TCR signaling. 
These signals result in the activation of the transcription factors  AP-1, NFκB and NFAT 
which regulate genes that guide T cell activation, proliferation and differentiation.  
14 
 
Digital activation of TCR pathways suggests that activation occurs when a 
certain signaling threshold is achieved such that activation only occurs in 
response to robust TCR stimulation. Nevertheless, productive CD8+ T cell 
responses can occur following stimulation by very low affinity antigen although 
these responses are characterized by qualitative differences T cell phenotype 
and response kinetics such as an abbreviated proliferative response (Zehn et 
al., 2009). Similarly, CD4+ T cells respond effectively to altered peptide 
ligands that mediate low affinity TCR interactions, however, altered antigen-
affinity also has a qualitative impact upon the T cell response, in particular, 
high affinity ligands promote Th1 type responses whilst low affinity ligands 
promote Th2 responses (Pfeiffer et al., 1995; Nicholson et al., 1995; Tao et al., 
1997b; Keck et al., 2014). Additionally, it has been suggested that TCR-signal 
strength determines the outcome of T cell proliferation with regards to T cell 
“fitness” e.g. T cells activated in response to high strength stimulation display 
enhanced survival, whilst T cells that receive weak stimulation undergo 
apoptosis and fail to proliferate in response to IL-2 and IL-7 when the 
activation stimulus is withdrawn (Gett et al., 2003).  
 
On the surface, these observations are difficult to reconcile with an all-or-
nothing digital TCR signaling response. One possibility is that these 
qualitative differences in T cell responses occurring in conjunction with 
different TCR signal strengths reflect different contributions of costimulatory 
signals towards activation. Additionally, it has been suggested that altered 
peptide ligands that display reduced TCR affinities alter TCR/CD3 
phosphorylation with an associated inhibition of ZAP-70 activation (Sloan-
15 
 
Lancaster et al., 1994; Madrenas et al., 1995). It has been suggested that 
incomplete ZAP-70 activation subsequently prevents SOS recruitment to 
phosphorylated LAT, preventing digital activation of the Ras-ERK pathway 
which becomes dependent upon less effective analog activation by RasGRP 
(Das et al., 2009). These upstream perturbations in the TCR signaling 
cascade lead to differences in transcription factor translocation to the nucleus. 
For example, differential AP-1 subunit composition including a prevalence of 
Jun-Jun homodimers, rather than Fos-Jun heterodimers that favor Th2 
differentiation, have been observed in response to reduced ERK activation by 
low affinity TCR-engagement (Jorritsma et al., 2003). Therefore, various 
components within the TCR signaling network display different activation 
thresholds such that decreased TCR stimulus strength leads to activation of 
elements, but not the entirety of the TCR-signaling cascade. Whilst this may 
be sufficient to mediate activation, it promotes qualitative differences in 
responding T cells.   
 
1.4. Signal two: CD28-costimulation  
As the predominant source of T cell costimulation, CD28-signaling promotes 
the generation of effector T cell populations through effects upon proliferation, 
survival and differentiation (Boomer and Green, 2010). CD28 is a 44kDa 
glycoprotein and comprises a membrane distal extracellular immunoglobulin 
variable-like domain (IgV) (Carreno and Collins, 2002). Interactions between 
CD28 and the structurally related B7 family members CD80 and CD86 are 
mediated via an MYPPPY motif within the FG loop of the IgV domain of CD28 
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(Evans et al., 2005). CD28 exists as a homodimer at the cell surface through 
a disulphide linkage between complimentary cysteine residues within the 
linker region that connects CD28 IgV and transmembrane domains (Schwartz 
et al., 2002) and the formation of a complimentary interface between 
corresponding IgV domains (Evans et al., 2005). Despite this dimerization, 
CD28 participates in monovalent interactions with CD80 and CD86 (Collins et 
al., 2002). These monovalent interactions are crucial to the regulation of 
CD28-signals because CD28 mutants that are capable of bivalent interactions 
are constitutively activated due to receptor clustering which promotes antigen-
independent T cell activation (Dennehy et al., 2006).  
 
Whilst CD28 is constitutively expressed by resting T cells its ligands CD80 
and CD86 are only upregulated by APCs in response to inflammation 
(Banchereau and Steinman, 1998) providing a mechanism to maintain control 
over T cell activation. The inductive nature of these ligands by APCs in 
response to either pathogen-associated molecular patterns or danger signals 
derived from damaged cells is central to the infectious-nonself and danger 
models of immune activation respectively (Matzinger, 2002).  
 
Upon interaction with CD80 and CD86, CD28 signaling has been strongly 
associated with the activity of phosphatidylinositol 3-kinase (PI3K) following its 
interaction with a YMNM motif with the CD28-cytoplasmic tail (Pagès et al., 
1994; Prasad et al., 1994; Cai et al., 1995). The generation of 
phosphatidylinositol (3,4)-bisphosphate (PIP2) and phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) by PI3-kinase promotes the recruitment of the 
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Plekstrin homology domain containing proteins Akt and phosphoinositide-
dependent kinase 1 (PDK1) to the plasma membrane (Boomer and Green, 
2010).  PDK1-deficient T cells fail to produce IL-2 following stimulation 
because PDK1 mediates functional NFκB activation. This occurs as PDK1 
participates in complex formation with PKCθ and CARMA1 which leads to 
sequential PKCθ and CARMA1 activation and ultimately to NFκB activation 
(Park et al., 2009). PDK1 also activates Akt by phosphorylation (Hemmings 
and Restuccia, 2012). Constitutive expression in T cells of active Akt negates 
the requirement for CD28-costimulation for functional T cell responses 
demonstrating a central role in the mediation of CD28-signals (Rathmell et al., 
2003). Upon activation, Akt promotes the activity of the serine/threonine 
kinase mammalian target of rapamycin (mTOR) (Hemmings and Restuccia, 
2012). By controlling various cellular and metabolic programs, mTOR directs 
the outcome of T cell stimulation by integrating cues received from activation 
signals and the microenvironment (Zeng and Chi, 2014). 
 
CD28-signals are additionally mediated via a PYAP motif. This facilitates 
signaling by several mediators involved in TCR-signal transduction, for 
example, Vav-1 and Lck (Boomer and Green, 2010). Indeed, genomic 
changes following CD28-costimulation are mediated by the transcription 
factors NFAT, AP-1 and NFκB in a similar fashion to TCR-driven signals 
(Boomer and Green, 2010). As such, transcriptional profiles induced by TCR- 
and CD28-activation show striking similarity with the main distinction being 
quantitative differences in the extent of gene upregulation rather than the 
number of genes induced (Riley et al., 2002). Indeed, it has been suggested 
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that CD28-costimulation primarily serves to compensate for a relatively weak 
TCR stimulus and vice versa through cooperation towards a combined 
activation threshold (Acuto and Michel, 2003). This is supported by the 
apparent amplification by CD28-costimulation of TCR induced Vav-1 (Michel 
et al., 2000), Lck (Holdorf et al., 2002), PKCθ (Coudronniere et al., 2000), 
Ca2+ and PLCγ1 (Michel et al., 2001) signals. This signal integration occurs to 
the extent that CD28-costimulation reduces the number of TCRs that are 
required to achieve activation thresholds (Viola and Lanzavecchia, 1996). 
 
1.5. Functions of CD28-costimulation 
Despite the significant overlap between TCR and CD28 signaling pathways, 
CD28 has a clear impact upon T cell activation and differentiation due to the 
amplification of TCR driven signals (Acuto and Michel, 2003). This is most 
clearly demonstrated by CD28-KO mice which display compromised T cell 
responses (Shahinian et al., 1993; Green et al., 1994). As a result of these 
positive impacts, CD28-costimulation has been widely viewed as an essential 
requirement for T cell activation and a control point that can be targeted 
therapeutically (Linsley and Nadler, 2009).    
 
1.5.1. Upregulation of IL-2 signaling 
Strongly linked with each of the outcomes of CD28-costimulation is the ability 
to enhance T cell expression of and signaling by the T cell growth factor IL-2.  
For example, CD28-costimulation promotes IL-2 gene expression (Fraser et 
al., 1991) and promotes the stability of IL-2 mRNAs (Lindstein et al., 1989); 
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together, these factors combine towards elevated IL-2 production following 
CD28-signals. IL-2 subsequently functions in an autocrine manner to 
influence T cell proliferation and differentiation (Boyman and Sprent, 2012). 
Additionally, CD28-KO mice display reduced expression of the IL-2-receptor 
(IL-2R) α-chain (CD25) following stimulation (Shahinian et al., 1993). This can 
be partially attributed to the deficiency of IL-2 resulting from the absence of 
CD28-costimulation since IL-2 positively regulates CD25 expression via a 
feed-forward loop (John et al., 1996). However, CD28 also appears to act by 
an IL-2 independent mechanism to induce CD25 expression (Toyooka et al., 
1996). Following expression, CD25 participates in the multimeric high-affinity 
IL-2R by associating with the IL-2Rβ subunit (CD122) and the common 
cytokine receptor-γ chain (CD132) (Boyman and Sprent, 2012). The dimeric 
IL-2Rβγ displays a low affinity for IL-2 (dissociation constant (Kd) = 10
-9 M). 
Although this is sufficient for some responsiveness to IL-2 binding, CD25 
expression significantly enhances the IL-2-R affinity for IL-2 (Kd = 10
-11 M) 
(Taniguchi and Minami, 1993). Thus by enhancing CD25 expression, CD28 
also enhances responsiveness to IL-2.  
 
1.5.2. T cell proliferation 
CD28-KO mice display significantly decreased activated T cell counts 
following TCR-stimulation (Shahinian et al., 1993; Green et al., 1994). The 
large alterations in cell counts arising from the presence of CD28-
costimulation can be the result of relatively subtle kinetic alterations in 
parameters affecting T cell proliferation (Gett and Hodgkin, 2000). However, 
the specific nature of the impact of CD28 upon the cell cycle has been 
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controversial and appears to vary depending upon the stimulation system that 
is used. For example, Gett and Hodgkin used a monoclonal antibody (mAb) 
driven stimulation system to demonstrate reduced time to division following 
stimulation in the presence of CD28-signals but no significant effect upon 
subsequent division time (Gett and Hodgkin, 2000). In contrast, Bonnevier 
and Mueller used an in vitro antigen-driven system to show that CD28-
costimulation controls T cell blastogenesis (occurring as T cells undergo the 
G0-G1 phase transition) as well as the subsequent division rate of T cell blasts 
(Bonnevier and Mueller, 2002). Consistent with these data, several studies 
have demonstrated a significant impact of CD28-costimulation upon cell cycle 
progression particularly at the G1-S phase transition (Boonen et al., 1999; 
Appleman et al., 2000; 2002; Song et al., 2007). This regulation of late G1 
events by CD28 is mediated by both IL-2 dependent and IL-2 independent 
signals (Appleman et al., 2000). 
 
1.5.3. T cell survival 
CD28-signaling also enhances the magnitude of T cell responses by 
enhancing the survival of proliferating T cells, for example, by promoting 
increased expression of the anti-apoptotic factor Bcl-xL (Noel et al., 1996). 
Also, CD28-dependent downregulation of TCR induced CD95-L expression 
(Collette et al., 1997) delays or inhibits Activation Induced Cell Death, a 
mechanism whereby TCR induced activation can ultimately lead to resolution 
of a T cell response through the induction of apoptosis within the effector 
population (Kerstan and Hünig, 2004). Again, CD28-mediated IL-2 signaling 
also serves to enhance the survival of activated T cells by maintaining 
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appropriate cell cycle progression (Boise and Thompson, 1996). 
 
1.5.4. Regulation of T cell metabolism 
Upon stimulation, T cells undergo an active metabolic shift from oxidative 
phosphorylation towards glycolysis in order to meet the elevated energy 
demands required by increasing cell growth, macromolecule biosynthesis and 
proliferation (Jones and Thompson, 2007). CD28-costimulation facilitates this 
switch through a PI3K-Akt dependent enhancement of glucose uptake and 
glycolytic rate that meets the energy demands required for effective T cell 
responses (Frauwirth et al., 2002; Jacobs et al., 2008). Of central importance 
to the coordination of T cell metabolic pathways by CD28 is its regulation of 
mTOR (Zheng et al., 2009). It has been suggested that the association 
between T cell anergy and the absence of costimulation is associated with 
this regulation of mTOR by CD28. For example, mTOR inhibition by 
rapamycin induces T cell anergy even in the presence of CD28-signaling 
(Powell et al., 1999). Thus, CD28 may act via mTOR to control T cell 
immunity or tolerance.  
 
1.5.5. T cell differentiation 
It is becoming increasingly clear that outcomes following T cell stimulation 
including T cell differentiation are determined by the nature of activation 
signals (van Panhuys et al., 2014; Keck et al., 2014). In keeping with this 
concept, CD28-costimulation has been proposed to favor Th2 differentiation 
whereas TCR-signals promote Th1 differentiation (Lenschow et al., 1996; Tao 
et al., 1997a). Additionally, CD28 costimulation promotes the generation and 
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maintenance of Tfh cells (Platt et al., 2010; Linterman et al., 2014; Wang et al., 
2015a). Similarly, the generation of nTreg in the thymus (Tai et al., 2005) and 
iTreg in the periphery (Guo et al., 2008) are CD28-dependent processes. 
Therefore, it is apparent that the availability of CD28-costimulation adjusts the 
nature and control of T cell responses through various effects upon T cell 
differentiation.  
 
1.5.6. Treg homeostasis 
In addition to enhancing the generation of Treg subsets, CD28 controls their 
maintenance and homeostasis within the periphery. For example, the 
development of autoimmune diabetes is promoted in CD80/CD86- or CD28-
deficient non-obese diabetic mice (NOD) relative to wild-type (WT) controls 
and this is associated with the absence of CD4+CD25+ Treg populations 
(Salomon et al., 2000). This loss of Treg in the absence of CD28 was found to 
occur due to effects upon both the generation of Treg in the thymus as well as 
their homeostasis in the periphery.  Specifically, CD28-signals were found to 
be required for IL-2 production by conventional T cells that supported Treg 
survival as well as maintaining Treg CD25 expression and therefore IL-2 
responsiveness (Tang et al., 2003). The requirement for a post-thymic cell –
intrinsic CD28-signal for the maintenance of Treg populations has been verified 
using inducible-CD28 deletion systems (Gogishvili et al., 2013; Zhang et al., 
2013). Bone marrow chimera experiments also demonstrated that IL-2 
derived from CD28-WT T cells could not rescue the survival of CD28-KO Treg 
thereby demonstrating an indispensible requirement for this CD28 signaling in 
Treg homeostasis (Gogishvili et al., 2013). Nevertheless, IL-2 also appears to 
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play an important role in Treg function and survival in the periphery because 
IL-2 deficiency in mice promotes a lethal autoimmune syndrome (Sadlack et 
al., 1995; Suzuki et al., 1995). Similarly, in humans, CD25 deficiency causes 
an IPEX-like syndrome that is characterized by immune dysregulation (Caudy 
et al., 2007). This occurs in conjunction with defects in Treg survival within the 
periphery but not induction within the thymus (D'Cruz and Klein, 2005; 
Fontenot et al., 2005). Furthermore, IL-2 signaling is required for Treg function 
(DeLaRosa et al., 2004; Furtado et al., 2002) at least partly by maintaining 
FoxP3 expression levels (Chen et al., 2011). However, Treg display an intrinsic 
defect in IL-2 production due to the suppression of the Il2 gene by the Treg 
transcription factor Helios and FoxP3 (Popmihajlov and Smith, 2008; Baine et 
al., 2013) and therefore depend upon CD28-mediated IL-2 production by local 
conventional T cells. These observations suggest that CD28 and IL-2 
signaling cooperate towards the maintenance of Treg homeostasis and 
function.  
 
1.6. Regulation of CD28-costimulation 
As the major source of T cell costimulation, the delivery of CD28-signaling is 
strictly regulated. This is largely achieved by limiting the availability of the 
CD28–ligands CD80/CD86 by both environmental factors and active 
regulatory mechanisms. Immature or resting APC subsets express low 
CD80/CD86 levels (Chung et al., 2003; Zheng et al., 2004; Mittelbrunn et al., 
2009) although CD86 can display a more constitutive expression pattern 
amongst certain professional APC subsets (Azuma et al., 1993). During 
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maturation, APCs increase CD80/CD86 expression levels and the molecular 
components required to participate in productive interactions with T cells. This 
maturation can be driven by an overwhelmingly proinflammatory environment 
(Banchereau and Steinman, 1998) or due to direct contact with T cells via the 
CD40-CD154 pathway (Caux et al., 1994). Additionally, immune responses 
are associated with increased recruitment of APCs to inflamed lymph nodes 
(MartIn-Fontecha et al., 2003) which promotes T cell acquisition of both TCR 
and costimulatory signals. 
 
Expression of the CD28-family member Cytotoxic T Lymphocyte Antigen-4 
CTLA-4 by both FoxP3+ Treg (Wing et al., 2008) and activated T cells 
(Manzotti et al., 2006; Wang et al., 2012) reflects the requirement to regulate 
the availability of CD28-signaling in order to suppress immune activation and 
control T cell activation. Like CD28, Cytotoxic T-Lymphocyte Antigen-4 
(CTLA-4) also interacts with CD80 and CD86 but with higher affinity. 
Furthermore, the functional consequences of interaction differ – whilst 
interaction with CD28 results in activation, CD80/CD86 binding to CTLA-4 
inhibits T cell responses (Sansom and Walker, 2006). The importance of this 
CTLA-4 mediated immune regulation is demonstrated by the lethal 
lymphoproliferative disorder that is associated with the absence of CTLA-4 in 
mice (Tivol et al., 1995; Waterhouse et al., 1995). The loss of immune 
regulation in CTLA-4-KO mice is driven by CD28 since the interruption of 
CD28-signaling prevents disease (Mandelbrot et al., 1999). In humans, 
heterozygous mutations in CTLA-4 that result in impaired expression levels or 
function are associated with severe immune dysregulation and autoimmunity 
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(Schubert et al., 2014; Kuehn et al., 2014). Similarly, various CTLA-4 
polymorphisms have been associated with risk factors for autoimmune 
diseases, for example rheumatoid arthritis (RA) (Li et al., 2012b), type I 
diabetes (Chen et al., 2013), primary biliary cirrhosis (Li et al., 2012a) and 
systemic lupus erythematosus (SLE) (Liu and Zhang, 2013). 
 
Temporal changes in the prevailing interactions between members of the 
CD28/CTLA-4:CD80/CD86 system occur throughout the course of T cell 
activation. This occurs due to differences in binding-affinities between 
receptor-ligand interactions along with differential patterns of expression and 
receptor dimerization. For example, in contrast to CD28, CTLA-4 is not 
expressed by resting T cells and is upregulated following activation such that 
peak expression levels are achieved 24-48 hours following stimulation 
(Linsley et al., 1992; Walunas et al., 1994). Therefore, in the early stages of T 
cell stimulation, interactions between CD28 and CD80/CD86 predominate to 
promote costimulatory signaling. Biophysical studies demonstrate that, 
relative to their CD28-binding affinity, CD80 and CD86 bind to CTLA-4 with 
approximately 8-fold and 20-fold increased affinities respectively (Collins et 
al., 2002). Therefore, CTLA-4 outcompetes CD28 for CD80/CD86 binding, 
and this represents an important parameter of the capacity for CTLA-4 to 
inhibit CD28-driven T cell activation that contributes towards the resolution of 
T cell responses (Walker and Sansom, 2011). Where CD28 and CTLA-4 are 
both expressed, a particular bias towards CTLA-4:CD80 interactions are 
observed. This occurs due to several factors, firstly, because CTLA-4 binds to 
CD80 with particularly high affinity (Kd = 0.2μM) while its affinity for CD86 is 
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lower (Kd = 2.6μM) (Collins et al., 2002). Furthermore both CTLA-4 and CD80 
form homodimers and interact bivalently; as such, CTLA-4:CD80 interaction 
results in the formation of oligomeric lattices at the T cell-APC interface which 
is thought to promote the avidity of interactions (Stamper et al., 2001). These 
factors suggest that CTLA-4 expression biases the CD28:CD80/CD86 
pathway in favor of relatively low-affinity CD28:CD86 interactions (Kd = 20μM) 
(Collins et al., 2002). It has been suggested that this may influence the 
phenotype of activated T cells due to qualitative differences between CD80 
and CD86-driven signals (Manzotti et al., 2006). Furthermore, it may partially 
underlie the observation that CD86 plays a more dominant role in 
costimulatory signaling compared to CD80 in that CD86-KO mice are more 
severely immunocompromised than CD80-KO mice (Borriello et al., 1997). 
 
Some disagreement has existed as to the exact manner by which CTLA-4 
functions to control T cell responses (Walker and Sansom, 2011). For 
example, CTLA-4 has been widely proposed to function by a cell-intrinsic 
mechanism i.e. by a direct effect upon the CTLA-4 expressing cell. This is 
proposed to occur through the generation of negative signaling delivered via 
CTLA-4 following its ligation by CD80/CD86. This is mediated by the 
recruitment of the protein tyrosine phosphatases Src-homology 2 domain-
containing phosphatase (SHP)-2 (Marengère et al., 1996; Lee et al., 1998) 
and protein phosphatase 2A (PP2A) (Chuang et al., 2000; Parry et al., 2005) 
by the CTLA-4 cytoplasmic domain. Functioning in this manner, CTLA-4 
ligation among conventional T cells has been found to reduce T cell 
proliferation and IL-2 production following anti-CD3/anti-CD28 stimulation 
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(Krummel and Allison, 1996; Brunner et al., 1999). One mechanism by which 
this may occur is through a CTLA-4 dependent inhibition of proximal TCR 
signaling events (Lee et al., 1998; Guntermann and Alexander, 2002) and 
prevention of lipid raft formation within the T cell membrane that serves to 
facilitate TCR-signaling (Martin et al., 2001). Additionally, CTLA-4 is thought 
to interfere with the TCR-stop signal whereby T cells make stable contacts 
with APCs upon antigen-stimulation (Schneider et al., 2006) and enhance the 
induction of FoxP3 and a regulatory phenotype by activated T cells (Zheng et 
al., 2006; Barnes et al., 2013). Additionally, it has been suggested that signals 
delivered via Treg associated CTLA-4 serve to maintain Treg suppressive 
function (Kong et al., 2011). However it is unclear how negative signaling in 
conventional T cells translates to positive signaling for Treg function; this 
represents one of several inconsistencies that have arisen between studies 
investigating the mechanisms and functional outcomes associated with CTLA-
4 mediated signaling in T cells (Walker and Sansom, 2015).  
 
Several lines of evidence suggest that CTLA-4 may function independent of 
the generation of negative signals. For example, CTLA-4 mutants that do not 
express a cytoplasmic domain maintain a regulatory capacity (Masteller et al., 
2000). Furthermore, bone marrow chimeric mouse models have 
demonstrated that CTLA-4-deficient T cells do not mediate lethal 
lymphoproliferative disease in the presence of CTLA-4-replete T cells, this 
suggests that CTLA-4 regulates the activity of other T cells in a cell-extrinsic 
manner (Bachmann et al., 1999; Chikuma and Bluestone, 2007). An important 
mechanism by which this occurs is via a process of CD80/CD86 trans-
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endocytosis in which CD80/CD86 are bound by CTLA-4 then transferred and 
subsequently degraded within the CTLA-4 expressing cell (Qureshi, et al., 
2011). The intracellular trafficking of CTLA-4 supports this process. In contrast 
to CD28, which is expressed at the cell surface, CTLA-4 expression is 
predominantly associated with intracellular vesicles (Sansom and Walker, 
2006). CTLA-4 cycles to the cell surface in response to elevated intracellular 
Ca2+ concentrations occurring due to TCR stimulation and localizes at the 
APC-T cell interface at sites of TCR engagement where interactions with 
CD80 and CD86 occur (Linsley et al., 1996). However, surface CTLA-4 is 
rapidly internalized and this is mediated via a clathrin-dependent mechanism 
that is mediated by the interaction between the clathrin adaptor protein (AP)-2 
and the CTLA-4 cytoplasmic domain via a tyrosine-based YVKM motif 
(Schneider et al., 1999). This endocytic motif is evolutionarily conserved 
which suggests selective pressure upon CTLA-4 receptor recycling and 
therefore that CTLA-4 intracellular trafficking is central to its function (Kaur et 
al., 2013). Upon internalization, CTLA-4 recycles to the cell surface via an 
association with recycling endosomes; alternatively, it can be directed to 
lysosomes where CTLA-4 and interacting CD80 and CD86 molecules that 
have been removed from the APC surface are degraded (Qureshi et al., 
2012). Therefore, the net result of CTLA-4 activity is the downregulation of 
CD80/CD86 from the APC surface that denies CD28-ligand interactions and 
inhibits CD28-dependent T cell activation (Qureshi et al., 2011; Hou et al., 
2015).  
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1.7. CD28-independent costimulatory pathways 
Although T cell responses in CD28-KO animals are inhibited, they are not 
entirely absent (Shahinian et al., 1993). This is demonstrated by the 
enhanced progression of autoimmune diabetes in CD28-KO NOD mice 
(Lenschow et al., 1996). Similarly, CD28-KO mice remain susceptible to the 
induction of experimental autoimmune encephalomyelitis (EAE) (Chitnis et al., 
2001). Cytotoxic T cell responses also occur in response to allostimulation in 
the absence of CD28 in that CD28-KO mice are capable of normal skin 
allograft rejection (Kawai et al., 1996) and acute lethal graft-versus-host 
disease (Speiser et al., 1997). These responses are mediated, at least in part, 
by various CD28-independent costimulatory pathways. 
 
1.7.1. TNF-receptor superfamily members 
Several members of the TNF-receptor superfamily have been suggested to 
provide costimulatory support to TCR-stimulation (Croft, 2009). Such 
alternative costimulatory molecules include OX40 which interacts with OX40-
ligand on APCs; inhibition of OX40 ligation suppresses T cell activation above 
the level that is seen by anti-CD80/anti-CD86 alone (Akiba et al., 1999). 
Similarly, OX40L blockade prevented the development of EAE in CD28-KO 
mice but had no impact on wild-type (WT) controls suggesting that OX40 
signals can compensate for an absence of CD28-costimulation (Chitnis et al., 
2001). This apparent costimulatory activity occurs relatively late during T cell 
activation since OX40 is only expressed by activated T cells (Weinberg et al., 
1998) where maximal expression appears dependent upon CD28-signals 
(Akiba et al., 1999; Walker et al., 1999). Acting in this way, OX40 signals 
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appear to fine-tune T cell responses via effects upon T cell differentiation, for 
example, by biasing T cell activation towards a Th2 type response by 
promoting IL-4 production by effector T cells (Ohshima et al., 1998). 
 
Similar to OX40, in the presence of CD28, signals delivered by the TNF-
superfamily members 4-1BB and CD27 modulate T cell effector function and 
the generation of memory T cells (Vinay and Kwon, 1998; Hendriks et al., 
2000; Wen et al., 2002; Denoeud and Moser, 2011). However, 4-1BB ligation 
can also compensate for an absence of CD28 to support the generation of T 
cell activation (DeBenedette et al., 1997; Bukczynski et al., 2003). Similarly, 
CD27 signals enhance TCR-driven T cell proliferation (Kobata et al., 1994; 
Hintzen et al., 1995), though this occurs in an IL-2 independent manner 
suggesting that this does not represent a true costimulatory signal (Watts and 
DeBenedette, 1999). Signals delivered via CD27 and 4-1BB are particularly 
important in CD8+ T cell responses (Shuford et al., 1997; Yamada et al., 
2005) that are thought to be less dependent upon CD28-costimulation 
(Goldstein et al., 1998; Wang et al., 2000), at least in part due to the relative 
prevalence of CD8+CD28- T cells (Borthwick et al., 2000). 
 
1.7.2. CD28-superfamily members 
The primary CD28-superfamily associated with the delivery of CD28-
independent costimulatory signaling is ICOS. This molecule is structurally and 
functionally related to CD28 and binds to its ligand ICOS-L (B7-H2) via a 
FDPPPY motif that is related to the MYPPPY motif of CD28 and CTLA-4 
(Chen and Flies, 2013). Whilst CD4+ T cells constitutively express CD28, 
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ICOS is only expressed upon activation (Simpson et al., 2010); furthermore, 
CD28 signals appear necessary for maximal ICOS expression (McAdam et 
al., 2000). Transcriptional profiles induced by the CD28-superfamily member 
ICOS show striking similarity to that induced by CD28 (Riley et al., 2002). As 
such, ICOS ligation provides efficient costimulation of in vitro T cell activation 
(Hutloff et al., 1999; Yoshinaga et al., 1999). Similarly, ICOS substitutes for 
CD28-costimulation to drive T cell responses in CD28-KO mice (Suh et al., 
2004) particularly when mice are crossed onto a background that confers 
constitutive ICOS expression (Linterman et al., 2009). In vivo models also 
demonstrate that ICOS signals not only cooperate with CD28 to promote T 
cell activation and proliferation but also are necessary for IL-4 production by 
activated T cells and T cell dependent B cell responses (Dong et al., 2001; 
Tafuri et al., 2001). As such, it has been suggested that ICOS signals are 
indispensable for humoral immune responses in CD28-KO mice (Suh et al., 
2004). These functions underlie the importance of ICOS expression by Tfh 
cells (Simpson et al., 2010) 
 
In contrast to ICOS, the CD28-superfamily member PD-1 promotes the 
inhibition of T cell responses following its ligation by PD-L1 (B7-H1) and PD-
L2 (B7-DC) (Francisco et al., 2010). PD-1 deficient mice are susceptible to the 
development of autoimmunity (Nishimura et al., 1999; 2001; Wang et al., 
2005; Zhang and Braun, 2014) but display a less aggressive phenotype than 
CTLA-4-KO mice (Riella et al., 2012b). Indeed, PD-1 functions differently to 
CTLA-4 (Parry et al., 2005) and it has been suggested that blockade of CTLA-
4 and PD-1 leads to a synergistic enhancement of T cell responses in cancer 
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therapy (Intlekofer and Thompson, 2013). Underlying the tolerogenic function 
of PD-1 is an inhibition of T cell activation signaling (Sheppard et al., 2004; 
Yokosuka et al., 2012; Wei et al., 2013) and positive effects upon Treg 
differentiation and function (Francisco et al., 2009; Chen et al., 2014). 
 
Novel B7 and CD28 superfamily members have been described where the 
interaction partners and consequences of interaction are not fully understood 
(Greenwald et al., 2005). For example, B7-H3 is expressed by fibroblasts, 
dendritic cells, and monocytes (Chapoval et al., 2001; Tran et al., 2008). The 
consequence of its interaction with an as yet unidentified receptor on 
activated T cells is controversial; some studies identify a role in the 
costimulation of T cell responses (Chapoval et al., 2001; Luo et al., 2004) and 
others suggest a co-inhibitory function (Ling et al., 2003; Leitner et al., 2009). 
Additionally, B and T lymphocyte attenuator (BTLA) is expressed by activated 
T cells and participates in inhibitory interactions with an as yet unidentified 
counter receptor (Watanabe et al., 2003). Several novel interactions between 
known B7 and CD28 superfamily members have also been described. For 
example, the interaction between PD-L1 and CD80 has been proposed to 
inhibit T cell responses (Butte et al., 2007; Park et al., 2010) whilst ICOS-L is 
thought to deliver a costimulatory signal via CD28 (Yao et al., 2011). The 
relative importance of these pathways is unclear but is likely to confer an 
added dimension to the control of T cell responses. The various interactions 
between CD28 and B7-superfamily members are summarized in fig. 1.2. 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CTLA-4 
CD86/ 
CD80 
CD28 
CD86/ 
CD80 
CD80 
PD-L1 ICOSL 
APC 
T cell 
PD-1 ICOS TCR 
MHC II 
PD-L2 
BTLA 
? B7-H3 
? 
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Fig. 1.2. Interactions between CD28- and B7- family members. CD28 is constitutively 
expressed by CD4+ T cells and interacts with the B7-family members CD80 and CD86. 
CD28 ligand binding results in signalling that positively impacts upon T cell activation 
and differentiation. These signals are regulated by CTLA-4 which also binds to CD80 
and CD86 but with higher affinity. Additional costimulatory signals are delivered following 
the ligation of ICOS upon activated T cells by ICOS-L. Productive  interactions between 
ICOS-L and CD28 has also been proposed. PD-1 participates in inhibitory signalling 
following ligation by PD-L1 and PD-L2. Additionally, PD-L1 has been found to interact 
with CD80 to inhibit T cell activation. BTLA on T cells and B7-H3 on APCs inhibit T cell 
activation in association with as yet unidentified interaction partners.  
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1.7.3 CD40-CD154 
The CD40-CD154 signalling axis has been recognized as a crucial CD28 
independent costimulatory pathway. CD154 is upregulated by activated T 
cells whilst CD40 is widely expressed by APC (Grewal and Flavell, 1996). 
Interactions between these molecules results in bidirectional signalling that 
induces change to the activation status and differentiation of both the T cell 
and the APC. For instance, CD154 engagement generates a costimulatory 
signal that facilitates TCR driven activation and proliferation (Wu et al., 1995; 
Munroe and Bishop, 2007). With regards to the APC, CD40 ligation induces 
an increase in the expression of costimulatory molecules (including CD80 and 
CD86) and MHC-II (Ma and Clark, 2009), whilst in macrophages, signals 
delivered via CD40 promote activation including the production of 
proinflammatory cytokines such as TNFα and IFNγ (Stout et al., 1996; 
Buhtoiarov et al., 2005). The absence of CD154 expression results in X-linked 
hyper IgM syndrome, which is characterized by a defect in germinal center 
formation and B cell isotype switching occurring as the result of reduced Tfh 
cell differentiation and function (Ma and Deenick, 2014).  
 
Importantly, the CD40-CD154 pathway has been found to represent a 
prominent signaling axis in transplantation rejection. As such, blocking 
antibodies against both CD154 and CD40 have been found to promote 
allograft survival in both mice and humans (Kinnear et al., 2013).  It is thought 
that this at least partly involves the loss of CD80 upregulation following CD40 
signaling in APC subsets (Hancock et al., 1996). However, a synergistic 
relationship between CD154 and CD80/CD86 blockade has been reported 
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(Yamada et al., 2002), suggesting that the impact of CD154 blockade upon of 
CD80/CD86 expression does not exclusively account for the defective 
alloresponse and likely involves costimulation delivered via CD154. Taken 
together, these lines of evidence demonstrate the capacity for modification of 
multiple aspects of an adaptive immune response induced by CD40-CD154 
signals.      
 
 
1.7.4 Adhesion molecules 
DC-T cell interactions mediated by adhesion molecules have been associated 
with direct costimulatory activities by means of increased T cell activation and 
proliferation including CD2-CD58 (Davis and van der Merwe, 1996), ICAM-3-
DC SIGN (Martinez, 2005), CD6-CD166 (Hassan et al., 2004) and CD31 
interactions (Elias et al., 1998). A widely cited interaction with a primary role in 
adhesion and a secondary role in costimulatory signaling is mediated by LFA-
1-ICAM-1 interactions (Wang et al., 2009). In CD28-KO mice it has been 
suggested that ICAM-1 is crucial for T cell responses (Gaglia et al., 2000). 
However, it seems likely that this occurs primarily through the stabilization of 
T cell interactions that enhance the delivery of TCR signals (Bachmann et al., 
1997).  
 
1.7.5. Cytokines/Chemokines 
Proinflammatory cytokines have been proposed to act as ‘signal 3‘ during T 
cell stimulation by guiding T cell differentiation and effector function 
(Curtsinger and Mescher, 2010). However, it is recognized that these signals 
have a direct effect upon T cell activation and proliferation. IL-1 represents an 
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example of this and has been widely reported to act as a costimulatory signal, 
in particular for Th2 cell proliferation (Lichtman et al., 1988; Huber et al., 
1998). In this context it has been found that IL-1 acts in a comparable manner 
to CD28 by synergizing with TCR signals to promote NF-κB activation 
(McKean et al., 1995). Subsequent effects upon proliferation are at least 
partially associated with an upregulation of IL-2 signaling (Kalli et al., 1998). 
Similarly, T cell activation and cytokine production is elevated in response to 
TCR-stimulation in combination with various immunomodulatory cytokines, for 
example, IL-4 (Brown et al., 1988; Gett and Hodgkin, 2000) and IL-12 
(Germann et al., 1993). Additionally, TNFα and IL-6 provide a costimulatory 
signal for CD8+ T cell activation driven by anti-CD3 stimulation (Sepulveda et 
al., 1999). Inhibition of IL-15 prevents CD28-independent CD8+ T cell driven 
transplant rejection (Ferrari-Lacraz et al., 2001). This cytokine stimulation 
occurs to the extent that T cell activation, in particular effector memory T cells, 
proliferate and acquire effector function in response to cytokine treatment, 
either IL-2 or IL-15 in combination with TNFα and IL-6, in the absence of overt 
TCR stimulation (Unutmaz et al., 1994; Sebbag et al., 1997; Brennan et al., 
2002; 2008).  
 
Another form of interaction that regulates T cell activation results from 
signaling by the chemokine receptors CCR5, CXCR12 and CCR7. These 
have been shown to provide costimulation and modulate T cell activation 
thresholds (Molon et al., 2005; Gollmer et al., 2009).  
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1.8. Therapeutic manipulation of the CD28 costimulatory 
pathway  
Despite the fact that several costimulatory pathways can, to some extent, 
compensate for a relative absence CD28, it is clear that CD28 is the apical 
checkpoint for T cell costimulation. Importantly, CD28-signaling is thought to 
play a key role in the pathogenesis of T cell mediated autoimmunity. For 
example, CD28 signals are required for the optimal induction of collagen-
induced arthritis (CIA) (Tada et al., 1999a), murine lupus (Tada et al., 1999b), 
EAE (Chang et al., 1999), autoimmune neuritis (Zhu et al., 2001) and graft-
versus-host disease (Yu et al., 1998). Furthermore, the particularly strong 
association between CTLA-4 polymorphisms and autoimmunity suggests that 
a failure to regulate CD28-signaling leads to a breakdown in tolerance (Gough 
et al., 2005). It could be suggested that polymorphisms in CTLA-4 are more 
strongly associated with susceptibility to autoimmunity than CD28 itself 
(Ahmed et al., 2001; Djilali-Saiah et al., 2001; Wood et al., 2002; Ban et al., 
2003). This highlights the importance of regulation of the CD28:CD80/CD86 
axis such that under homeostatic conditions tolerance predominates and that 
during infection that immune responses can be promoted. Various strategies 
have been utilized, either to interfere with the availability of CD28-
costimulation so as to skew this system in favor of immune tolerance, or, to 
promote CD28-signaling thereby enhancing immune responses in cancer 
therapy. These strategies are summarized in fig. 1.4. 
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1.8.1. Blocking anti-CD80/anti-CD86  
Blocking antibodies to CD80 and CD86 were developed as a first strategy for 
blocking the CD28/CTLA-4/B7 pathway but have not been widely used in a 
clinical setting. Results from animal models in which they were tested are 
somewhat confusing as anti-CD86 inhibited autoimmune diabetes in non-
obese diabetic (NOD) mice (Lenschow et al., 1995a), but enhanced disease 
in models of EAE (Racke et al., 1995; Miller et al., 1995). By contrast, anti-
CD80 alone accelerated diabetes but reduced EAE pathology (Lenschow et 
al., 1995; Miller et al., 1995). In transplantation models, several studies 
identified that a combination of anti-CD80 and anti-CD86 were required for 
optimal suppression of T cell activation, but that anti-CD86 alone was more 
effective than anti-CD80 (Lenschow et al., 1995b; Pearson et al., 1997; 
Woodward et al., 1998). These results are reminiscent of CD80 and CD86 
knock-out mice in which CD86 KO display the more profoundly 
immunocompromised phenotype (Borriello et al., 1997). Furthermore, they 
highlight the necessity to ensure adequate blockade of CD86 in 
immunosuppressive treatment. An additional limitation of these strategies is 
that the relative roles of CD80 and CD86 in CD28 and CTLA-4 biology remain 
somewhat unclear. It is possible that a better understanding of any differences 
may facilitate more subtle and targeted manipulation of T cell activation. 
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Fig. 1.3. Outcomes associated with manipulation of the CD28/CTLA-4 pathway. Several 
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1.8.2. Soluble CTLA-4 analogues 
CTLA-4 has been exploited as an inhibitor of CD28-costimulation mainly in 
the context of the fusion protein CTLA-4-ig. By competing with CD28 for 
ligand binding, CTLA-4-ig has been shown to inhibit T cell responses in 
models of EAE (Khoury et al., 1995), CIA (Webb et al., 1996), SLE (Finck et 
al., 1994) and autoimmune diabetes (Lenschow et al., 1995a). Furthermore, 
CTLA-4-ig promoted allograft survival in several transplantation models 
(Porier, et al. 2011).  
 
A humanized version of CTLA-4-ig incorporating a modified IgG Fc domain 
(Abatacept; Bristol-Myers Squibb) is approved by the FDA and EMA for the 
treatment of moderate to severe RA in patients who have not responded to 
other disease-modifying anti-rheumatic drugs (DMARDs).  Its efficacy in the 
treatment of RA has been verified in numerous placebo-controlled clinical 
trials in which it shows similar efficacy to other biological RA therapies such 
as TNFα antagonists (Buch et al., 2008).  
 
Despite the utilization of abatacept in the treatment of RA, an apparent lack of 
efficacy of abatacept was found in non-human primate models of 
transplantation (Larsen et al., 2005). This was proposed to occur due to the 
inherently low affinity of native CTLA-4 for CD86 and led to the development a 
higher affinity CTLA-4-ig variant, LEA29Y (Belatacept; Bristol-Myers Squibb) 
which differs in two amino acid residues within the CTLA-4 binding region. 
This modification translates into around 4 and 2 times elevated avidities for 
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CD86 and CD80 respectively with an associated increased potency of CD28-
blockade (Larsen et al., 2005). Belatacept has subsequently been approved 
for clinical use in immunosuppression regimens following renal transplantation 
as a result of favorable results from clinical trials. In the context of renal 
transplantation, alternatives to T cell antagonism with calcineurin-inhibitors 
such as cyclosporine A (CsA) are particularly desirable due to the long-term 
nephrotoxic side-effects of such drugs (Nankivell et al., 2003). In a phase III 
clinical trial evaluating the efficacy of belatacept in immunosuppression 
following renal transplantation (Vincenti et al., 2010), belatacept promoted 
equivalent patient/graft survival at a 12 month end point in comparison to CsA 
based treatment. Furthermore, compared to CsA, belatacept was associated 
with the preservation of renal function as indicated by mean glomerular 
filtration rate. However, belatacept treatment was associated with an 
increased prevalence of acute rejection when compared to CsA treated 
patients. This effect was not observed in the previous phase II trials (Vincenti 
et al., 2005) and remains to be confirmed. However, if such enhanced acute 
rejection is a real side-effect it is clearly of clinical significance and the 
mechanisms underlying it deserve considerable attention.  
 
Despite a relatively clear rationale for the application of CTLA-4-ig in terms of 
its ability to outcompete CD28 for B7 ligand, the actual mechanisms 
underlying clinical responses are controversial. Despite results which 
demonstrated the induction of T cell anergy following CTLA-4-ig treatment in 
vitro (Tan et al., 1993), there is little evidence to suggest that either abatacept 
or belatacept promote long-term tolerance. For example, in a non-human 
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primate transplantation model, a treatment regimen including belatacept 
promoted allograft survival, however, withdrawal of belatacept therapy was 
followed by acute rejection (Lo et al., 2013). It is therefore possible that rather 
than completely attenuating T cell activation, which may be predicted based 
upon the perspective that costimulation is essential for T cell activation, that 
the clinical effects of abatacept could be attributed to qualitative differences in 
T cell differentiation. For example, it has been suggested that abatacept 
prevents Tfh differentiation that results in defective T cell dependent-B cell 
responses (Platt et al., 2010).  Induction of a negative signal into the APC 
following B7 engagement of CTLA-4-ig has also been suggested as a 
mechanism of CTLA-4-ig action. This signal has been proposed to alter 
proinflammatory cytokine expression (Wenink et al., 2012), migration (Bonelli 
et al., 2012) or involve induction of indoleamine 2,3-dioxygenase (IDO) with 
subsequent immunomodulatory effects upon tryptophan metabolism 
(Grohmann et al., 2002). However, induction of IDO may be a product of the 
CTLA-4-ig variant used since abatacept inhibited T cell responses 
independent of IDO (Davis et al., 2008). Furthermore, treatment of APCs with 
either abatacept or belatacept in vitro failed to induce transcriptional changes 
in APCs (Carman et al., 2009).  
 
1.8.3. Blocking anti-CTLA-4 antibody 
The role of CTLA-4 as a negative regulator of CD28-signaling has led to the 
development of blocking CTLA-4 antibodies in cancer therapy with the aim of 
promoting T cell anti-tumour responses. The efficacy of this approach has 
been demonstrated in clinical trials evaluating the fully humanized anti-CTLA-
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4 antibodies ipilimumab and tremelimumab in numerous tumour types 
(Grosso and Jure-Kunkel, 2013). Significantly, ipilimumab is now approved for 
the treatment of advanced or metastatic melanoma. This therapy induces an 
increase in the ratio of Teff relative to Treg and the basis of how this works 
demonstrates the mechanism of CTLA-4 mediated control of immunity. Whilst 
a decrease in absolute tumour-infiltrating Treg counts has been reported in a 
murine melanoma model, this was found to occur in an FcR dependent 
manner by antibody-dependent cell-mediated cytotoxicity (ADCC) rather than 
interfering with any requirement by Treg for CTLA-4 ligation (Simpson et al., 
2013). Furthermore, in patients with either melanoma or metastatic renal cell 
cancer, ipilimumab therapy has been found to promote both CD4+ and CD8+ T 
cell activation rather than exerting effects on Treg function (Maker et al., 2005). 
This is consistent with a model of CTLA-4 functioning in a cell extrinsic 
manner. For example, the absence of CTLA-4 mediated trans-endocytosis 
leads to elevated B7 expression by APCs that promotes the availability of 
CD28-signaling and thereby enhances T cell activation. Accordingly, 
melanoma patients who achieve clinical responses to therapy are more likely 
to experience immune-related adverse events (i.e. to break tolerance in 
association with anti-CTLA-4 therapy) (Attia et al., 2005). Whilst this is 
unsurprising when considering that CTLA-4 KO mice exhibit a lethal 
lymphoproliferative disorder (Tivol et al., 1995), it demonstrates the 
importance of CTLA-4 to the regulation of T cell activation thresholds. 
Furthermore, it shows that by modifying this threshold via CTLA-4 inhibition 
that T cell responses, albeit poorly controlled ones, can be generated. 
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1.8.4. CD28-specific antibodies 
A drawback to B7 blockade is its potential to inhibit other important co-
inhibitory and co-stimulatory interactions, an example being the interaction of 
CD80 with PD-L1 (Butte et al., 2007; Park et al., 2010). At present the precise 
role of these additional interactions is poorly understood but may nonetheless 
impact in vivo function. One way to bypass this is to directly target CD28 
using antagonistic anti-CD28. However, where the aim is to suppress T cell 
activation, these antibodies need to be screened for agonist activity (Gardner 
et al., 2014). A degree of complexity exists in predicting the functional 
outcome of bivalent anti-CD28 in terms of agonistic vs. antagonistic 
properties, for example, the anti-CD28 mAb JJ319 behaves as an agonist 
during in vitro T cell stimulation and an antagonist using in vivo systems 
(Poirier et al., 2011). To avoid these difficulties, interest has turned towards 
the use of monovalent Fab fragments in costimulation blockade which are 
incapable of clustering CD28-molecules and consequential costimulatory 
signalling following cross-linking (Vanhove et al., 2003). For example, a 
monovalent anti-CD28 domain antibody inhibits in vitro T cell proliferation and 
cytokine production and T cell-dependent B cell responses in cynomolgous 
macaques (Suchard et al., 2013). Furthermore, in cynomolgous macaques, 
monovalent antagonistic anti-CD28 inhibits acute and chronic rejection of 
heart allografts especially when used in association with CsA (Poirier et al., 
2010).  
 
An alternative approach is to utilize the pro-regulatory function of CD28 using 
agonistic anti-CD28. A profound example of the agonistic capacity of anti-
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CD28 is demonstrated by the induction of T cell activation and proliferation in 
the absence of overt TCR stimulation (Siefken et al., 1997; Tacke et al., 
1997). Furthermore, these superagonists have been found to promote 
tolerance in several in vivo models via an amplification of Treg (Beyersdorf et 
al., 2005a; Rodríguez-Palmero et al., 2006; Kitazawa et al., 2008; Beyersdorf 
et al., 2009; Wang et al., 2010b). Nevertheless, initial use of the CD28-
superagonist TGN1412 in clinical trials was halted after treatment induced 
severe adverse events mediated by a cytokine-release syndrome (Hünig, 
2012). This has been proposed to occur due to an unexpected CD28-driven 
hyper stimulation of effector memory T cells (Römer et al., 2011). Further 
studies have suggested that the use of TGN1412 at much lower 
concentrations than the initial clinical trial can result in the selective expansion 
of Treg without influencing proinflammatory cytokine expression by 
conventional T cells (Tabares et al., 2014).  
 
1.9. Rheumatoid arthritis: The role of T cells 
RA is a chronic, inflammatory autoimmune disease that affects 0.5-1% of the 
population with a female to male ratio of 3:1 (Humphreys et al., 2013). The 
characteristic foci of the inflammatory process are the peripheral joints where 
the interactions between a mixed inflammatory infiltrate and an expanded 
stromal network mediate synovial hyperplasia and ultimately bone and 
cartilage destruction. Additional systemic pathology including cardiovascular 
and pulmonary involvement can also contribute towards adverse clinical 
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outcomes including an elevated mortality rate among RA patients (McInnes 
and Schett, 2011).  
 
Genetic and environmental risk factors play an important and interacting role 
in the development and progression of RA (Yarwood et al., 2014). Studies of 
RA heritability in twin studies suggest that genetic risk factors accounts for 
just 60% of RA disease susceptibility (MacGregor et al., 2000). This is 
indicative of a strong environmental component to RA susceptibility. 
Nevertheless, RA is a heterogeneous disease where genetic risk factors 
cluster with specific environmental risk factors between patient sub-groups. 
The strongest genetic association with RA is provided by the MHC-II locus 
and is suggestive of a role played by CD4+ T cells in RA susceptibility, 
perhaps by responding to antigens presented by MHC molecules.  
 
Recent advances in treatment strategies, for example, the use of biological 
therapies, have improved prognosis for patients including the potential, in 
some patients, to induce disease remission and avoid the risk of the 
development of erosive disease (Klarenbeek et al., 2010) particularly when 
treatment is started early after symptom onset  (van der Linden et al., 2010). 
A number of strategies that have been successfully utilized in the treatment of 
RA target (or at least have the potential to target) T cells, either directly or 
indirectly. A direct effect upon T cell activation and differentiation can be 
mediated by drugs such as CsA, abatacept, tocilizumab (an anti-IL-6 receptor 
mAb). Indirect effects include the inhibition of APC maturation (e.g. with TNFα 
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antagonists). The success would be predicted based upon the viewpoint that 
T cells play a central role in RA pathology (Cope et al., 2007) 
 
1.9.1. The role of T cells in early RA 
T cells are widely held to play an important role in RA pathogenesis. However, 
in contrast to other organ specific autoimmune diseases, the identification of a 
defined joint-specific autoantigen underlying the initiation of RA has been 
problematic (Cope et al., 2007). However, recent studies have suggested that 
RA may be associated with immunity towards neo-epitopes created by protein 
post-translational modifications including citrullination (Schellekens et al., 
1998), carbamylation (Shi et al., 2011) or acetylation (Juarez et al., 2015). 
The best-characterized example is protein citrullination. Anti-citrullinated 
peptide antibodies (ACPA) can be detected prior to symptom onset (Nielen et 
al., 2004) and this facilitates the detection of ACPA as a diagnostic and 
prognostic indicator for RA (Zendman et al., 2006). A similar role for post-
translational modifications of antigen is seen in other autoimmune diseases, 
for example, coeliac disease (which also has a strong HLA association) where 
the antigen (gluten) is well defined but deamidation catalyzed by 
transglutaminase 2 affects antigen presentation (Sollid and Jabri, 2011). 
 
A role played by post-translational protein modifications such as citrullination 
in the development of the autoimmune response underlying RA has a genetic 
and environmental basis that is consistent with RA etiology. For example, 
citrullination promotes the stability of pMHC complexes and subsequent T cell 
priming in mice that are engineered to express the shared epitope (Hill et al., 
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2003). The observation that the shared epitope could represent a risk factor 
for the initiation of immune responses towards citrullinated peptides has been 
supported by the observation that the shared epitope positively correlates with 
patients who display ACPA seropositivity (Huizinga et al., 2005). However, the 
shared epitope/ACPA paradigm also has a significant environmental basis. 
For instance, smoking represents an important risk factor for the development 
of RA (Stolt et al., 2003). By inducing peptide citrullination, previous smoking 
strongly correlates with the presence of ACPA, furthermore, this relationship 
was only observed in the presence of the shared epitope (Klareskog et al., 
2006).  Thus an interaction between a genetic risk factor (HLA-DR β1 shared 
epitope) and an environmental risk factor (smoking) interact to promote the 
development of ACPA-seropositive RA. This observation is consistent with RA 
initiation occurring at mucosal surfaces where the generation of citrullinated 
peptides occurs not only through exposure to tobacco smoke but also the 
mucosal microbiome (Catrina et al., 2014). Additionally, these studies 
demonstrate the concept of RA as a heterogeneous disease in that ACPA-
seropositive RA is strongly associated with HLA-DR β1 alleles but ACPA-
seronegative RA is not (Klareskog et al., 2009). The clustering of RA genetic 
risk factors and features of pathology within RA patient subgroups suggest 
that various biomarkers could be utilized to predict patient prognosis and 
optimise treatment strategies (Choy et al., 2013).  
 
Several further genetic risk factors for the development of RA are associated 
with T cell activation and signaling. For example, PTPN22 encodes a 
phosphatase that negatively regulates Lck following TCR stimulation and an 
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allelic variant (620W) is associated with several autoimmune diseases 
including RA (Gregersen et al., 2006). It should be noted that the association 
between PTPN22 and RA does not automatically implicate T cells as the 
causative cell type underlying the development of RA since PTPN22 variants 
may function in other leukocytes e.g. neutrophils (Bayley et al., 2015). 
However, an association between mutations in the negative regulators of T 
cell activation signaling CTLA-4 and PD-1 and RA development have also 
been reported (Lin et al., 2004; Prokunina et al., 2004). Additionally, 
polymorphisms within the IL2RA and IL2RB genes that encode the IL-2R α 
and β chains respectively appear to correlate with RA (Cope et al., 2007) and 
could theoretically affect either T cell activation or Treg homeostasis. Together, 
these studies provide genetic evidence that suggest that T cells play a role in 
the development and pathology of RA.  
 
1.9.2. The role of T cells in established RA 
T cells play a prominent role in the inflammatory processes occurring within 
affected joints in RA. Here T cells infiltrate the synovial membrane and 
interact with other lymphocytes. In some cases T cells coalesce with B cells to 
form tertiary lymphoid like structures that potentially facilitate B cell 
differentiation and high-affinity autoantibody production (Pitzalis et al., 2014).  
Additionally, T cells interact with and modify the behavior of resident stromal 
and myeloid cells. For example, T cells promote the release of 
proinflammatory mediators by monocytes, macrophages and fibroblasts 
during in vitro co-culture experiments (McInnes et al., 1997; Sebbag et al., 
1997; Tran et al., 2007; van Hamburg et al., 2011). Th17 cells appear to play a 
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particularly prominent role in mediating inflammation in RA. This may be 
predicted based upon the observation of impaired induction of CIA in IL-17 
deficient mice (Nakae et al., 2003). Similarly, in humans, patients with early 
RA display increased Th17 cell frequencies in the peripheral blood along with 
a selective enrichment of Th17 cells in synovial fluid samples (Leipe et al., 
2010). Additionally, in patients with established RA, disease activity positively 
correlates with Th17 frequencies (Leipe et al., 2010). Although FoxP3
+ Treg are 
present within the synovial lining of inflamed joints, these display a reduced 
suppressive capacity within an overwhelmingly inflammatory environment (Nie 
et al., 2013; Gao et al., 2015) and an increased tendency towards Th17 
plasticity (Wang et al., 2015b).  
 
A key feature of the T cell response in rheumatoid arthritis is its non-resolving 
nature (Cope, 2008). However, this does not necessarily mean that the 
activity and contribution the T cells are consistent throughout the course of RA 
pathology. For example, cytokine analysis within synovial fluid samples shows 
a number of T cell derived cytokines including IL-2, IL-4 and IL-17 in samples 
derived from early RA patients but not from established RA patients (Raza et 
al., 2005). Indeed, T cells from established arthritis demonstrate an anergic 
phenotype that is characterized by hyporesponsiveness to activation signals 
and an absence of IL-2 production (Firestein et al., 1988; Allen et al., 1995). 
Nevertheless, synovial T cells also display resistance to apoptosis (Salmon et 
al., 1997; Raza et al., 2006) thus their proinflammatory interactions with 
resident cells and other lymphocytes persist. These observations appear to 
suggest a pattern where T cells actively initiate an autoimmune inflammatory 
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response in early RA but play a more passive role in established RA through, 
for example, interactions with resident stromal cells. It could therefore be 
suggested that where T cells are targeted in RA therapy, this would be most 
effective when treatment is administered early after symptom onset where T 
cells play a more active role in mediating inflammation. Indeed, the APIPPRA 
(Arthritis Prevention in the Pre-clinical Phase of Rheumatoid Arthritis with 
Abatacept) trial is currently evaluating the efficacy of abatacept therapy in 
individuals who are at high-risk for the development of RA prior to joint 
swelling with the aim of inhibiting T cell activation at a very early stage of 
pathology.   
 
1.9.3. The role of abatacept in the treatment of RA 
The inhibition of CD28-costimulation by abatacept has been utilized as a 
strategy in the treatment of RA. The safety and efficacy of this approach has 
been demonstrated by several phase II and phase III clinical trials (Moreland 
et al., 2002; Kremer et al., 2003; 2005; Genovese et al., 2005; Kremer et al., 
2006a; Schiff et al., 2008). Briefly, the phase III ATTAIN (Abatacept Trial in 
Treatment of Anti-TNF Inadequate Responders) trial demonstrated that 
abatacept was effective for the treatment of patients with established RA (with 
a mean duration of disease of 12.2 years) who had not responded to TNFα 
inhibition, i.e. a difficult to treat population with longstanding disease 
(Genovese et al., 2005). Furthermore, a direct comparison of abatacept with a 
TNFα blocking agent (infliximab) in the phase III ATTEST (Abatacept or 
infliximab vs. placebo, a Trial for Tolerability, Efficacy and Safety in Treating 
rheumatoid arthritis) study demonstrated that the efficacy of abatacept was 
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equivalent to that of TNFα inhibition in a population of RA patients defined by 
their prior inadequate response to methotrexate (Schiff et al., 2008). These 
studies contributed to the utilization of abatacept in the treatment of RA 
patients who have failed several conventional and biological DMARDs and to 
the approval of this drug in the UK by the National Institute for Health and 
Care Excellence (NICE) (NICE, 2013). Whilst these trials have shown the 
therapeutic benefits of abatacept in controlling disease activity in established 
RA, the ADJUST (Abatacept study to Determine the effectiveness in 
preventing the development of rheumatoid arthritis in patients with 
Undifferentiated inflammatory arthritis and to evaluate Safety and Tolerability) 
trial has suggested that abatacept could be utilized to delay RA development 
in patients with early undifferentiated arthritis (Emery et al., 2010). This 
observation is consistent with the idea of T cells playing an active role in the 
initiation and early phases of RA and support the suggestion that abatacept 
may be particularly useful for the treatment of patients with early RA.  
 
1.10. Project Aims 
A consistent finding of studies evaluating the efficacy of abatacept for the 
treatment of RA is a degree of variability between patient responses to 
treatment. For example, in the ATTAIN patient cohort with active RA who did 
not respond well to anti-TNFα therapy, only 50% of abatacept-treated patients 
achieved an American College of Rheumatology (ACR)-20 response 
(denoting a 20% improvement in several disease activity indicators) 
(Genovese et al., 2005). Similarly, in the abatacept treatment arm of the 
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ATTEST study, only 67% patients achieved an ACR 20 response (Schiff et 
al., 2008).  
These studies demonstrate that a proportion of patients achieve a negligible 
response to treatment and the factors underlying this are unclear. One 
possibility is that these patients may be refractory to all available treatment. 
Alternatively, and consistent with the idea of RA as a heterogeneous disease, 
this may represent a different RA sub-population in which T cells play a less 
prominent role. Finally, a key hypothesis in relation to this work is that under 
some conditions, CD28-costimulation may not always be essential to T cell 
activation and other stimulatory pathways may compensate for its absence. 
As such the initial the initial aim of this thesis is: 
1. To develop and utilise in vitro assays to identify factors and 
conditions that influence the relative contribution of CD28 
toward T cell activation. This will inform clinical decisions relating 
to improving responses and predicting outcomes of abatacept 
treatment. 
 
One strategy to counteract the failure for abatacept to work in some RA this 
would be to combine abatacept with other treatments that target CD28-
independent costimulatory pathways. An initial attempt to evaluate the 
feasibility of combining abatacept with anti-TNFα treatment did not enhance 
the efficacy of treatment and was associated with adverse events concerns 
including serious infections (Weinblatt et al., 2007), potentially due to the dual 
suppression of adaptive immunity and an important mediator of innate 
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immunity. Furthermore, this approach was hindered by a lack of clarity 
associated with the roles played by various CD28-independent costimulatory 
pathways.  
 
2. To use an understanding of conditions where CD28-
independent activation occurs to investigate the potential 
utilization of abatacept in combination with other 
immunomodulatory agents in order to promote the outcome of 
therapy. The potential for cooperation between abatacept and 
vitamin D3 towards the suppression of T cell activation will be 
investigated. Vitamin D3 supplementation has previously been 
found to promote the upregulation of CTLA-4 during T cell 
activation. This suggests the possibility for an overlap between 
abatacept and vitamin D3 mediated suppression of T cell activation. 
As such, the hypothesis underlying this area of work is that vitamin 
D3 supplementation will promote the efficacy of abatacept during in 
vitro T cell stimulation. 
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Chapter 2: Materials and Methods 
 
2.1. Cell culture 
Transfected Chinese hamster ovary (CHO) cells were cultured in DMEM (Life 
Technologies, Paisley, UK) supplemented with 10% (v/v) foetal bovine serum 
(FBS; Biosera Ltd, Uckfield, UK), 50U/mL penicillin and streptomycin (Life 
Technologies) and 200μM L-glutamine (Life Technologies) and incubated at 
37°C in a humidified atmosphere of 5% CO2. Cells were passaged upon 
confluence, typically every 48-72 hrs. CHO cell lines expressing CD80, CD86, 
FcRγII (CD32; FcR) or FcR/CD80 were generated by other laboratory 
members and as previously described (Qureshi et al., 2011). 
 
2.2. PBMC isolation 
PBMCs were isolated from leukocyte reduction system cones (National Blood 
Service, Birmingham, UK) by Ficoll-Paque (GE healthcare, Buckingham, UK) 
density gradient centrifugation. 25mL blood diluted 1:4 with PBS was layered 
onto 15mL Ficoll-Paque in 50mL Falcon tubes. Following 25 min 
centrifugation (1060g, 25 min) PBMCs were retrieved from the Ficoll-Plasma 
interface using sterile Pasteur pipettes. Subsequently, PBMCs were washed 
twice by centrifugation in PBS, once at 1060g for 10 min and once at 260g for 
5 min. Cells were subsequently washed twice (490g, 5 min) in MACS buffer 
(2mM EDTA, 0.5% (w/v) BSA in PBS) followed by re-suspension at 100 x 106 
PBMC/mL in MACS buffer. 
56 
 
 
2.3. CD4+CD25- T cell purification 
CD4+CD25- T cells were purified using a custom EasySep™ CD4+CD25- 
enrichment kit (StemCell Technologies, Meylan, France) according to 
manufacturer’s instructions. Briefly, 50μL/mL PBMCs enrichment antibody 
cocktail was added and incubated for 5 min at room temperature. EasySep® 
Magnetic particles were then added at 100μL/mL PBMCs and incubated for 5 
min at room temperature followed by purification using an EasySep® magnet 
according to manufacturer’s instructions. Purified cells were washed twice by 
centrifugation in PBS (490xg, 5 min) and resuspended in RPMI medium. Cell 
purity was determined by immunofluorescence labeling and flow cytometric 
analysis and was frequently found to be ≥97% CD3+CD4+CD25-.  
 
2.4. Monocyte purification and culture 
Monocytes were purified by negative selection using an EasySep™ monocyte 
enrichment kit (StemCell Technologies) according to manufacturer’s 
instructions. Purified monocytes were washed by centrifugation twice in PBS 
(490xg, 5 min) and were resuspended at 1 x106 cells/well in 24 well plates. 
For monocyte-derived dendritic cell (DCs) differentiation, monocytes were 
cultured in RPMI 1640 (Life Technologies, Paisley, UK) supplemented with 
10% (v/v) foetal bovine serum (FBS; Biosera Ltd), 50U/mL penicillin and 
streptomycin and 200μM L-glutamine (subsequently referred to as RPMI/FBS) 
and in the presence of GM-CSF (800 U/mL; Berlex laboratories, Richmond, 
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CA, USA) and IL-4 (500 U/mL; Miltenyi Biotec, Bisley, UK) for 7 days, 
incubated at 37°C/5% CO2. Where indicated, DCs were matured by exposure 
to 100ng/mL lipopolysaccharide (LPS) (Sigma) for 24hrs for analysis of 
surface markers. 
 
2.5. CD4+CD25- T cell stimulation 
All T cell stimulations were performed in 96 well flat-bottom plates in RPMI-
FBS. For DC-driven stimulations, 1x105 T cells per well were co-cultured with 
DCs at DC:T cell ratios of 1:5, 1:10, 1:20 or 1:40. Stimulation was generally 
carried out over a period of 5 days unless otherwise stated. Stimulations were 
treated with anti-CD3 (OKT3; 0.5μg/mL, unless otherwise stated). 
Alternatively, T cell stimulation was driven by toxic shock syndrome toxin 
(TSST)-1 at indicated concentrations (Toxin Technology, Sarasota, FL, USA). 
Analysis of TSST-1 driven activation was accompanied by identification of T 
cells expressing variable β2+ (vβ2) TCRs by immunofluorescence labeling 
which display high affinity for TSST-1. 
 
For CHO cell driven stimulations CHO-transfectants were glutaraldehyde fixed 
prior to stimulation. Briefly, 4x106 CHO cells were incubated in 1 mL 0.025% 
(w/v) glutaraldehyde for 3 minutes. Fixed cells were then washed once with 
RPMI/FBS then twice with PBS by centrifugation. Cells were subsequently 
resuspended in RPMI-FBS. For stimulation, 1x105 T cells were cultured in the 
presence of 0.5μg/mL anti-CD3 and fixed CHO transfectants at CHO:T cell 
ratio of 1:5 in RPMI-FBS incubated at 37°C for 5 days. Where indicated, CHO 
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FcR were used to mediate T cell activation in response to cross-linked anti-
CD3 or anti-CD28 (clone 9.3) used at indicated concentrations, generally 
0.5μg/mL.  
 
Where indicated, T cells were also stimulated for 5 days with Dynabeads® 
Human T-activator CD3/CD28 beads (Life Technologies) according to 
manufacturer’s instructions.  
 
T cell stimulations were also variously treated with abatacept (20μg/mL; 
Bristol Myers Squibb), 1,25(OH)2D3 (10nM; Sigma-Aldrich), IL-2 (200U/mL; 
Peprotech) or CsA (at indicated concentrations; Sigma-Aldrich). The 
concentration of 1,25(OH)2D3 used were determined from previous 
experience (Jeffery et al., 2012) and similar to those used by others (Penna et 
al., 2007; Palmer et al., 2011). The vehicle for 1,25(OH)2D3 was ethanol, 
which was diluted to a final concentration of 0.01% (v/v) during experiments; 
vehicle controls showed no effect upon experimental outcomes. PBS vehicle 
was used for all other reagents. 
 
2.6. Flow cytometry 
Antibodies used for immunofluorescence labeling are detailed in table 2.1. 
For analysis of cell surface proteins, cells were recovered following 
stimulation and washed once by centrifugation in PBS and incubated with 
relevant antibodies in PBS supplemented with 2% (v/v) goat serum (Sigma-
Aldrich) for 30 min at 4°C. T cell counts per sample were determined relative 
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to AccuCheck counting beads (Invitrogen) in which the addition of 7μL beads 
represented 7000 counting beads. All data were acquired using a CyAn™ 
ADP Flow Cytometer (DakoCytomation, Ely, UK) and were analysed using 
FlowJo™ software (TreeStar, Ashland, OR, USA).  
 
2.7. Intracellular FoxP3 and CTLA-4 staining  
A FoxP3 staining buffer kit (eBioscience) was used for intracellular staining of 
FoxP3 and total CTLA-4 expression in accordance with manufacturer’s 
instructions. Briefly, samples were added to 5ml polypropylene tubes and 
washed once by centrifugation in PBS (490g, 5 min). Cells were fixed by re-
suspending in 500μg/mL FoxP3 Fixation/Permeabilization solution 
(eBioscience) and incubating at 4°C overnight. Cells were subsequently 
washed twice by centrifugation (490g, 5 min), once in PBS then with FoxP3 
permeabilization Buffer (eBioscience). Cells were subsequently stained for 
FoxP3, CTLA-4 and CD25 expression for 45 min at 4°C then washed twice by 
centrifugation (490g, 5 min), again, once with FoxP3 Permeabilization Buffer 
(eBioscience) then once in PBS (490g, 5 min).  
 
2.8. Phosflow staining  
Staining for pSTAT5 was performed using a BD Phosflow™ buffer kit (BD 
Biosciences). Briefly, T cells were stimulated under indicated conditions, then 
washed by centrifugation in PBS (490g, 5 min). Cells were fixed by addition of 
an equal volume of BD Phosflow™ Fix buffer I (BD Biosciences) warmed to 
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37°C for 12 min. Cells were then washed by centrifugation in PBS-FBS (600g, 
6 min). Cells were permeabilized by adding 1mL cold (-20°C) BD Phosflow™ 
Perm buffer III then incubated for 30 min at 4°C. Cells were then washed 
twice by centrifugation in 3mL PBS-FBS (600g, 6 min) and stained at room 
temperature with anti-pSTAT5 for 40 min followed by flow cytometric analysis. 
 
2.9. Intracellular cytokine staining 
For the detection of cytokine expression, T cells were stimulated for 5 days 
under indicated conditions and then restimulated for 4 hours with 50ng/mL 
PMA (Sigma-Aldrich) and 1μM ionomycin (Sigma-Aldrich) in the presence of 
10μg/mL brefeldin A (Sigma-Aldrich). Cells were then washed by 
centrifugation (490g, 5 min), with PBS then fixed with 3% (w/v) 
paraformaldehyde in PBS for 12 min at room temperature. Subsequently cells 
were permeabilized with 0.1% (w/v) saponin in PBS and stained at room 
temperature for 30 min.  
 
2.10. IL-2 ELISA 
Supernatants from T cell stimulations were collected at indicated time points 
following stimulation and stored at -20°C until analysis. IL-2 levels were 
determined using a human IL-2 Ready-SET-Go!® ELISA kit (eBioscience) 
according to manufacturer’s instructions.  
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Table 2.1. List of Antibodies used in immunofluorescence staining for flow 
cytometry analysis. (Abbreviations: Fluorescein isothiocyanate (FITC), 
Phycoerythrin (PE), Cyanine (Cy), Peridinin chlorophyll (PerCP), eFluor® 450 (e450) 
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2.11. CD4+ T cell proliferation assays  
Prior to stimulation, CD4+CD25- T cells were labeled with CellTrace™ Violet 
(CTV; Life Technologies). T cells were resuspended in 1mL PBS and CTV 
was added at a 1/1000 dilution for a final concentration of 5μM. Cells were 
incubated for 20 min at 37°C and protected from light. Unbound dye was 
quenched by addition of 20mL RPMI/FBS (10% v/v) for 10 min at 37°C. Cells 
were washed twice by centrifugation (490g, 5 min) in PBS prior to stimulation. 
 
Following stimulation T cell proliferation was analysed by flow cytometry. 
Proliferation profiles were modeled using the Flowjo proliferation platform to 
determine various parameters defining T cell proliferation. Each of these 
statistics have advantages and disadvantages (Roederer, 2011). Division 
index represents the average number of divisions undergone by all cells in the 
original culture. In contrast, the proliferation index excludes undivided cells 
and is thus a measure of how far cells have divided. CD28-costimulation 
influences both the number of cells that enter the cell cycle and the number of 
divisions undergone. The division index accounts for both these parameters of 
T cell proliferation and was therefore frequently used to express T cell 
proliferation following stimulation. 
 
2.12. Detection of T cell apoptosis 
Following 5 days incubation, T cell apoptosis was determined by analysis of 
mitochondrial depolarization, a marker of early apoptosis (Zamzami et al., 
1995). Cells were washed and incubated with 23ng/mL 3,3' 
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dihexyloxacarbocyanine iodide (DiOC6) (Molecular Probes, Eugene, OR, 
USA) for 20 minutes at 37°C. Cells were then washed twice by centrifugation 
in PBS (490g, 5 min) and suspended in 400μL RPMI/FBS (2% v/v). Cells 
were analysed by flow cytometry and apoptotic cells were characterized as a 
DiOC6
low population that was verified by forward/side scatter profiles. 
 
2.13. Stimulation of early arthritis patient PBMC samples 
Heparinized peripheral blood samples were collected from patients within the 
Birmingham Early Arthritis cohort. Research ethics committee approval was 
obtained for the collection of this material and all patients gave written 
informed consent. Blood samples were diluted 1:2 with PBS supplemented 
with 2% (v/v) FBS (PBS-FBS). PBMCs were isolated by Ficoll-Paque (GE 
healthcare) density gradient centrifugation as previously described. Purified 
PBMCs were then washed by centrifugation in PBS-FBS, once at 1060g for 
10 min, then once at 260g for 5 min, finally once at 490g, 5 min. PBMCs were 
then resuspended in RPMI-FBS. 
 
PBMC populations were characterized by immunofluorescence labeling 
followed by flow cytometric analysis. Specifically PBMCs samples were 
considered in terms of monocyte:CD4 T cell ratios by CD14+ and CD3+CD4+ 
expression respectively. The CD4+ naïve:memory ratio was determined by 
differential expression of CD45RO positivity for memory T cells and CD45RA 
positivity for naïve T cells. Relative Treg frequencies within the CD3
+CD4+ 
population were determined by CD25highCD127low expression.  
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PBMCs were stimulated in 96 well flat-bottom plates in a total volume of 
200μL/well RPMI/FBS with 2x105 PBMCs/well. PBMCs were stimulated with 
concentrations ranging from 0.5-0.00005μg/mL anti-CD3 for 4 days at 37°C 
either in the presence or absence of 20μg/mL abatacept.  
 
Following stimulation, PBMCs were stained for surface marker expression. 
Ki67, a marker of proliferation, was primarily used to indicate T cell activation. 
This was stained for following cell fixation and permeabilization using a FoxP3 
staining buffer kit (eBioscience) as described previously. 
 
2.14. Statistics 
Statistical analyses were performed using SPSS version 22 (SPSS, Inc., 
Chicago, IL, USA) or using Prism 5.0 software (GraphPad Software, La Jolla, 
CA, USA). Interactions between two factors, for example, 1,25(OH)2D3 and 
abatacept, were analysed by repeated measures within-subjects two-factor 
analysis with Huynf-Felt correction. Normality was determined as part of this 
analysis by the distribution of residuals from the mean values in quantile-
quantile plots as described (Ghasemi and Zahediasl, 2012). Where indicated, 
data were log10 transformed in order to reduce skewing of data that did not 
appear to be normally distributed. P values for the interaction effect and main 
effects for the individual factors are reported. Interaction reflects the impact of 
one factor upon the other (Slinker, 1998), for example, the extent to which the 
presence of 1,25(OH)2D3 impacts upon the effect of abatacept. Where 
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significant interaction effects were identified, main effects for the individual 
factors are not reported and individual comparisons between experimental 
groups were made using two-tailed, paired t tests. P values <0.05 were 
considered significant. 
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Chapter 3: Impact of relative APC numbers on T 
cell CD28-costimulation requirements 
 
3.1. Introduction 
Several clinical trials have demonstrated abatacept to be effective in the 
treatment of RA, however, a significant proportion of patients display a limited 
clinical response to treatment (Buch et al., 2008). This inherent variability 
between patient responses to abatacept is reminiscent of clinical responses to 
other biological therapies used in the treatment of RA (Maneiro et al., 2013).   
 
Differences between clinical responses to abatacept blockade may be 
attributed to various factors. RA is a heterogeneous disease and variable 
responses to treatment may reflect differences in underlying disease 
processes between patients that determine outcomes of treatment. For 
example, T cells may play a more dominant role in some subgroups. 
Additionally, the potency of abatacept blockade has been proposed to be 
suboptimal, especially in the context of non-human primate models of organ 
transplantation and this prompted the development of a CTLA-4-ig variant 
(belatacept) that binds to CD80/CD86 with higher affinity (Larsen et al., 2005). 
Alternatively, the timing of costimulation blockade may not overlap with a time 
frame in which CD28 is actively contributing towards T cell activation. Finally, 
CD28 may not always be crucial to T cell activation and other T cell 
stimulatory pathways may compensate for an absence of CD28-costimulation 
as seen in CD28-deficient mice. The identification of conditions under which 
CD28 requirements are limited may therefore identify strategies for 
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combination therapies or other approaches that promote patient responses to 
costimulation blockade. 
 
In this chapter, the impact of abatacept blockade upon in vitro T cell 
stimulation was determined. The results show that the level of abatacept 
sensitivity is inversely correlated with the strength of TCR stimulation. 
Surprisingly, the DC:T cell ratio at which T cells are stimulated partly 
influences T cell activation thresholds such that TCR-stimulation is more 
effective in the presence of high relative DC numbers. As such, DC:T cell ratio 
influences CD28-costimulation requirements and therefore the efficacy of 
CD28-costimulation blockade.  
 
3.2. Results 
3.2.1. Abatacept inhibits T cell proliferation driven by both CD80 and 
CD86 
Initially, to test the efficacy of T cell stimulation blockade by abatacept in vitro, 
CTV-labeled CD4+CD25- human T cells were stimulated with soluble anti-CD3 
and CHO cells expressing either CD80 or CD86 to provide CD28-
costimulation. Treatment with abatacept at a concentration of 20μg/mL 
robustly inhibited T cell proliferation driven by either CD80 or CD86 (fig. 3.1). 
As predicted, abatacept had no impact upon T cell proliferation driven by anti-
CD3/anti-CD28 coated beads due to the absence of CD28 ligands in this 
system (fig. 3.1). These experiments therefore established both the specificity 
and efficacy of abatacept blockade for future experiments.  
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Fig. 3.1. Abatacept inhibits CD28-driven T cell proliferation. CTV labeled 
CD4+CD25- T cells were incubated with 0.5µg/mL anti-CD3 and either CHO-CD80, 
CHO-CD86 or anti-CD3/anti-CD28 coated beads and with or without 20µg/mL 
abatacept for 5 days followed by flow cytometric analysis of CTV dilution. 
Representative flow cytometry data from one representative experiment of more than 
5 performed.  
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Fig. 3.2. Relative APC numbers determine T cell CD28-costimulation 
requirements. CTV labeled T cells were co-cultured with DCs at indicated DC:T cell 
ratios and stimulated with 0.5µg/mL anti-CD3 for 5 days -/+ (20µg/mL) abatacept. A) 
Representative flow cytometric data. CTV proliferation data from independent 
experiments (n = 14) was modeled and expressed as either division index (B) or 
proliferation index (C). D) CTVlow (i.e. divided) T cell counts were determined relative 
to a known quantity of beads added to each sample prior to flow cytometric analysis. 
p values are derived from two-way ANOVA. Further analyses was performed using 
paired, two-tailed t tests; ns not significant *p ≤0.05 **p ≤0.01, ***p ≤0.001.  
C 
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3.2.2. High relative DC numbers inhibit suppression of T cell activation 
by abatacept 
In order to further assess the impact of CD28-costimulation upon T cell 
activation T cells were again stimulated with 0.5μg/mL soluble anti-CD3 but 
this time with monocyte-derived dendritic cells (DCs) as a source of 
costimulation in the presence or absence of abatacept. Interestingly, very 
limited inhibition of T cell proliferation by abatacept was observed when DCs 
were used at high numbers relative to responder T cells (fig. 3.2A; 1 DC: 5 T 
cell). However, reducing this DC:T cell ratio (down to 1:40) progressively 
increased abatacept sensitivity both in terms of T cell proliferation (fig. 
3.2A/B) and absolute T cell counts (fig 3.2D). This indicated that T cell 
activation driven by low relative DC numbers was more dependent upon 
CD28-costimulation.  
 
In addition to effects upon abatacept-sensitivity, relative DC numbers had 
striking effects upon T cell proliferation. CTV plots were modeled and T cell 
proliferation was expressed as both division index and proliferation index. 
These statistics differ in that division index accounts the average number of 
divisions undergone by the overall T cell population whereas proliferation 
index represents the average number of divisions by divided T cells only and 
therefore remains uninfluenced by the proportion of T cells that enter the cell 
cycle. Unsurprisingly, the proportion of T cells that entered the cell cycle 
decreased as DC numbers were reduced suggesting that DC 
contact/costimulation became limiting at low numbers (fig. 3.2A). This heavily 
influenced the T cell division index, this significantly decreased as relative DC 
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numbers were reduced (fig. 3.2B). Interestingly, there was also an apparent 
inhibition in the extent of T cell division in response to high relative DC 
numbers.  Although more T cells committed to proliferation in response to 
high DC:T cell ratios they tended to undergo fewer divisions. As such, there 
was a trend towards increased proliferation index as DC:T cell was reduced 
(fig. 3.2C). Together, these data therefore demonstrate that the DC:T cell 
ratio at which  T cells are stimulated affects not only the suppression by 
abatacept but also the extent of the proliferative response following T cell 
stimulation. In general, the concept that high intensity T cell stimulation results 
in more proliferation commitment but lower numbers of divisions is a 
consistent finding throughout this thesis. 
 
In order to rule out the obvious possibility that 20μg/mL abatacept was 
insufficient to saturate the increased amounts of CD80/CD86 expression 
when higher DC numbers were used, T cells were stimulated in the presence 
of either high (1 DC:5 T cell) or low (1 DC: 20 T cells) relative DC numbers 
with CD28-costimulation blockade by higher abatacept concentrations. 
However, increasing abatacept dose beyond 20μg/mL did not increase 
inhibition of T cell proliferative responses (fig. 3.3). Moreover, the dose 
response to abatacept was parallel between the two ratio’s albeit set at 
different division levels. This further suggested that the difference in efficacy 
of abatacept treatment was not limited by the concentrations used. 
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Fig. 3.3. Increased abatacept concentrations fail to inhibit abatacept-resistant T 
cell proliferation. CTV-labeled T cells were stimulated with 0.5µg/mL anti-CD3 at a 
DC:T cell ratio of 1:5 or 1:20 and were treated with indicated abatacept 
concentrations. T cell proliferation was determined by flow cytometric analysis. Mean 
division index values ±S.E. from independent experiments (n = 4).  
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Fig. 3.4. Abatacept saturates DC CD80/CD86 expression levels. Immature DCs 
(iDC) were differentiated from monocytes by exposure to GM-CSF/IL-4 for 7 days. 
Mature DCs (mDC) were generated by further exposure to 100ng/mL LPS for 24 
hours. (A) CD80 and CD86 expression levels were determined by 
immunofluorescence staining followed by flow cytometric analysis. (B) iDC and mDC 
were incubated with various abatacept concentrations, abatacept binding was 
subsequently detected by secondary staining with anti-IgG (Fc specific)-FITC. MFI 
values were determined by flow cytometric analysis. Mean values ±S.E. from 
independent experiments (n = 4).  
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In the above assays, T cells were incubated in the presence of immature DCs 
which express relatively low CD80/CD86 levels. However, these levels are 
upregulated during the course of T cell stimulation by direct contact with T 
cells and exposure to inflammatory cytokines (Banchereau and Steinman, 
1998). This upregulation of CD80/CD86 could be mimicked by exposure to 
100ng/mL LPS for 24 hours (fig. 3.4A). To check the saturation of 
CD80/CD86 levels by abatacept on both immature and LPS matured DCs, 
these cells were incubated with various abatacept concentrations. Abatacept 
binding was subsequently detected by staining for the abatacept-Fc domain 
with anti-IgG-FITC. These data showed increased anti-IgG-FITC MFI for 
mDCs compared to iDCs as expected. No substantial increase in anti-IgG-
FITC MFI was observed when mDCs were exposed to abatacept 
concentrations greater than 20μg/mL (fig. 3.4B). Together, these data 
indicate that almost maximal saturation of CD80/CD86 occurs with abatacept 
at 20μg/mL. A concentration of 20μg/mL abatacept was therefore used in 
subsequent experiments which is broadly equivalent to steady state plasma 
concentrations achieved in RA patients treated with a standard dosing 
regimen (Ma et al., 2009).  
 
Taken together, these data suggest that T cell proliferation occurring in the 
presence of abatacept was due to CD28-independent T cell activation. 
Importantly, the presence of increased relative DC numbers altered CD28-
dependency despite saturating abatacept levels and no overt change in the 
intensity of the TCR signal provided at the level of an individual TCR. This is 
indicated by the illustration in fig. 3.5.  
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Fig. 3.5. Visual representation of in vitro T cell stimulation at high vs. low DC: T 
cell ratios. An equivalent number of T cells are stimulated with an equivalent anti-
CD3 concentration but different relative DC numbers. This would be predicted to 
influence the proportion of T cells that undergo activation but not the quality of 
stimulation received on a per cell basis. 
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Fig. 3.6. T cell apoptosis is increased by stimulation at high DC:T cell ratios. 
CTV-labeled T cells were stimulated with 0.5µg/mL anti-CD3 at a DC:T cell ratio of 
either 1:5 or 1:20 and -/+ (20µg/mL) abatacept for 5 days. T cell apoptosis was 
determined by DiOC6 labeling followed by flow cytometric analysis where DiOC6
low 
cells are apoptotic. A) Flow cytometry data from one representative experiment. B) 
Data from independent experiments (n = 3) showing the % DiOC6
low T cell when 
gating on CTVlow populations. Mean values ±S.E. C) The % DiOC6
low T cells 
expressed according to CTV division number. Data points represent mean values 
±S.E.  
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3.2.3. High relative DC numbers promote T cell death 
Previous work has demonstrated increased DO11.10 T cell apoptosis when 
stimulated by high relative OVA-pulsed DC numbers. (Höpken et al., 2005). 
This resulted in a similar proliferative arrest observed in fig. 3.2A/C when T 
cells were stimulated at high DC:T cell ratios (e.g. 1:5). Therefore, the impact 
of the DC:T cell ratio on T cell death during anti-CD3 driven T cell activation 
was investigated. Following 5 days stimulation, an increasing proportion of 
divided (CTVlow) but subsequently apoptotic (DiOC6
low) T cells appeared as 
relative DC number increased (fig. 3.6A). This finding is indicative of elevated 
T cell apoptosis among proliferating T cells when stimulation was driven at 
high DC:T cell ratios reminiscent of activation induced death seen with high 
levels of TCR stimulation (Kishimoto and Sprent, 1999; Boissonnas and 
Combadiere, 2004). CD28-blockade by abatacept had a limited overall impact 
upon T cell death (fig. 3.6B). However by expressing T cell death according 
to the T cell division number, a trend was apparent whereby there was 
decreased death with the presence of abatacept treatment among T cells that 
had undergone ≥4 divisions but only at a high DC:T cell ratio (fig. 3.6C). 
However, CD28-costimulation is viewed as a pro-survival signal during T cell 
activation (Noel et al., 1996). The effect of abatacept on T cell 
survival/apoptosis is thus likely to be contextual and suggests that CD28 does 
not necessarily provide a survival signal under all stimulation conditions. 
Together, these data suggest that anti-CD3 driven T cell stimulation at 
elevated DC:T cell ratios promotes activation induced T cell death and at least 
partially underlies the reduced expansion of T cell populations under these 
conditions. 
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Fig. 3.7. Analysis of early T cell activation markers following CD28-
costimulation blockade by abatacept. CD4+CD25- T cells were stimulated with 
0.5µg/mL anti-CD3 and DCs at a ratio of 1 DC:5 T cells for 2 days. The expression 
levels of the T cell activation markers, CD69 (A), OX40 (B), ICOS (C) and PD-1 (D) 
were assessed by immunofluorescence staining and flow cytometric analysis. 
Representative flow cytometry data and mean MFI values from independent 
experiments (n = 6 for A, B and D; n = 5 for C). *p ≤0.05, two-tailed Wilcoxon-
matched pairs test.  
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Fig. 3.8. High-dose anti-CD3 promotes abatacept-resistant proliferation of T 
cells with an altered phenotype.  Activated T cells stimulated for 5 days with DCs 
(at a DC:T cell ratio of 1:5) and 0.5µg/mL anti-CD3 -/+ (20µg/mL) abatacept were 
assessed for CD25 (A), CTLA-4 (B), PD-1 (C), ICOS (D) and CD28 (D) expression 
by flow cytometric analysis. Representative data (gated only on CTVlow T cells) are 
shown as histograms and mean fluorescence intensity (MFI) values at each CTV 
division number from 8 independent experiments for which data points represent 
mean ±S.E values. p values are derived from two-way ANOVA but the main effect 
of abatacept only is represented. 
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3.2.4. Abatacept-blockade alters the expression of effector molecules on 
proliferating T cells 
Although T cell proliferation remained largely unaffected by abatacept when 
stimulating with at high DC:T cell ratios, experiments were performed to 
determine whether the absence of costimulatory signaling via CD28 affected 
the phenotype of activated T cells. The expression of various T cell effector 
molecules was therefore assessed following T cell activation with 0.5μg/mL 
anti-CD3 and DCs either with or without abatacept treatment. Initially, the 
expression of activation markers following 2 days stimulation was determined, 
which is prior to T cell proliferation. Considering there was limited impact upon 
T cell proliferation at a DC:T cell ratio of 1:5 it was unsurprising that we found 
no impact of abatacept treatment upon CD69 expression (fig. 3.7A). Whilst 
we observed limited expression levels of the TNF-superfamily member OX40 
at very early time points, this expression did appear to be inhibited by CD28-
costimulation blockade (fig. 3.7B) which is consistent with previous studies 
(Walker et al., 1999). Despite previous reports suggesting an inhibition of the 
CD28-superfamily members ICOS and PD-1 by abatacept treatment (Platt et 
al., 2010), a non-significant impact upon the expression of these molecules 
was observed following costimulation blockade at this early (2 day) time point, 
although a trend towards inhibition was observed (fig. 3.7C/D).   
 
The expression of T cell activation markers at a later stage of activation was 
also determined at 5 days following T cell proliferation. In contrast to the 
earlier time point, these experiments revealed that the expression of CD25 
was markedly reduced on T cells activated in the presence of abatacept (fig. 
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3.8A). Markers of T cell regulation were also differentially affected by 
abatacept in that the expression of CTLA-4 was inhibited (fig. 3.8B) but PD-1 
was slightly increased. Specifically, the absence of CD28-costimulation 
prevented the downregulation of PD-1 by T cells in higher division numbers 
(fig. 3.8C). At this time-point a significant inhibition of ICOS expression by 
abatacept was observed (fig. 3.8D). The levels of CD28 itself were also 
significantly higher among T cells activated in the presence of abatacept (fig. 
3.8E). Therefore whilst blockade of costimulation at a DC:T cell ratio of 1:5 did 
not stop T cell proliferation, the phenotype of proliferating T cells (gated on 
dilution of CTV) was nonetheless affected by abatacept. 
 
3.2.5. Anti-CD3 cross-linking promotes CD28-independent T cell 
activation  
In order to investigate the nature of CD28-independent T cell activation in the 
context of anti-CD3, I compared T cells activated with various CHO cell 
transfectants (as artificial APCs) in the presence of a single dose of soluble 
anti-CD3 (0.5μg/mL anti-CD3) (fig. 3.9A). As a control, T cell proliferation 
driven by anti-CD3/anti-CD28 coated beads was not suppressed by abatacept 
due to the absence of CD80/CD86 in this system. In contrast, abatacept 
strongly inhibited T cell proliferation driven by CHO-CD80, even when present 
at concentrations as low as 0.5μg/mL (fig. 3.9B). Strikingly, abatacept failed 
to suppress T cell proliferation mediated by cells expressing an Fc receptor 
(CD32) and CD80 (CHO-FcR/CD80). This transfectant model was generated 
in order to evaluate the impact of anti-CD3 crosslinking upon signal strength. 
Thus, strong anti-CD3 signaling could drive CD28-independent T cell 
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proliferation, however, in order for this signal to reach the threshold for T cell 
activation there was a requirement for FcR mediated anti-CD3 cross-linking 
between T cell and APC. As such, the potency of anti-CD3 stimulation 
appeared to be the critical factor in determining T cell activation in the 
absence of CD28-costimulation. 
 
In order to further explore the impact of anti-CD3 cross-linking upon CD28-
signal requirements, CD4+CD25- T cells were stimulated with glutaraldehyde-
fixed CHO FcR/CD80 at varying CHO:T cell ratios (fig. 3.10). These 
experiments revealed a similar effect upon abatacept sensitivity to that seen 
with DC-driven activation in that abatacept blockade became more effective 
with decreasing CHO FcR/CD80:T cell ratios. Importantly, this observation 
demonstrated that elevated CD28-requirements at low relative APC numbers 
were not the result of a specific DC effect as the APC used in this context was 
a fixed CHO transfectant cell. Rather, there appeared to be a fundamentally 
different signaling experience received by T cells at different relative APC 
numbers despite no change in the amount of TCR agonist present. 
Specifically, there appeared to be enhanced efficacy of anti-CD3 stimulation 
in the presence of high relative APC numbers such that CD28 costimulation 
was not required for T cell proliferation. One plausible concept which could 
explain such observations is that commitment of T cells to cell division may 
involve more than a single APC interaction and that the numbers of DC-T cell 
interactions within a certain time-frame is important. 
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Fig. 3.9. Anti-CD3 cross-linking promotes abatacept-resistant T cell 
proliferation. CTV-labeled T cells were stimulated -/+ (20 µg/mL) abatacept with 
anti-CD3/anti-CD28 beads or 0.5µg/mL anti-CD3 in the presence of either CHO-
CD80 or CHO-FcR/CD80 for 5 days. CTV dilution was determined by flow cytometric 
analysis. (A) Representative flow cytometry data. (B) Relative division index data 
normalized to 0µg/mL abatacept controls. Mean values ±S.E. from independent 
experiments (n = 3). 
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Fig. 3.10. Relative APC numbers influence abatacept sensitivity when T cell 
activation is driven by fixed CHO cells. CTV-labeled T cells were stimulated with 
0.5µg/mL anti-CD3 in conjunction with CHO-FcR/CD80 for 5 days. A) Representative 
flow cytometry data showing CTV dilution. B) Division index data from independent 
experiments (n = 4). Horizontal bars represent mean values. 
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Since the nature of anti-CD3 stimulation affected abatacept-sensitivity in a 
CHO cell driven T cell activation system, I wanted to determine the impact of 
directly altering the potency of anti-CD3 stimulation in DC-driven T cell 
stimulation. T cells were therefore stimulated with a variety of anti-CD3 
concentrations and in the presence of either high or low relative DC-numbers.  
Interestingly, these experiments showed that T cell activation could occur in 
response to anti-CD3 concentrations significantly lower than 500ng/mL (fig. 
3.11). Furthermore, when stimulating at a DC:T cell ratio of 1:5, T cell 
proliferation at low anti-CD3 concentrations (≤0.5ng/mL) were abatacept 
sensitive, again indicating sufficient abatacept was available in the presence 
of high DC numbers to saturate CD80/CD86 expression levels (fig. 3.11A/B). 
In contrast, stimulation at higher anti-CD3 concentrations was abatacept-
resistant. As such, we identified statistically significant interaction effects 
between anti-CD3 concentration and abatacept upon both T cell division index 
and actual T cell counts (fig. 3.11B). This confirmed that the effect of 
abatacept was dependent upon anti-CD3 concentration at this DC:T cell ratio. 
In contrast, T cell proliferation driven by low relative DC numbers (1DC:20 T 
cells) was abatacept sensitive regardless of anti-CD3 concentration (fig. 
3.11C). Together, these data strongly suggest that the efficacy of CD28-
blockade by abatacept is dependent upon the strength of TCR-stimulation, 
and that stimulation at high relative DC numbers in some way enhances the 
potency of anti-CD3 driven stimulation such that significant T cell proliferation 
can occur in the absence of CD28-costimulation. 
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Fig. 3.11. Efficacy of CD28-blockade by abatacept is dependent upon the 
strength of TCR-stimulation.  CTV-labeled T cells were co-cultured with DCs at a 
DC:T cell ratio of 1:5 or 1:20 and stimulated with indicated anti-CD3 concentrations 
for 5 days. A) Representative flow cytometry showing CTV dilution for T cells 
stimulated at DC:T cell ratio of 1:5. Division index values and CTVlow T cell counts are 
shown for T cell stimulations driven at a DC:T cell ratio of 1:5 (B) and 1:20 (C) from 
multiple independent experiments (n = 8 for 1 DC:5 T cells, n = 5 for 1 DC:20 T cells). 
Data points represent mean values ±S.E. p values are derived from two-way ANOVA. 
Further analyses was performed using paired, two-tailed t tests; *p ≤0.05 **p ≤0.01, 
***p ≤0.001.  
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Fig. 3.12. Naïve and Memory T cells have distinct CD28-costimulation thresholds. 
A) CD4+CD25- were separated into naïve and memory populations based upon 
CD45RA+ for naïve T cells and CD45RO+ for memory T cells. B) Representative flow 
cytometry data showing CTV dilution following naïve and memory T cell stimulation with 
various anti-CD3 concentration and DCs at a ratio of 1 DC:5 T cells for 5 days. C) 
Relative division index values where abatacept treated samples are normalized to 
untreated controls (n = 4). Data points represent mean values ±S.E. 
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Fig. 3.13. Naïve T cells display a tendency towards reduced proliferation when 
stimulated at low DC:T cell ratios. CTV-labeled CD4+CD45RA+ naïve T cells and 
CD4+CD45RO+ memory T cells were stimulated with 0.5µg/mL anti-CD3 and DCs at a 
DC:T cell ratio of 1:5 or 1:20. Representative flow cytometry data and data from 
multiple experiments (n = 3) where division index values from stimulation at a ratio of 
1 DC:20 T cells are normalized to 1DC:5 T cell stimulations. Data points represent 
mean values ±S.E. 
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3.2.6. Naïve and Memory T cells have distinct CD28-costimulation 
thresholds.  
Evidence suggesting that abatacept-sensitivity during in vitro T cell stimulation 
was determined by the strength of TCR stimulus was obtained by stimulation 
of a CD4+CD25- population where the relative proportions of naïve and 
memory T cells varied between donors. We therefore compared the impact of 
abatacept upon purified naïve and memory T cell populations separately, 
since naïve T cells are known to display different activation thresholds 
(Rogers et al., 2000). These populations were purified on the basis of 
differential CD45 isoform expression where naïve T cells are 
CD45RA+CD45RO- and memory T cells are CD45RA-CD45RO+ (fig. 3.12A). 
Consistent with published data (Croft et al., 1994; London et al., 2000), we 
found that memory T cell proliferation was more abatacept-resistant than that 
of naive T cells when stimulation was driven by high anti-CD3 concentrations, 
however, memory T cell proliferation became abatacept sensitive at low anti-
CD3 concentrations (fig. 3.12B/C). Interestingly, a pattern was observed 
whereby there was a relative increase in naïve T cell proliferation in the 
presence of abatacept at intermediate anti-CD3 concentrations (5ng/mL anti-
CD3) relative to higher concentrations (fig 3.12B/C). The factors underlying 
this effect are unclear but these data demonstrate that the intensity of anti-
CD3 stimulation affects the CD28-costimulation requirements of both naïve 
and memory T cells although the nature of this impact appears to differ.  
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Fig. 3.14. Cyclosporin A in combination with abatacept inhibits CHO FcR/CD80 
driven T cell stimulation. CTV-labeled T cells were stimulated with glutaraldehyde 
fixed 0.5µg/mL anti-CD3 with various CsA concentrations and 20µg/mL abatacept for 5 
days. CTV dilution was determined by flow cytometric analysis. Representative flow 
cytometry data and mean division index data ±S.E. from multiple independent 
experiments (n = 4).  
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Having assessed the impact of varying the anti-CD3 concentration on 
abatacept sensitivity, we then determined the impact of varying DC numbers 
on naïve and memory T cell stimulation. These data suggest that the 
proliferative response of naïve T cells was inhibited by stimulation at lower 
DC:T cells (1 DC:20 T cells; fig. 3.13). Whilst the response of memory T cells 
was also inhibited this did not appear to occur to the same extent. Further 
experiments are required for appropriate statistical analysis of these trends. 
Nevertheless, these data appear to support the concept that naïve T cells 
have a higher activation threshold than memory T cells and that this can be 
achieved through the provision of CD28-costimulation, high anti-CD3 
concentration or stimulation by high relative DC numbers. 
 
3.2.7. Abatacept-resistant T cell proliferation is CsA-sensitive 
The calcineurin inhibitor, CsA acts to inhibit NFAT translocation to the nucleus 
(Matsuda and Koyasu, 2000) and acting in this manner has been defined as a 
TCR-specific inhibitor of T cell activation (Geginat et al., 2000). In contrast, 
CD28-drives CsA-resistant T cell activation (June et al., 1987).  T cells were 
therefore activated in the presence of CsA and abatacept in order to further 
explore the interplay between TCR and CD28 driven signals. To verify this 
approach we initially activated T cells using fixed CHO-FcR/CD80 cells. 
These data demonstrate that the presence of CsA, even at low concentrations 
(0.025μg mL), attenuates abatacept-resistant T cell proliferation under these 
conditions (fig. 3.14). These data suggest that targeting TCR-stimulation (e.g. 
using CsA) promotes the efficacy of CD28-costimulation blockade by 
abatacept. 
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Fig. 3.15. Cyclosporin A and abatacept act in synergistic manner to inhibit T cell 
proliferation. CTV-labeled T cells were co-cultured with DCs at indicated DC:T cell 
ratios and stimulated with 0.5µg/mL anti-CD3 with various CsA concentrations and 
20µg/mL abatacept where indicated for 5 days. CTV dilution was determined by flow 
cytometric analysis. A) Representative flow cytometry data. B) Mean division index 
data ±S.E. from multiple independent experiments (n = 3).  
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In order to explore the interaction between strength of TCR-stimulation and 
relative DC numbers, T cells were again stimulated in the presence of both 
CsA and abatacept using DCs as the APCs. As with CHO-FcR/CD80-driven 
stimulation, the combination of CsA and abatacept inhibited DC mediated T 
cell proliferation to a greater extent than with abatacept alone (e.g. compare 
red traces 0.025μg/mL CsA vs. 0μg/mL CsA fig. 3.15A). This effect was 
observed at all DC:T cell ratios tested. However, the CsA concentration 
required to entirely inhibit T cell proliferation was higher at elevated DC:T cell 
ratios (e.g. see blue traces 0.025μg/mL CsA; fig. 3.15A). This suggests that 
at high DC:T cell ratios, TCR signaling is more potent, more CsA-resistant 
and more CD28-independent. These data also demonstrate the extent to 
which the inhibition by CsA treatment alone was influenced by the DC:T cell 
ratio (e.g. compare solid lines between different DC:T cell ratios fig. 3.15B). 
For instance, when stimulated at a DC:T cell of 1:40, an inhibition of T cell 
proliferation occurred in response to low CsA concentrations alone (≥ 0.1 
μg/mL CsA). In contrast, at a ratio of 1:5, T cell proliferation still occurred at 
the highest CsA concentrations tested (fig. 3.15A/B). It has been suggested 
that costimulatory signaling underlies this CsA-resistant T cell activation 
(Geginat et al., 2000). Therefore, CD28-dependent T cell proliferation also 
appeared to occur more effectively at high DC:T cell ratios.  
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Fig. 3.16. Antigen-independent TCR downregulation tends to be increased when 
T cell stimulation is mediated by high relative DC numbers. CTV-labeled T cells 
were co-cultured with anti-CD3 and DCs. vβ2 TCR expression levels were 
determined by immunofluorescence staining followed by flow cytometric analysis. A) 
T cells were stimulated with indicated anti-CD3 concentrations at a DC:T cell ratio of 
1:5 for 5 days. Data points represent mean values ±S.E. from independent 
experiments (n = 3). B) T cells were stimulated with 0.5µg/mL anti-CD3 at a DC:T cell 
ratio of 1:5 or 1:20, -/+ 20µg/mL abatacept for 5 days. Representative flow cytometry 
data and combined data showing vβ2 TCR MFI (gated on CTVlow T cells) from 
independent experiments (n = 5).    
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3.2.8. T cell stimulation at high DC:T cell ratios promotes TCR-
downregulation 
The extent of TCR downregulation following stimulation has been identified as 
a putative marker of the strength of TCR stimulus (Monjas et al., 2004). TCR-
downregulation can occur as a result of endocytosis following TCR-ligation. 
Alternatively, protein tyrosine kinase dependent signals prompt 
downregulation of non-engaged TCRs (San José et al., 2000; Monjas et al., 
2004). Since it seemed that T cell activation at high DC:T cell ratios altered 
the intensity of T cell activation signals I wanted to determine whether 
differences in TCR downregulation could be detected between different DC:T 
cell ratios. To determine the validity of this approach T cells were stimulated 
at a DC:T cell ratio of 1:5 but with different anti-CD3 concentrations to 
manipulate TCR signals and measured the surface expression of vβ2+ TCRs 
as a proxy for all TCRs. These data demonstrated that by increasing anti-CD3 
concentration the surface expression of vβ2 TCRs tended to be reduced, 
indicating that TCR downregulation maybe promoted by high intensity anti-
CD3 stimulation (fig. 3.16A). Furthermore, downregulation of vβ2 TCR 
surface expression levels following stimulation at low DC:T cell ratios (1DC:20 
T cell) appeared to be less compared to a higher (1DC:5 T cell) ratio (fig. 
3.16B), however, additional experiments are required for appropriate 
statistical analysis of this trend.  These differences did not appear particularly 
robust which may be due to the lack of direct TCR-engagement during anti-
CD3 driven stimulation. However, the trend did support the conclusion that 
stimulation at high DC:T cell ratios enhances the intensity of T cell activation 
signals. 
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Fig. 3.17. Superantigen affinity, concentration and relative DC numbers 
determine T cell CD28-requirements. CTV-labeled T cells were stimulated with 
various TSST-1 concentrations and DCs -/+ (20µg/mL) abatacept for 5 days. vβ2 TCR 
expression levels were determined by immunofluorescence staining followed by flow 
cytometric analysis. A) Representative flow cytometry data. B) Mean division index 
values for CD4+vβ2- T cells. Data points represent mean values ±S.E. from 
independent experiments (n = 7). C) Mean division index values for CD4+vβ2+ T cells. 
Data points represent mean values ±S.E. from independent experiments (n = 7). D) 
vβ2 TCR expression levels were determined in T cells stimulated at a DC:T cell ratio 
of 1:5 compared to 1:20 and expressed as MFI. Data points represent mean values 
±S.E. from independent experiments (n = 7). p values are derived from two-way 
ANOVA. Further analyses was performed using paired, two-tailed t tests; ns not 
significant *p ≤0.05 **p ≤0.01. 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
1.05 9.42
76.812.7
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.62 9.94
83.55.94
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.58 10.1
84.44.89
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.34 10.7
86.22.82
0
 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
8.98 5.86
79.65.61
97 
 
3.2.9. DC:T cell ratio influences T cell activation thresholds in 
superantigen-driven T cell activation 
To further explore the interaction between TCR stimulus strength and CD28-
costimulation requirements and to ensure that the impact of DC:T cell upon 
abatacept-sensitivity was not an artifact of anti-CD3 stimulation, T cells were 
stimulated with the staphylococcal superantigen TSST-1. TSST-1 facilitates 
simultaneous interaction between TCRs that contain the vβ2 domain and 
MHC-II molecules (Li et al., 1999). Therefore, this model allowed us to alter 
parameters that affect the intensity of TCR-stimulation in the context of 
different DC:T cell ratios using a system other than anti-CD3 crosslinking. 
Results from these experiments further supported the hypothesis that strong 
TCR stimulation overcomes CD28-requirements. Firstly, at higher TSST-1 
concentrations, the induction of T cell activation by TSST-1 was less restricted 
to vβ2+ T cell responders since lower affinity vβ2- T cells also proliferated (fig. 
3.17A/B). However, whilst abatacept did not affect the proliferation of vβ2+ T 
cells at this high dose of TSST-1, proliferation of vβ2- T cells was inhibited by 
abatacept and was therefore CD28-dependent (e.g. 2.5ng/mL TSST-1 fig. 
3.17A). Thus, CD28-costimulation was required to support T cell proliferation 
in association with low affinity TCR-engagement but was not necessarily 
required by high affinity TCRs. Similar to observations with anti-CD3 
stimulation, abatacept had no impact upon vβ2+ T cell proliferation in 
response to high TSST-1 concentrations (≥0.25ng/mL TSST-1), however, at 
low TSST-1 concentrations stimulations became abatacept-sensitive (fig. 
3.17A/C). Therefore, CD28-costimulation also drives T cell proliferation when 
superantigen is at low concentration. Importantly, vβ2+ T cell proliferation 
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became abatacept sensitive at ten-fold higher TSST-1 concentration when 
stimulating with a DC:T cell ratio of 1:20 compared to a 1:5 ratio (fig. 3.17C). 
This suggests that high DC:T cell ratios can compensate for reduced antigen-
load by enhancing the potency of TCR-driven stimulation. In support of this, 
greater vβ2 TCR downregulation was apparent when stimulating with high 
TSST-1 concentrations in 1:5 instead of 1:20 DC:T cell co-cultures (fig. 
3.17A/D). Since TCR downregulation broadly correlates with strength of 
stimulation, these data provide further evidence that increasing the DC:T cell 
ratio promotes the delivery of T cell activation signals that facilitate CD28-
independent T cell proliferation. 
 
3.3. Discussion 
As the predominant source of T cell costimulation, CD28-signaling enhances 
the generation of T cell effector populations via effects upon proliferation, 
survival and differentiation (Boomer and Green, 2010). Blocking this signal 
using abatacept is effective for the treatment of several T cell related diseases 
(Linsley and Nadler, 2009). However, responses to treatment are variable and 
suboptimal in a large proportion of patients. Therefore, the identification of 
factors that influence treatment responses along with the development of 
approaches to enhance responsiveness is an important clinical challenge.  
 
The blockade of T cell activation by abatacept is dependent upon the extent to 
which CD28 contributes to T cell activation. However, the fact that T cell 
responses can occur in the absence of CD28-costimulation has been 
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demonstrated in CD28-knock out (KO) mouse models. In these models, in 
vitro T cell responses to concanavalin A, anti-CD3 and alloantigen were 
impaired but not entirely absent (Shahinian et al., 1993; Green et al., 1994). 
Interestingly, in vivo humoral responses were also highly defective (Shahinian 
et al., 1993) consistent with a role for CD28 in the development of T follicular 
helper cell differentiation (Platt et al., 2010). In contrast, T cell mediated 
immune responses to lymphocytic choriomeningitis virus which is widely 
regarded as a strong antigenic stimulus were normal (Shahinian et al., 1993). 
CD28-KO T cells are also capable of mediating both skin allograft rejection 
(Kawai et al., 1996), acute lethal graft-versus-host disease (Speiser et al., 
1997) and diabetogenic responses in NOD mice (Lenschow et al., 1996). 
Thus T cell mediated immunity persists in a CD28-deficient environment.  
 
T cell activation in CD28-knock out models has been found to be dependent 
upon the strength (Bachmann et al., 1996) and duration (Kündig et al., 1996) 
of TCR stimulation. This suggests that strong TCR-stimulation can 
compensate for a deficit of CD28-costimulation. Consistent with this concept, 
we have found that in the context of in vitro T cell activation, factors that 
increase the strength of TCR signaling can override T cell CD28-requirements 
and therefore promote abatacept-resistance. For example, we found that 
abatacept robustly inhibited T cell proliferation driven by soluble anti-CD3 and 
CHO-CD80 cells, in contrast, cross-linked anti-CD3 (at the same dose) 
mediated by CHO-FcR/CD80 promoted abatacept resistant T cell activation. 
Additionally, as a specific inhibitor of TCR signaling events (Geginat et al., 
2000), we found that the combination of CsA and CD28-costimulation 
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blockade by abatacept synergize to potently suppress T cell activation, 
indicating that reducing TCR signaling increases abatacept responsiveness. 
Similarly, while responses to TSST-1 by high affinity T cells (vβ2+ TCR) were 
abatacept-resistant and therefore did not depend upon CD28 costimulation, 
proliferation became increasingly CD28-dependent at lower TSST-1 
concentrations. Interestingly, we also observed T cell proliferation by cells 
expressing low affinity (vβ2-) TCRs, however, this was abatacept-sensitive 
and therefore CD28-dependent, even at high TSST-1 concentrations. 
Together these data make a clear case for the intensity of TCR signaling 
affecting abatacept sensitivity. 
 
In keeping with previous observations, we have found that naïve T cells 
display greater CD28-requirements in comparison to memory T cells. These 
differences are associated with the reduced threshold for memory T cell 
activation that underlies the generation of rapid and robust secondary 
responses to antigen (Farber, 2009). Interestingly, distinct differences in TCR 
signal transduction between naïve and memory T cells have been observed 
wherein the magnitude of downstream TCR signals are enhanced in memory 
relative to naïve T cells (Kalland et al., 2011). These differences may reflect 
elevated expression levels or function of TCR-signaling mediators such as 
Zap-70 (Chandok et al., 2007), NFAT (Dienz et al., 2007), PLC-γ1 (vonEssen 
et al., 2010) or PKC-θ (vonEssen et al., 2013). Similarly, memory T cells 
express higher levels of adhesion molecules that promote the stability of 
interactions with APCs in memory compared to naïve T cell subsets (Sanders 
et al., 1988; Buckle and Hogg, 1990; Hamann et al., 1997). Several studies 
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have suggested differences between the impact of distinct CD45 isoforms that 
define naïve and memory subsets upon TCR signaling pathways (Novak et 
al., 1994; McKenney et al., 1995; Leitenberg et al., 1996). Additionally, more 
substantial lipid rafts with a greater content of TCRs and proximal signaling 
molecules within the plasma membrane of memory compared to naïve CD8+ 
T cells has been suggested to enhance the magnitude of downstream TCR 
signaling upon antigen exposure (Kersh et al., 2003). Together these 
differences favor TCR-driven responses in memory T cells and would appear 
to promote CD28-independent responses that are not inhibited by abatacept. 
Nonetheless it is probably the case that memory T cells are still costimulation 
sensitive albeit over a different dose range of TCR stimulation compared with 
naïve T cells. 
 
These results demonstrate that robust TCR stimulation can overcome a 
deficiency of CD28-costimulation and vice versa. Therefore factors that 
promote TCR driven responses such as increased antigen density or affinity 
or memory/naïve status promote CD28-independent T cell responses. 
Nonetheless, CD28-signaling does appear to impact T cell differentiation. I 
have shown that an absence of costimulation modifies the expression of 
markers of effector function by activated T cells including an inhibition of pro-
regulatory outcomes. These data therefore support the concept that TCR and 
CD28 cooperate towards a combined activation threshold (Acuto and Michel, 
2003). There is a clear biological basis for the idea that CD28 acts a 
quantitative support to TCR stimulation in that there is a significant degree of 
overlap between TCR and CD28 signaling mediators. A substantial function of 
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CD28 engagement appears to be the amplification of TCR signaling pathways 
(Michel et al., 2000; 2001; Holdorf et al., 2002) which may underlie the 
reduced TCR signaling threshold for T cell activation that occurs in the 
presence of costimulation (Viola and Lanzavecchia, 1996). Furthermore, the 
analysis of gene expression following CD28 engagement alone shows 
significant overlap to that induced by TCR-stimulated cells (Diehn et al., 2002; 
Riley et al., 2002; Wakamatsu et al., 2013). Nonetheless, the relative 
resistance of CD28-signaling to CsA as well as phenotypic changes supports 
the possibility that some CD28 signals are unique. 
 
An interesting observation reported here is that the number of antigen 
presenting cells influences the strength of TCR signaling. Accordingly this 
affects the requirement for CD28-costimulation and ultimately abatacept 
sensitivity. Whilst it is easy to appreciate that the number of APCs may 
influence the actual number of T cells that become stimulated (see fig. 3.5.), it 
is less obvious why the intensity of TCR signals should change with APC 
number. In particular why do higher numbers of APC appear to enhance TCR 
pathway stimulation as seen by TCR downregulation, sensitivity to CsA and 
resistance to abatacept?   
 
In simplistic terms, T cell activation occurs as the result of the integration of 
TCR and costimulatory signals following interactions with APCs. Generally, 
this has been thought to arise as the result of a productive interaction 
between a T cell and an APC presenting cognate antigen. Such interactions 
occur as T cells scan the surface of DCs for cognate antigen:MHC complexes 
103 
 
in an antigen-independent manner that utilizes interaction between ICAM-3 
with DC-specific ICAM-3 grabbing non-integrin (DC-SIGN) (Montoya et al., 
2002). High affinity interactions between pMHC and TCR subsequently 
produce threshold signaling events and the generation of a TCR “stop signal” 
which is largely mediated by conformational changes in T cell LFA-1 (Dustin 
and Springer, 1989; Dustin et al., 1997). However, cognate interactions 
between T cells and APCs within a 3D collagen matrix were characterized by 
transient encounters that nevertheless support activation signaling (Gunzer et 
al., 2000). These results prompted a new paradigm for T cell priming in which 
activation thresholds can be achieved by the summation of multiple, sub 
threshold interactions rather than as a result of a single “all or nothing” 
signaling event (Friedl and Gunzer, 2001).  
 
This concept of sequential interactions between APC and T cell during 
priming has been supported using in vivo mouse models in which T cell 
interactions with APCs are visualized within lymphoid tissue using multi-
photon microscopy. These studies have led to the characterization of a multi-
phase process (Mempel et al., 2004) whereby T cells encountering cognate 
antigen initially assume transient contacts with APCs for around 8 hours 
which resemble non-specific interactions with APCs. However, these 
interactions lead to CD69 upregulation and support the transition towards a 
phase (lasting ~12 hours) that is characterized by more stable APC:T cell 
interactions. The transition to these stable interactions is essential to the 
generation of effective CD4+ T cell responses (Celli et al., 2007). The 
dynamics associated with this progression from sequential to more stable 
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contacts between T cells and APCs are modified by various factors including 
APC maturation state (Hugues et al., 2004; Mittelbrunn et al., 2009) and the 
activity of Treg (Tang et al., 2006; Tadokoro et al., 2006). Crucially, elevated 
antigen dose (Henrickson et al., 2008) or TCR-affinity (Skokos et al., 2007) 
decreases the duration of phase one and facilitates the transition to more 
stable APC:T cell interaction. This implies that the number of interactions 
required to meet activation thresholds are decreased if T cells can accumulate 
TCR signals more effectively from serial contacts. 
 
Our results suggest that a serial encounter model for T cell activation can 
modify T cell CD28-requirements due to the interactive nature between TCR 
and costimulatory signaling. We find that in vitro T cell activation driven by 
soluble anti-CD3 and allogeneic T cells becomes increasingly CD28-
dependent as DC:T cell ratios are reduced. This observation cannot be 
explained by a mechanism of T cell activation in which stimulatory signals are 
delivered by a single encounter between DC and T cell. Such a concept would 
only account for a change in the proportion of T cells that are activated in 
response to different relative DC numbers, i.e. more DC should support the 
priming of more T cells but not change the quality of the TCR signal. Instead, 
we observe increased potency of anti-CD3 stimulation in the presence of high 
relative DC numbers (thereby reducing abatacept efficacy) which strongly 
suggests that T cells integrate anti-CD3 driven activation signals as a result of 
multiple interactions with DCs. Importantly, the influence of the DC:T cell ratio 
upon CD28-requirements was not restricted to stimulation driven by anti-CD3 
but was also apparent in superantigen-driven activation and seen using a 
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fixed transfectant model. Accordingly, we found that T cell responses to 
TSST-1 became abatacept sensitive at a 10 fold higher TSST-1 concentration 
when stimulating at a DC:T cell of 1:5 compared to 1:20. Furthermore, as a 
putative marker of T cell stimulus strength, we observed more significant 
TCR-downregulation associated with high- compared to low-relative DC 
numbers. Given that we observed the same effects using FcR/CD80 
transfected cells, this effect of APC number influencing TCR potency is not 
restricted to DCs but is a general feature of the number of APCs. 
 
The frequency of interactions between APC and T cell during activation may 
act to modify the signaling experience of T cells in at two least ways. Firstly, 
the accumulation of signals between successive APC interactions may 
directly influence signal intensity. The summation of TCR-signals from 
multiple DC interactions imposes a requirement for T cell “memory” of 
previous interactions. It has been proposed that this memory is analogous to 
the temporal summation of presynaptic potentials into the magnitude of 
postsynaptic potentials in neuronal cell activation (Rachmilewitz and 
Lanzavecchia, 2002). It has been found that a proportion of naïve T cells 
progress from G0 to the G1 phase of the cell cycle but remain undivided 
following short term, sub threshold periods of stimulation. These cells 
subsequently respond to a second sub-threshold period of stimulation 
whereas cells that remained in G0 following the primary stimulation did not. 
Therefore, T cells that enter G1 integrate multiple sub-threshold stimulations in 
order to reach the threshold to for proliferation (Munitic et al., 2005).  
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A mechanism has been identified whereby T cells may ‘remember’ signals 
from previous APC interactions through the temporal dynamics that are 
associated with NFAT translocation to the nucleus following TCR signaling 
(Marangoni et al., 2013) – whilst NFAT import occurs rapidly, export from the 
nucleus is much slower, such that sequential interactions can trigger NFAT 
translocation when a signal has not yet entirely resolved from a previous 
interaction. The result is an incremental rise in NFAT translocation between 
DC:T cell interactions which acts to propagate the outcome of TCR signaling. 
Similarly, transient TCR signals facilitate the upregulation and phosphorylation 
of the AP-1 component cFos, importantly, the active cFos levels remain 
elevated for at least 24 hours following this suboptimal TCR stimulation 
thereby reducing the activation threshold for subsequent TCR-signals (Clark 
et al., 2011).  
 
In the context of results presented in this study, DC:T cell contacts are 
frequent in the presence of high relative DC numbers which could allow for an 
overlap between sub threshold signaling events that arise as a result of serial 
interactions. The summation of these events ultimately meets T cell activation 
thresholds, even in the absence of costimulation. In contrast, during T cell 
activation at low DC:T cell ratios, contacts between DC and T cell are rare to 
an extent that does not facilitate summation of TCR signaling within an 
appropriate time frame (Celli et al., 2005). As such, T cell activation becomes 
more dependent upon CD28-costimulation.  
 
The reduction in CD28-costimulation requirements at high DC:T cell has 
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implications not only for the inhibition of T cell responses by abatacept but 
also for CTLA-4 mediated control of T cell activation in immune regulation by 
trans-endocytosis of CD80 and CD86 (Qureshi et al., 2011). In this way, 
CTLA-4 is essential to the activity of FoxP3+ Treg which modify the availability 
of CD28-costimulation below a threshold level that is inhibitory to the initiation 
of autoimmune responses under tolerogenic conditions (Wing et al., 2008). 
Similarly, conventional T cells express CTLA-4 and regulate T cell activation 
in a cell-extrinsic manner (Corse and Allison, 2012; Wang et al., 2012), 
potentially via a feedback mechanism whereby T cells reduce the stimulatory 
capacity of APCs to promote the resolution of a response. Elevated relative 
APC numbers within a system can serve to inhibit CTLA-4 mediated 
suppression of T cell activation in at least two ways. Firstly, the corresponding 
increase in CD80/CD86 levels serves to increase the availability of CD28-
costimulation to T cells within the system and therefore the amount of CTLA-4 
mediated trans-endocytosis that is required to inhibit T cell activation (Hou et 
al., 2015). Secondly, as shown here, due to the facilitation of TCR stimulation 
in the presence of high relative DC numbers, T cell activation can occur 
independent of CD28 and is therefore outside the control of CTLA-4. Under 
such conditions, inhibition of T cell activation mediated by PD-1 may become 
more important to immune regulation as this has been found to target early 
TCR signaling events (Sheppard et al., 2004; Yokosuka et al., 2012; Wei et 
al., 2013).  
 
An important consideration in relation to this work is the extent to which these 
observations are translated to T cell priming during in vivo stimulation. Indeed, 
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several factors add extra layers of complexity to the impact of DC:T cell ratios 
upon in vivo T cell priming within lymphoid tissue. For example, lymphoid 
architecture is maintained in vivo in such a way that maximizes cellular 
interactions. This occurs to the extent that a single DC may contact as many 
5000 T cells per hour (Miller et al., 2004).  As such the capacity for T cells to 
integrate signals from multiple DCs in vivo is extensive. Despite this, high 
affinity interactions between TCR and cognate antigen are rare within the 
lymph node. As such, many interactions between T cells and DCs may 
appear non-productive. Nevertheless, these low-affinity interactions have 
been found to be crucial to antigen responsiveness by generating ‘basal 
activation’ among T cells that facilitates subsequent responses to stimulation 
(Stefanová et al., 2002; Contento et al., 2010; Römer et al., 2011). These 
lines of evidence suggest that the frequency of DC:T cell interactions may 
modify T cell activation thresholds during both in vivo and in vitro stimulation.  
 
These lines of evidence demonstrate that an important future direction is to 
test how these factors affect the extent to which DC:T cell ratios affect 
costimulation requirements using in vivo models. For example, a mouse 
model of DC depletion has been reported in which CD11c+ express the 
diphtheria toxin receptor and are deleted upon administration of diphtheria 
toxin (Hochweller et al., 2010). T cells derived from mice depleted of DCs are 
characterized by impaired TCR signaling and immune synapse formation 
upon exposure to cognate antigen in vitro. This model could be utilized with a 
mixed bone marrow chimera approach to delete different relative numbers of 
DCs in order to determine the impact of DC:T cell ratio upon costimulation 
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requirements.  Similarly, Henrickson, et al. utilized an adoptive cell transfer 
approach in which different relative numbers of AG-pulsed DCs were 
transferred to recipient mice in order to test the impact of lymph node APC 
density upon parameters of T cell activation (Henrickson et al., 2008). An 
alternative approach to these experiments would be to change the number of 
Ag specific T cells relative to fixed DC numbers. In relation to this, bone 
marrow chimeras between Recombination-activating gene (RAG)-2 deficient 
and TCR transgenic mice have been generated which display variable 
frequency of Ag-specific T cells (Laouar and Crispe, 2000).  
 
Overall, the results presented in this chapter demonstrate a mechanism 
whereby TCR stimulus strength is determined by the initial DC:T cell ratio at 
which T cells are activated such that in the presence of high DC numbers, T 
cell activation can occur independently of CD28-costimulation. This 
observation suggests that the relative availability of local APCs acts as 
environmental cue that changes the signaling experience delivered during T 
cell priming. This has clear implications for the use of abatacept in the 
treatment of T cell mediated diseases. Additionally, these observations are 
important to the interpretation of results of experiments in which T cells have 
been stimulated in vitro. For example, Davis, et al. demonstrated robust 
suppression by abatacept of allogeneic DC-driven T cell activation at a DC:T 
cell ratio of 1:50 (Davis et al., 2008). However, our results suggest that any 
such suppression is context specific and depends strongly upon the DC:T cell 
ratio at which T cell stimulation is induced.   
 
110 
 
 
Chapter 4: 1,25(OH)2D3 promotes the efficacy of 
CD28-costimulation blockade by abatacept 
 
4.1. Introduction 
The extent to which CD28-blockade by abatacept inhibits T cell activation is 
dependent upon the capacity for other stimulatory pathways to compensate 
for the absence of CD28-signals. However, studies of CD28-KO mice suggest 
that although T cell responses are impaired they are not entirely absent As 
such, a lack of efficacy associated with CD28-blockade in therapy, for 
example in the treatment of RA or in immunosuppression following renal 
transplantation, may be expected in some situations where T cell stimulation 
is driven by non-CD28 signals. Consistent with this, an improvement in the 
outcome of T cell responses following costimulation blockade has been 
identified by combining CTLA-4-ig with other immunomodulatory agent. For 
example, interruption of the CD40:CD154 pathway in association with CTLA-
4-ig therapy results in the synergistic enhancement of allograft survival in both 
murine and non-human primate transplantation models (Gilson et al., 2009; 
Badell et al., 2012). Administration of alefacept, a CD2 specific fusion protein 
(leukocyte function-associated antigen (LFA)-3-ig) led to memory T cell 
depletion and promoted renal allograft survival in a non-human primates 
following abatacept treatment (Weaver et al., 2009).  Likewise, belatacept in 
combination with the mTOR inhibitor sirolimus promoted allograft survival to a 
greater extent than with belatacept therapy alone (Lo et al., 2013). These 
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studies challenge the perspective of CD28 as a fundamental requirement for 
T cell activation. As such, evidence suggests that optimal responses to CD28-
blockade require its combination with other immunomodulatory agents. 
 
It has been argued that CD28-signaling acts as a quantitative support to TCR 
stimulation (Acuto and Michel, 2003), i.e. that the relative absence of TCR-
signals can be compensated for by a predominantly CD28-driven response. In 
support of this, results from chapter 3 suggest that substantial T cell activation 
can occur in the presence of abatacept treatment using in vitro assays and 
that this activation is associated with the potency of TCR-stimulation.  
Furthermore, a combination of CsA (which essentially targets the productivity 
of TCR-signaling) and CTLA-4-ig led to potent suppression of T cell activation 
above the level of suppression seen by CsA or abatacept alone (Geginat et 
al., 2000). 
 
Results in this chapter suggest that the active form of vitamin D3, 
1,25(OH)2D3, acts in a similar manner to CsA by acting directly upon T cells to 
inhibit TCR-driven stimulation in the absence of costimulation.  Thus, by 
increasing reliance on CD28-costimulation, 1,25(OH)2D3 renders T cell 
responses more abatacept-sensitive. These data suggest that vitamin D3 
supplementation may be a simple approach to improve outcomes of CD28-
blockade in treatment for patients with T cell mediated inflammatory diseases. 
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Fig. 4.1. 1,25(OH)2D3 increases the suppression of T cell proliferation by 
abatacept. CTV labeled CD4+CD25- were incubated with 500ng/mL anti-CD3 and 
allogeneic DCs with or without 20µg/mL abatacept and 10nM 1,25(OH)2D3 for 5 days. 
A) Flow cytometric data showing CTV dilution from one representative experiment. 
Combined data from independent experiments expressed as either division index 
values or total numbers of proliferating (CTVlow) T cells for stimulations at a DC:T cell 
ratio of 1:5 (B) or 1:20 (C). Horizontal bars represent mean values. p values are 
derived from two-way ANOVA. Further analyses were performed using paired, two-
tailed t tests where **p ≤0.01, ***p ≤0.001.  
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4.2. Results 
4.2.1. 1,25(OH)2D3 enhances the efficacy of abatacept via a T cell 
intrinsic mechanism 
Previous studies have identified effects of 1,25(OH)2D3, upon CD4
+ T cell 
activation and differentiation (Peelen et al., 2011). I determined how 
1,25(OH)2D3 affected the inhibition of T cell responses by abatacept. 
Interestingly, the combination of 1,25(OH)2D3  and abatacept inhibited T cell 
proliferation to a greater extent than was observed with abatacept alone  (fig. 
4.1A). Two-way ANOVA analysis of T cell proliferation data from multiple 
donors where T cell activation was driven at a DC:T cell ratio of 1:5 data 
demonstrated a non-significant interaction effect between 1,25(OH)2D3 and 
abatacept; however, significant overall effects were observed for both agents 
(fig. 4.1B). These observations suggest that 1,25(OH)2D3 and abatacept 
combine to suppress T cell proliferation through an additive rather than a 
synergistic effect under these conditions. The combination of 1,25(OH)2D3 
with abatacept almost entirely inhibited T cell proliferation where T cell 
proliferation was driven at a lower DC:T cell ratio (1DC:20 T cells; fig 4.1A/C). 
However, under these conditions, abatacept alone robustly inhibited T cell 
proliferation, which was considered to occur due to reduced potency of anti-
CD3 signaling as suggested by data in chapter 3 of this thesis fig 4.1C. 
Together, these data suggested that 1,25(OH)2D3 supplementation enhances 
the efficacy of abatacept treatment and that the cooperation is more beneficial 
at higher DC:T cell ratios where the strength of TCR stimulation is higher. 
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Fig. 4.2.  Abatacept in conjunction with 1,25(OH)2D3 does not influence T cell 
apoptosis. CTV-labeled CD4+ CD25- were activated with 0.5µg/mL anti-CD3 and 
DCs at a ratio of 1 DC:5 T cells in association with 20µg/mL abatacept and 10nM 
1,25(OH)2D3 for 5 days. Activated T cells were stained with DiOC6 and analysed by 
flow cytometry with DiOC6
low cells representing apoptotic cells. Representative flow 
cytometry data and mean ±S.E values values from independent experiments (n=3). 
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Fig. 4.3. 1,25(OH)2D3 increases the suppression of T cell proliferation by 
abatacept via a T cell intrinsic mechanism. CTV labeled CD4+CD25- were 
incubated with 500ng/mL anti-CD3 and glutaraldehyde fixed CHO-FcR/CD80 with or 
without 20µg/mL abatacept and 10nM 1,25(OH)2D3 for 5 days. Flow cytometric data 
showing CTV dilution from one representative experiment. Combined data from 
independent experiments expressed as division index values. Horizontal bars 
represent mean values. p value for interaction between 1,25(OH)2D3 and abatacept 
was determined by two-way ANOVA. Further analyses were performed using paired, 
two-tailed t tests where **p ≤0.01.  
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Fig. 4.5. 1,25(OH)2D3 promotes suppression of T cell proliferation by abatacept in 
superantigen stimulations. CTV labeled CD4+CD25- were incubated with indicated 
TSST-1 concentrations and allogeneic DCs and with 20µg/mL abatacept, 10nM 
1,25(OH)2D3 or both for 5 days. A) Flow cytometric data showing CTV dilution of vβ2
+ 
T cells from one representative experiment. B) CD4+vβ2+ T cell counts were 
determined relative to a known quantity of beads added to each sample prior to flow 
cytometric analysis. Horizontal bars represent mean values from independent 
experiments (n = 7). Data were log10 transformed prior to statistical analysis. p values 
were determined by two-way ANOVA. Further analyses were performed using paired, 
two-tailed t tests where *p ≤0.05, **p ≤0.01.  
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These differences in the proliferative response resulting from the combination 
of 1,25(OH)2D3 with abatacept did not appear to be associated with 
differences in the induction of T cell apoptosis since the combination of 
1,25(OH)2D3 with abatacept did not strongly influence the proportion of 
DiOC6
low staining cells following 5 days stimulation relative to abatacept-
treatment alone (fig. 4.2). 
 
T cells were stimulated with anti-CD3 in association with fixed CHO 
FcR/CD80 to determine whether 1,25(OH)2D3 was acting upon the DC, T cell, 
or both. This system provided costimulation via a fixed artificial APC that 
could not be influenced by 1,25(OH)2D3. Interestingly, 1,25(OH)2D3 alone 
failed to inhibit T cell proliferation under these conditions of stimulation (fig. 
4.3) in contrast to DC-mediated activation (fig. 4.1). Importantly, in the 
absence of 1,25(OH)2D3-responsive APCs, 1,25(OH)2D3 continued to 
enhance suppression of T cell proliferation by abatacept (fig. 4.3). These data 
therefore support a T cell intrinsic mechanism whereby 1,25(OH)2D3 acts to 
enhance the control of T cell responses by abatacept in the absence of APCs. 
Furthermore, having previously found that this abatacept-resistant 
proliferation was associated with the strength of TCR-stimulation, it appeared 
that 1,25(OH)2D3 specifically targeted TCR-driven T cell activation. 
 
4.2.2. T cell alloresponses are inhibited by abatacept 
The impact of the combination of abatacept with 1,25(OH)2D3  upon T cell 
activation and proliferation was determined under a variety of activation 
conditions that were independent of anti-CD3 cross-linking. For instance 
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allogeneic DCs alone were used to determine the effect of 1,25(OH)2D3 upon 
T cell  alloresponses. These data suggested that when stimulating T cells with 
allogeneic DCs at a ratio of 1 DC:5 T cells that the response was minimal; 
frequently just 2-5% CD4+ T cells were observed to be CD25highCTVlow 
following 5 days stimulation (fig. 4.4A). Unsurprisingly, reducing the number 
of allogeneic DCs limited the potency of this response (fig. 4.4B). Consistent 
with previous data this response was CD28-dependent as suggested by the 
inhibition of T cell proliferation by abatacept. Therefore, the combination of 
1,25(OH)2D3 with abatacept was not significantly beneficial under these 
conditions. Together, these data suggest that alloresponses do not represent 
a suitable system to analyze CD28-independent T cell responses.   
 
4.2.3. 1,25(OH)2D3 promotes suppression of superantigen-driven T cell 
activation by abatacept 
To determine the impact of 1,25(OH)2D3 in a system in which TCR-stimulus 
strength could be controlled, T cells were activated with TSST-1.  Again, no 
significant advantage was observed when combining 1,25(OH)2D3 with 
abatacept in terms of the activation of low affinity vβ2- responder T cells since 
abatacept alone was inhibitory to T cell activation (fig. 4.5A). However, 
1,25(OH)2D3 and abatacept cooperatively inhibited vβ2
+ T cell proliferation at 
lower TSST-1 concentrations. For example, significant interaction effect 
between 1,25(OH)2D3 and abatacept was observed when stimulation was 
driven by 0.025ng/mL TSST-1 (fig. 4.5B). This indicates that suppression by 
abatacept was dependent upon the presence of 1,25(OH)2D3. At an even 
lower TSST-1 concentration (0.0025ng/mL), no interaction between 
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1,25(OH)2D3 and abatacept was observed, however, both agents had overall 
independent effects and therefore combined in an additive manner to 
suppress vβ2+ T cell proliferation (fig. 4.5B). In contrast, during stimulation 
with a higher TSST-1 concentration of 0.25ng/mL, the proliferation of high 
affinity vβ2+ responder T cells was abatacept-resistant, even in the presence 
of 1,25(OH)2D3 (fig. 4.5A/B). These data demonstrate that strong TCR-
stimulation overcomes the impact of 1,25(OH)2D3 upon abatacept-resistant T 
cell proliferation. 
 
4.2.4. The combination of 1,25(OH)2D3 and abatacept suppress 
proinflammatory cytokine expression by activated T cells 
Vitamin D3 has previously been previously shown to affect the expression of 
pro-inflammatory cytokines. The impact of 1,25(OH)2D3 and abatacept co-
treatment on the expression of inflammatory cytokines by activated T cells 
was therefore investigated. These data revealed independent, additive effects 
of abatacept and 1,25(OH)2D3 in reducing the frequencies of proliferating T 
cells that were IFNγ+ and TNFα+ (fig. 4.6A/D). Thus, the combination of both 
agents favored the suppression of these inflammatory cytokines. Interestingly, 
a trend towards increased IL-17+ T cells was observed when blocking CD28-
costimulation, in keeping with previous observations (Bouguermouh et al., 
2009; Riella et al., 2012a), however, this effect was lost in the presence of 
1,25(OH)2D3 (fig. 4.6B/D).  Finally, there was a striking inhibition of IL-21 by 
activated T cells in the presence of 1,25(OH)2D3 although no effect was 
observed following abatacept-treatment alone (fig. 4.6C/D). Together, these 
data suggest that the combination of 1,25(OH)2D3 supplementation enhances 
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the efficacy of abatacept treatment affecting both T cell proliferation and 
inflammatory cytokine production. 
 
4.2.5. 1,25(OH)2D3 amplifies CD28-dependent FoxP3 and CTLA-4 
expression 
In order to explore the apparent interaction between 1,25(OH)2D3 and 
abatacept, their impact upon FoxP3 and CTLA-4 expression by activated T 
cells was explored. Interestingly, T cell stimulation in the presence of 
abatacept inhibited the induction of markers of T cell regulation, specifically, 
FoxP3, CTLA-4 and CD25 among proliferating T cells (fig. 4.7A). In contrast, 
1,25(OH)2D3 supplementation promoted the induction of these proteins which 
is consistent with previous data (Jeffery et al., 2009). However, this was not 
observed when CD28-costimulation was blocked by abatacept (fig. 4.7A). As 
such, significant interaction effects between 1,25(OH)2D3 and abatacept were 
identified for CD25 and CTLA-4 MFI as well as the proportion of proliferating T 
cells that expressed FoxP3 (fig. 4.7B). This suggests that the effect of 
1,25(OH)2D3 upon these proteins is dependent upon the presence of CD28-
costimulation. Exogenous IL-2 supplementation partially restored the 
1,25(OH)2D3 mediated upregulation of  FoxP3 and CTLA-4 expression by 
proliferating T cells in the presence of abatacept (fig. 4.7A). The interaction 
effect between 1,25(OH)2D3 and CD28-blockade in the expression of CD25 
and CTLA-4 was not observed in the presence of exogenous IL-2 which 
implicated the CD28-driven IL-2 production in the expression of these proteins 
(fig. 4.7B). However, the interaction effect between 1,25(OH)2D3 and 
abatacept was maintained for FoxP3 expression by proliferating T cells even 
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in the presence of IL-2 which suggests non-IL-2 mediated effects of CD28-
signals upon FoxP3 induction (fig. 4.7B). Together, these data demonstrate a 
degree of CD28-dependence in the induction of a regulatory T cell phenotype 
that occurs in association with 1,25(OH)2D3 treatment. Part of this interaction 
appears to involve the CD28-driven production of IL-2. 
 
The interaction between 1,25(OH)2D3 and CD28-costimulation in the induction 
of a regulatory phenotype of activated T cells may be attributed to the fact that 
1,25(OH)2D3 promoted CD28-expression by T cells (fig. 4.8). Therefore, 
1,25(OH)2D3 appeared to bias T cell activation in favor of CD28-driven 
activation that could facilitate elevated CD25, FoxP3 and CTLA-4 expression. 
 
Experiments were also performed to determine the impact of 1,25(OH)2D3 
supplementation upon PD-1 expression which is another CD28-superfamily 
member that is involved in T cell regulation (Francisco et al., 2010). 
Interestingly, whilst 1,25(OH)2D3 enhanced CTLA-4 expression, it inhibited 
that of PD-1. In contrast, T cell proliferation occurring in the presence of 
abatacept, which, was mediated by anti-CD3 stimulation, tended to result in 
slightly higher PD-1 levels (fig. 4.9). Therefore, the altered contribution of 
CD28 towards T cell activation appears to be associated with a rebalance 
between CTLA-4 and PD-1 mediated regulation such that CTLA-4 is 
increased in association with a more CD28-driven response. 
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Fig. 4.6. 1,25(OH)2D3 in combination with 
abatacept promotes the inhibition of 
proinflammatory cytokine production by 
activated T cells. CTV-labeled CD4+CD25- T 
cells were stimulated with anti-CD3 and DCs for 
5 days. Activated T cells were restimulated with 
PMA/ionomycin for 4 hours then fixed, 
permeabilized and stained for indicated 
cytokines. Bivariate flow cytometry plots gated 
on CTVlow T cells and showing IFNγ/TNFα (A) 
IFNγ/IL-17 (B)  and IL-2/IL-21 (C). D) Data from 
multiple experiments for indicated cytokines. 
Horizontal bars represent mean values. p values 
are derived from two-way ANOVA.  
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Fig. 4.7.  Abatacept inhibits the induction of a regulatory T cell phenotype 
following 1,25(OH)2D3 supplementation. CD4
+CD25- were activated with 0.5µg/mL 
anti-CD3 and allogeneic DCs. Where indicated, stimulations were treated with 20µg/
mL abatacept, 10nM 1,25(OH)2D3 or 200U/mL IL-2. A) Activated T cells were fixed, 
permeabilized and stained for CD25, FoxP3 and CTLA-4 by immunofluorescence 
staining. Representative flow cytometry data. B) Data from multiple experiments (n = 
8) gated on CTVlow T cells showing CTLA-4/CD25 MFI values and %FoxP3+. p values 
are derived from two-way ANOVA, further analyses were performed using paired, 
two-tailed t tests where ns not significant, *p ≤0.05, **p ≤0.01, ***p ≤0.001.  
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Fig. 4.8. 1,25(OH)2D3 promotes CD28 expression by activated T cells. CTV-
labeled CD4+CD25- were stimulated with 0.5µg/mL anti-CD3 and allogeneic DCs in 
the presence or absence of 10nM 1,25(OH)2D3 for 5 days. CD28 expression was 
determined by immunofluorescence labeling and flow cytometric analysis. 
Representative flow cytometry data and data from multiple experiments showing 
CD28 MFI values among CTVlow T cells. Horizontal bars represent median values. ns 
not significant *p ≤0.05 paired, two-tailed Wilcoxon-matched pairs test.  
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Fig. 4.9. 1,25(OH)2D3 inhibits PD-1 expression by activated T cells. CTV labeled 
CD4+CD25- were stimulated with 0.5µg/mL anti-CD3 and allogeneic DCs and with 
either 20µg/mL abatacept and 10nM 1,25(OH)2D3 or both for 5 days. PD-1 expression 
was determined by immunofluorescence labeling and flow cytometric analysis. 
Representative flow cytometry data and data from multiple experiments showing PD-1 
MFI values among CTVlow T cells. Horizontal bars represent mean values. p values 
are derived from two-way ANOVA.  
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4.2.6. T cell proliferation occurs in response to cross-linked anti-CD3 or 
anti-CD28 alone 
Since T cell proliferation in the presence of abatacept occurred in the context 
of high intensity anti-CD3 signaling, but was rendered abatacept sensitive by 
1,25(OH)2D3, I explored the hypothesis that 1,25(OH)2D3 targets the 
TCR/CD3 pathway thereby making T cell proliferation more CD28-dependent. 
To compare the TCR/CD3 and CD28 pathways directly, T cells were activated 
using anti-CD3 or anti-CD28 cross-linked by FcR transfected CHO cells. In 
this system, both pathways promoted T cell proliferation when stimulation was 
induced at antibody concentrations ≥0.05 μg/mL, with anti-CD28 potentially 
acting in a comparable manner to CD28-superagonists (fig. 4.10). A 
concentration of 0.5μg anti-CD3 or anti-CD28 was used in subsequent 
experiments as this concentration tended to induce the most comparable 
proliferation levels. It is important to note that at this concentration fewer T 
cells committed to cell division in response to anti-CD28 compared to anti-
CD3, however, those T cells that entered the cell cycle underwent an 
equivalent number of divisions following 5 days stimulation.  
 
A variety of experiments were performed in order to demonstrate that 
stimulation by cross-linked anti-CD3 and anti-CD28 engagement was 
fundamentally different. For example, the sensitivity of anti-CD3 and anti-
CD28 stimulations to CsA was determined. As expected, given the reliance of 
TCR signaling on the calcineurin/NFAT pathway, CsA potently inhibited 
proliferation of anti-CD3-treated cells whilst anti-CD28 stimulated T cells were 
less affected by CsA (fig. 4.11). Analysis of T cell activation markers also 
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revealed differences between anti-CD3 and anti-CD28 stimulated T cells. For 
example, anti-CD28 promoted increased expression of ICOS and CD80 
relative to anti-CD3 stimulated T cells (fig. 4.12). Similarly, OX40 and 
transferrin receptor (CD71) were more strongly upregulated following CD28-
driven activation (fig. 4.12). Finally, no evidence of CD62L and CD27 
downregulation was observed following anti-CD3 stimulation but this did occur 
in response to anti-CD28 driven activation (fig. 4.12).  Together, these data 
are indicative of differences between anti-CD3 and anti-CD28 stimulation. 
 
The impact of anti-CD3 or anti-CD28 driven activation upon markers of T cell 
regulation was determined. These experiments demonstrated a stronger bias 
towards a regulatory T cell phenotype with increased FoxP3 and CTLA-4 and 
CD25 expression levels when proliferation was induced by cross-linked anti-
CD28 compared to anti-CD3 (fig. 4.13). CTLA-4 and CD25 expression levels 
could be increased to levels that were comparable with anti-CD28 driven 
activation through the combined activity of 1,25(OH)2D3 and exogenous IL-2. 
Interestingly, 1,25(OH)2D3 treatment only significantly increased FoxP3 
expression when activation was driven by anti-CD28. In contrast, FoxP3 
expression levels remained low following anti-CD3 stimulation regardless of 
1,25(OH)2D3 and IL-2 supplementation. In keeping with the effect of abatacept 
and 1,25(OH)2D3 upon DC-driven T cell activation, the data suggest that 
1,25(OH)2D3 works in association with CD28-costimulation to enhance 
FoxP3 expression by activated T cells. Importantly, these data demonstrate 
several points of distinction between T cell differentiation when stimulation is 
mediated by either cross-linked anti-CD3 or anti-CD28.  
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Fig. 4.10. T cell proliferation occurs in response to cross-linked anti-CD3 and 
anti-CD28 independently. CTV labeled T cells were stimulated with fixed CHO-FcR 
and either anti-CD3 or anti-CD28 for 5 days. Representative histograms showing 
CTV dilution, shaded histograms represent CHO-FcR alone. Combined data from 4 
independent experiments are also summarized. Data points represent mean values ± 
S.E.	
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11. The impact of CsA upon anti-CD3 and anti-CD28 driven T cell 
proliferation. T cells were stimulated with fixed CHO-FcR and either anti-CD3 or 
anti-CD28. Stimulations from were treated with indicated CsA concentrations. CTV 
dilution was analysed following 5 days stimulation. Bar charts show the division index 
values at each concentration plotted as a percentage of the division index for the 
untreated control from independent experiments (n = 3). Data points represent mean 
values ± S.E. 
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Fig. 4.12. T cell activation driven by anti-CD3 and anti-CD28 promotes distinct 
effector T cell phenotypes. T cells were stimulated with fixed CHO-FcR and either 
anti-CD3 or anti-CD28 for 5 days. Expression of indicated surface markers by dividing 
T cells was measured by immunofluorescence labeling and flow cytometric analysis. 
Representative histograms gated on CTVlow T cells from n > 3 experiments are 
shown.  
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Fig. 4.13 T cell activation driven by anti-CD28 promotes a pro-regulatory 
phenotype. T cells stimulated with anti-CD3 or anti-CD28 were stained for CTLA-4, 
CD25 and FoxP3 and expression measured by flow cytometry. Flow cytometry data 
from one representative experiment of  5 independent experiments that were 
performed.  
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4.2.7. 1,25(OH)2D3 suppresses anti-CD3 but not anti-CD28 driven T cell 
activation 
Having characterized a system in which CD3 and CD28-driven responses 
could be compared directly, the impact of 1,25(OH)2D3 on T cell responses 
driven by anti-CD3 or anti-CD28 pathways was assessed.  These 
experiments demonstrated that 1,25(OH)2D3 markedly reduced the 
proliferation of T cells stimulated by anti-CD3, but did not affect T cells 
stimulated by anti-CD28 (fig. 4.14) suggesting that 1,25(OH)2D3 treatment 
predominantly targets T cells stimulated via the CD3 pathway. One of the 
primary endpoints of CD28-costimulation is an upregulation of IL-2 signaling 
(Boomer and Green, 2010). Interestingly, by supplementing exogenous IL-2 
the inhibition of anti-CD3 driven activation by 1,25(OH)2D3 was no longer 
seen (fig. 4.15). Similar experiments were performed to determine how IL-2 
supplementation affected the cooperation between 1,25(OH)2D3 and 
abatacept in DC-driven assays. These data suggested that IL-2 could 
substitute for the lack of CD28-signaling both in the presence or absence of 
1,25(OH)2D3 treatment, (fig. 4.16A) although a modest overall effect of 
abatacept was still observed across multiple donors following IL-2 
supplementation (fig. 4.16B).  
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Fig. 4.14. 1,25(OH)2D3 suppresses TCR but not CD28 induced T cell proliferation.  
CD4+CD25- CTV labeled T cells were stimulated with anti-CD3 or anti-CD28 in 
association with CHO-FcR with or without 10nM 1,25(OH)2D3 T cell proliferation was 
determined by flow cytometry. A) Representative CTV histograms showing the impact 
of 10nM 1,25(OH)2D3 on anti-CD3 and anti-CD28 driven T cell at 5 days. Data from 
multiple experiments are summarized in B. Horizontal bars indicate median values. 
Significance was tested by Wilcoxon matched pairs tests. **p ≤0.01  	
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Fig. 4.15. Exogenous IL-2 prevents 1,25(OH)2D3 mediated suppression of anti-
CD3 driven proliferation. CD4+CD25- CTV labeled T cells were stimulated with anti-
CD3 or anti-CD28 in association CHO-FcR for 5 days and were treated with 10nM 
1,25(OH)2D3, 200U/mL IL-2 or both. CTV dilution was determined by flow cytometry. 
Representative CTV histograms showing the impact of 1,25(OH)2D3 and exogenous 
IL-2 upon T cell proliferation. Data from multiple experiments are also summarized 
where the effect of 1,25(OH)2D3 upon T cell division index is normalized to untreated 
controls. Horizontal bars indicate median values. Significance was tested by Wilcoxon 
matched pairs tests. ns not significant  *p ≤0.05 	
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Fig. 4.16. Exogenous IL-2 prevents the inhibition of T cell proliferation mediated 
by the combination of 1,25(OH)2D3 and abatacept. CD4
+CD25- CTV labeled T cells 
were stimulated with anti-CD3 and DCs at a DC:T cell ratio of 1:5 and in the presence 
of 20µg/mL abatacept, 10nM 1,25(OH)2D3, or 200U/mL IL-2. CTV dilution was 
determined by flow cytometry. Representative CTV histograms. Data from multiple 
experiments expressed as T cell division index are also summarized. Horizontal bars 
represent mean values. P values are derived from two-way ANOVA 	
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These experiments suggested that the 1,25(OH)2D3 resistant T cell 
proliferation that was mediated by anti-CD28 driven stimulation may have 
been at least partially associated with increased IL-2 signaling occurring 
under these conditions. The analysis of IL-2 production following either anti-
CD3 or anti-CD28-driven stimulation clearly demonstrated that anti-CD28 
stimulation promoted high and sustained IL-2 production (fig. 4.17A; see red 
traces) that was more pronounced than with anti-CD3 driven activation). In 
contrast, anti-CD3 driven stimulation led to transient IL-2 production by T cells 
that could not be detected beyond 24-36h stimulation (fig. 4.17A; see blue 
traces). This limited IL-2 production following anti-CD3 stimulation was 
necessary for activation because anti-IL-2 treatment entirely inhibited both 
anti-CD3 and anti-CD28-driven activation (data not shown). Consistent with 
this, comparable levels of STAT5 phosphorylation (pSTAT5), which is a 
proximal component of the IL-2 signaling pathway (Lin and Leonard, 2000), 
could be detected following anti-CD3 and anti-CD28 driven T cell stimulation 
at 16h (fig. 4.17B).  However, following 6 days stimulation, pSTAT5 could 
only be detected in anti-CD28 driven cultures (fig. 4.17B).  This reflected 
sustained IL-2 production following strong CD28-costimulation. Importantly, 
1,25(OH)2D3 did not appear to inhibit T cell proliferation in the absence of 
CD28-costimulation via a direct impact upon IL-2 production since IL-2 
production (fig. 4.17A) and signaling (fig. 4.17B) in the context of anti-CD3 
stimulation did not appear to be affected by 1,25(OH)2D3. 
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Fig. 4.17. 1,25(OH)2D3 does not alter IL-2 production by activated T cells 
following either anti-CD3 or anti-CD28 driven proliferation. CD4+CD25- CTV 
labeled T cells were stimulated with anti-CD3 or anti-CD28 in association CHO-FcR in 
the presence of absence of 10nM 1,25(OH)2D3. Supernatants were recovered at 
indicated time points. A) IL-2 concentration was determined by ELISA. Data points 
represent mean values ± S.E. from 3 independent experiments. B) T cells were stained 
for pSTAT5 expression levels following either 16h or 144h. Representative flow 
cytometry data from 1 independent experiment of 3 performed. 	
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4.2.8. 1,25(OH)2D3 does not interact with low dose CsA to modify 
abatacept-sensitivity  
Results suggested that 1,25(OH)2D3 acted in a similar manner to CsA (see fig. 
3.14) by targeting abatacept-resistant T cell proliferation that was driven by 
anti-CD3 stimulation. Experiments were performed to determine how CsA 
interacted with 1,25(OH)2D3 in the context of CD28-blockade particularly at 
CsA concentrations that did not entirely inhibit T cell proliferation in 
association with abatacept treatment. The presence of CsA at higher 
concentrations (>0.1μg/mL CsA) overwhelmingly inhibited T cell proliferation 
when combined with abatacept blockade in both CHO FcR/CD8 and DC-
driven stimulations (fig. 4.18). However, some T cell proliferation occurred 
when abatacept was combined with lower CsA concentrations. At these CsA 
concentrations, the presence of CsA did not strikingly inhibit T cell 
proliferation above the level of combination of 1,25(OH)2D3 and abatacept 
alone (fig. 4.18). As such, inhibition of TCR-driven activation by 1,25(OH)2D3 
did not seem to compensate for suboptimal TCR inhibition by CsA to promote 
abatacept sensitivity.  
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Fig. 4.18. 1,25(OH)2D3 does not interact with low dose CsA to modify abatacept-
sensitivity. CD4+CD25- CTV labeled T cells were stimulated with either anti-CD3 and 
CHO FcR/CD80 (A) or anti-CD3 and DCs (B) and in the presence of 20µg/mL 
abatacept, 10nM 1,25(OH)2D3, or indicated CsA concentrations. CTV dilution was 
determined by flow cytometry. Data from multiple experiments (n = 4) expressed as T 
cell division index are summarized. Data points represent mean values ± S.E. 	
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4.2.9. 1,25(OH)2D3 acts to inhibit anti-CD3 driven proliferation rather than 
signal intensity 
The inhibition of anti-CD3 driven T cell proliferation by 1,25(OH)2D3  could 
theoretically have arisen from either decreased signal intensity which 
subsequently reduced proliferation or alternatively via a direct impact upon the 
proliferative response by inhibiting cell cycle progression. Since the VDR is 
expressed at low levels by resting T cells and is induced following TCR-
stimulation (Provvedini et al., 1983; vonEssen et al., 2010) it seemed more 
likely that the effect would be a later one that targeted the proliferative 
response. Various experiments were performed to test this hypothesis. By 
assessing T cell proliferation at different points in response to anti-CD3 driven 
activation it was apparent that early T cell proliferation remained largely 
unaffected following 1,25(OH)2D3 supplementation (fig. 4.19; day 3) but 
became more evident at later time points (fig. 4.19; day 5/6). Similar effects 
were observed in DC driven stimulations. For instance, a relatively constant 
division rate was observed under control conditions particularly when T cells 
were stimulated at a DC:T cell ratio of 1:20 (fig. 4.20). However, T cell 
expansion appeared to stall after 4 days stimulation following 1,25(OH)2D3 
treatment both in the presence and absence of abatacept which seemed 
indicative of defective T cell proliferation (fig. 4.20). Interestingly, this stalled T 
cell proliferation was still apparent in conjunction with 1,25(OH)2D3 treatment 
alone suggesting that CD28-costimulation only partly overcomes the impact of 
1,25(OH)2D3 upon proliferation under these conditions.   
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Fig. 4.19. Limited inhibition of early anti-CD3 driven T cell proliferation by 
1,25(OH)2D3. CD4
+CD25- CTV labeled T cells were stimulated with anti-CD3 or anti-
CD28 in association with CHO-FcR with or without 10nM 1,25(OH)2D3. T cell 
proliferation was determined at various time-points by flow cytometry. Representative 
CTV histograms and data from multiple experiments (n = 3). Data points represent 
mean values ± S.E.	
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Fig. 4.20. Limited inhibition of T cell proliferation by 1,25(OH)2D3 and abatacept 
at early time-points CD4+CD25- CTV labeled T cells were stimulated with anti-CD3 
and DCs at a DC:T cell ratio of 1:5 or 1:20 with either 20µg/mL abatacept,10nM 
1,25(OH)2D3 or both. T cell proliferation was determined at various time-points by flow 
cytometry. Representative CTV histograms showing T cell stimulation at a DC:T cell 
ratio of 1:5. Also, data from multiple experiments (n = 3). Data points represent mean 
values ± S.E.	
Untreated 
Abatacept 
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
Cell trace violet 
C
e
lls
 (
%
 o
f 
m
a
x
) 1,2
5
(O
H
)
2 D
3  a
d
d
itio
n
 
D
a
y
 0
 
D
a
y
 1
 
D
a
y
 2
 
D
a
y
 3
 
D
a
y
 4
 
CHO FcR  
+ anti-CD3 
CHO FcR  
+ anti-CD28 
Untreated 1,25(OH)2D3 
Fig. 4.21. The impact of delayed 1,25(OH)2D3 supplementation upon anti-CD3 
driven T cell proliferation.  CD4+CD25- CTV labeled T cells were stimulated with anti-
CD3 or anti-CD28 in association with CHO-FcR. 10nM 1,25(OH)2D3 was supplemented 
at indicated time-points where day 0 is prior to stimulation. T cell proliferation was 
determined by flow cytometry following 5 days stimulation. Representative CTV 
histograms and data from multiple experiments (n = 3). Data points represent mean 
values ± S.E.	
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Fig. 4.22. 1,25(OH)2D3 supplementation fails to inhibit CD69 expression following 
24 hrs. stimulation.  CD4+CD25- CTV labeled T cells were stimulated with anti-CD3 
and DCs and treated with 10nM 1,25(OH)2D3  or 0.1µg/mL CsA either with or 20µg/mL 
abatacept. CD69 expression levels were determined by immunofluorescence staining 
and flow cytometric analysis. A) Representative flow cytometric data. B) Data from 
multiple experiments (n = 3) showing proportion of CD4+ T cells staining positive for 
CD69. Data points represent mean values± S.E. C) T cell proliferation was determined 
by flow cytometry following 5 days stimulation.  Representative CTV histograms. 	
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These results appeared to suggest that 1,25(OH)2D3 was acting to inhibit anti-
CD3 driven T cell proliferation via a late effect rather than inhibiting the 
intensity of initial activation signal.  However, by supplementing 1,25(OH)2D3 
at different time points post-anti-CD3 stimulation it was apparent that addition 
beyond 2 days did not appreciably inhibit T cell proliferation (fig. 4.21). Thus, 
1,25(OH)2D3 may target a relatively early activation event following anti-CD3 
stimulation but this effect does not become apparent until T cell proliferation 
has occurred. 
 
CD69 expression can be used as a tool to identify early T cell activation since 
peak expression is observed around 24 hours following TCR stimulation 
however mRNA is detected less than an hour following stimulation (Testi et 
al., 1994). To confirm that 1,25(OH)2D3 was not affecting the strength of the 
initial TCR-signal the impact of 1,25(OH)2D3 upon the early activation marker 
CD69 was determined. The data revealed no significant impact of 
1,25(OH)2D3 on CD69 expression following 24 hours stimulation (fig. 4.22 
A/B); indeed, a trend was observed towards increased CD69 in the presence 
of  1,25(OH)2D3 relative to control conditions across several experiments (fig. 
4.22B). The impact of CsA upon CD69 was also utilized a control since this is 
known to directly target TCR signaling via the calcineurin inhibition and could 
therefore be predicted to inhibit early T cell activation events. However, CsA 
treatment was only associated with a modest decrease in CD69 expression 
(fig. 4.22A/B) even when used in combination with abatacept where a robust 
inhibition of T cell proliferation was observed following 5 days stimulation (fig. 
4.22C). As such these data suggest that CD69 positivity does not necessarily 
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define a T cell that will go on to proliferation. However, the fact that 
1,25(OH)2D3 fails to inhibit CD69 expression suggests that it inhibits a TCR-
driven activation event after the initial TCR signal. 
 
4.3. Discussion 
T cell activation thresholds are achieved following the integration of TCR and 
CD28-signals (Viola and Lanzavecchia, 1996). As such, results presented 
throughout this chapter demonstrate that strategies which selectively reduce 
the strength of the TCR stimulation act to promote CD28-costimulation 
requirements. For example, the calcineurin inhibitor, CsA, has been regarded 
a TCR-pathway selective inhibitor (Geginat et al., 2000), whilst CD28 
costimulation promotes CsA insensitive T cell responses (June et al., 1987). 
When used at a low concentration, CsA, like abatacept, failed to inhibit T cell 
proliferation, however, the combination of a low CsA concentration with 
abatacept was highly effective at inhibiting activation. Other groups have also 
demonstrated synergy between CsA and either anti-CD80/CD86 blocking 
antibodies or CTLA-4-Ig for the inhibition of alloresponses in in vitro mixed 
lymphocyte reactions and organ transplantation models (Bolling et al., 1994; 
Van Gool et al., 1994; Perico et al., 1995; Ossevoort et al., 1999). Thus CsA, 
which is already used in the treatment of T cell mediated inflammatory 
diseases including RA (Cope et al., 2007), may serve to improve clinical 
responses to abatacept therapy. However, the adverse effects of calcineurin 
inhibition limit the viability of this option (van den Borne et al., 1999; Gremese 
and Ferraccioli, 2004; Liu et al., 2007). As such, the identification of 
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alternative TCR specific inhibitors is of interest. Here, a novel role for the 
active form of vitamin D3, 1,25(OH)2D3, as an inhibitor of TCR but not CD28 
driven T cell responses is reported. Importantly, like CsA, 1,25(OH)2D3  was 
able to enhance the efficacy of abatacept in the blockade of anti-CD3 and DC 
driven T cell stimulations.  
 
Data presented here suggest that, under conditions of sufficient TCR 
stimulation, T cell responses can occur in the absence of CD28-costimulation. 
Likewise, the availability of CD28-costimulation compensates for a weak TCR 
signal to promote T cell activation. For instance, T cell proliferation occurred in 
the absence of TCR stimulation in response to CD28-engagement alone 
mediated by cross-linked anti-CD28. This did not occur in response to soluble 
anti-CD28 alone suggesting that FcR-mediated cross-linking was crucial to 
the generation of threshold signaling, potentially relating to the size-
dependent exclusion of CD45 from the T cell-CHO-FcR interface as predicted 
by the kinetic segregation model of T cell activation signaling (Davis and van 
der Merwe, 2006). As with other conventional agonistic anti-CD28 mAb, 9.3 
binds to an epitope related to the CD28-MYPPPY ligand-binding motif (Peach 
et al., 1994). In contrast, superagonistic anti-CD28 binds to the membrane-
proximal C”D loop of the CD28 immunoglobulin like domain (Lühder et al., 
2003). However, our results using cross-linked 9.3 appear to be analogous to 
the utilization of CD28-superagonists as a mechanism to drive T cell 
activation by CD28-engagement in the absence of an obvious TCR-stimulus 
(Siefken et al., 1997; Tacke et al., 1997). In this manner, CD28-superagonists 
have been found to expand Treg populations in various model systems 
149 
 
(Beyersdorf et al., 2005b) consistent with my observations of a pro-regulatory 
phenotype driven by CD28-costimulation. Despite these results, the use of the 
CD28 superagonist TGN1412 in clinical trials led to cytokine storm potentiated 
by widespread T cell activation particularly among effector memory T cell 
populations (Hünig, 2012). This example clearly demonstrates the importance 
of balancing both the pro-stimulatory and pro-regulatory functions of CD28 
during the therapeutic modification of CD28-costimulation (Sansom and 
Walker, 2013). In this work, signaling via CD28 in isolation facilitated the 
comparison between TCR and CD28 driven signals in terms of their sensitivity 
to 1,25(OH)2D3.  
 
Vitamin D has been widely investigated in terms of its influence on T cell 
activation and effector function due to a strong correlation between vitamin D3 
deficiency and autoimmunity (Holick, 2007). This is thought to arise due to 
diverse immunomodulatory properties of vitamin D, influencing both innate 
and adaptive immunity. Chromatin immunoprecipitation analysis in 
lymphoblastoid cell lines suggests 229 genes to be differentially affected by 
1,25(OH)2D3 treatment (Ramagopalan et al., 2010). Since both APCs and T 
cells express the VDR, effects of 1,25(OH)2D3 on T cell responses may occur 
through either a direct effect on the T cell or an indirect effect via the APC 
(Peelen et al., 2011). By using an artificial fixed CHO system to stimulate T 
cells it was apparent that 1,25(OH)2D3 can act via a T cell intrinsic mechanism 
to inhibit TCR-induced proliferation and promote abatacept sensitivity. An 
important consideration will be to verify these findings using in vivo models of 
autoimmunity or transplantation. In particular the potential to test the efficacy 
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of CD28-blockade using these models on a VDR deficient background would 
be valuable. Nevertheless, the widespread expression of the VDR 
complicates the interpretation of these experiments. As such, models in which 
VDR-deficient T cells can be transferred to wild-type recipients would be 
advantageous. 
 
It has been speculated that the primary mechanisms by which vitamin D3 
regulates T cell responses is via effects upon T cell proliferation and cytokine 
production (Cantorna and Waddell, 2014). In this study, various lines of 
evidence suggest that, in the absence of CD28-costimulation, 1,25(OH)2D3 
targets the proliferative response to T cell stimulation rather than the initial 
intensity of stimulation. For example, the inhibition of anti-CD3 T cell 
stimulation was more pronounced at later time points (i.e. following 5 days 
stimulation) whereas at earlier time points (i.e. day 3-4) inhibition was less 
prominent. In support of this, several reports suggests vitamin D3 mediated 
inhibition of cell cycle progression in various cell lineages, particularly at the 
G1/S phase transition (Samuel and Sitrin, 2008). This may be at least partly 
associated with the capacity of vitamin D3 (or vitamin D3 analogs) to 
upregulate the cyclin-dependent kinase (CDK) inhibitors p21 and p27 that 
control entry into S phase (Liu et al., 1996; Kawa et al., 1997; Cozzolino et al., 
2001). However, preliminary experiments have revealed no significant 
differences in the expression of either p21 or p27 following 1,25(OH)2D3 
supplementation (data not shown). 
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During T cell proliferation, the G1/S phase transition is strongly associated 
with CD28-signaling (Appleman et al., 2000). However, in the absence of 
CD28-costimulation, it has been found that TCR-driven, Jak3 dependent 
cytokine signals can drive late G1 events such as the upregulation of cyclin 
D3, cyclin E and cyclin A (Shi et al., 2009). An attractive hypothesis for the 
interaction between vitamin D3 and abatacept may be the inhibition of TCR-
driven cytokine signaling by vitamin D3.  
 
IL-2 is an example of a cytokine that signals via a Jak-3 dependent 
mechanism (Kirken et al., 1995). Furthermore, the T cell G1/S phase transition 
is at least partially IL-2 dependent (Appleman et al., 2000). Although CD28 is 
most strongly associated with increased IL-2 signaling resulting both from an 
upregulation of IL-2 expression (Fraser et al., 1991) and mRNA stability 
(Lindstein et al., 1989), IL-2 expression is also upregulated, albeit to a lesser 
extent, following TCR stimulation alone (Umlauf et al., 1995; Shapiro et al., 
1997). Several studies have suggested an inhibition of IL-2 production 
following vitamin D3 treatment (Tsoukas et al., 1984; Rigby et al., 1984; 1985; 
Thien et al., 2005) which has been thought to arise due to a direct inhibition of 
NFAT binding activated vitamin D receptor (VDR) at the IL-2 promoter (Alroy 
et al., 1995). Interestingly, NFAT appears to be important to the expression of 
IL-2 by TCR signaling alone (Shapiro et al., 1997) suggesting vitamin D could 
suppress TCR induced IL-2 whilst abatacept targets CD28 induced IL-2. 
However, although the absence of CD28 strongly inhibited IL-2 production, I 
have found no difference between IL-2 expression levels resulting from 
1,25(OH)2D3 exposure either in the presence or absence of CD28-
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costimulation in contrast to these previous studies. Furthermore, 1,25(OH)2D3 
promotes CD25 expression and is therefore likely to facilitate IL-2 signaling.  
This suggests that vitamin D3 does not enhance abatacept efficacy by a direct 
effect upon IL-2 signaling. It is important however to note that IL-2 
supplementation did overcome the defect in proliferation caused by the 
combination of vitamin D3 and abatacept, this suggests that high IL-2, either 
through supplementation or as a result of costimulation, antagonizes vitamin 
D3 mediated inhibition of T cell proliferation.  
 
Another example of a cytokine that signals in a Jak-3 dependent manner is IL-
21 (Leonard and Spolski, 2005). Interestingly, IL-21 can compensate for the 
absence of IL-2 as a growth factor (Attridge et al., 2012). Strikingly, 
1,25(OH)2D3 treatment results in an inhibition of IL-21 by activated T cells 
following 1,25(OH)2D3 treatment which is consistent with other studies (Jeffery 
et al., 2009; Bruce et al., 2011; Jeffery et al., 2012). These results suggest 
that abatacept could act to inhibit CD28-driven IL-2 production rendering T 
cell proliferation dependent upon TCR driven IL-21 production. The inhibition 
of IL-21 production by vitamin D3 would therefore inhibit T cell proliferation 
under these conditions. The potential for suppression of IL-21 suggests some 
degree of overlap between vitamin D3 mediated effects upon T cell 
proliferation and proinflammatory cytokine expression. A useful future 
direction would be to determine the outcome of abatacept blockade in models 
of inflammation or transplantation upon an IL-21 deficient background to 
further explore the interaction between IL-21 and costimulation thresholds.  
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An important conclusion from the work presented in this chapter is that the 
impact of vitamin D3 upon T cell proliferation is dependent upon the context of 
the activation conditions. This is reflected by previous studies, for example, 
whilst vitamin D3 inhibits in vitro T cell activation driven by 
phytohemagglutanin (Rigby et al., 1984; Lemire et al., 1984; Tsoukas et al., 
1984; Correale et al., 2009) this does not occur when T cells receive 
costimulation via anti-CD28 (Vanham et al., 1989). Similarly, no effect by 
vitamin D3 upon T cell proliferation is observed when T cells are stimulated 
with anti-CD3/anti-CD28 coated beads (Jeffery et al., 2009). I have shown 
that although 1,25(OH)2D3 suppresses T cell proliferation driven by anti-CD3 
and DCs, no impact is observed when stimulating with anti-CD3 and 
FcR/CD80 expressing CHO cells (which express significantly more CD80 than 
DCs) or by anti-CD28 stimulated T cells. These discrepancies appear to be 
associated with the relative contributions of TCR and CD28 to T cell 
activation. Therefore, just as strength of TCR-stimulation underlies abatacept-
resistant T cell proliferation, robust CD28-costimulation may mediate vitamin 
D3-resistant T cell responses despite the inhibition of TCR signaling pathways 
by vitamin D3. This feature of vitamin D3 mediated inhibition of T cell 
responses may underlie an apparent lack of efficacy in some clinical trials 
analyzing the use of vitamin D3 supplementation for the treatment of the T cell 
mediated inflammatory diseases such as multiple sclerosis (Kampman et al., 
2012).  
 
In addition to influencing T cell activation, vitamin D has been widely reported 
to modify T cell effector function, for example, by inhibiting proinflammatory 
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cytokine production by Th1, Th9 and Th17 cells (Reichel et al., 1987; Lemire et 
al., 1995; Jeffery et al., 2009; Colin et al., 2010; Palmer et al., 2011) and 
biasing differentiation towards Th2 responses (Boonstra et al., 2001). Notably, 
vitamin D also promotes a regulatory phenotype characterized by increased 
expression of FoxP3 and CTLA-4 (Jeffery et al., 2009). It is possible that 
these effects are at least partly associated with redistribution in the relative 
contributions of TCR and CD28 signals towards T cell activation that results 
from vitamin D3 supplementation. This concept is consistent with the 
observation that T cell differentiation is influenced by the nature of activation 
signals (van Panhuys et al., 2014; Keck et al., 2014). For example, Th1 (Tao 
et al., 1997a) and Th17 (Bouguermouh et al., 2009) type responses are 
favored following TCR-driven activation which appears to be inhibited by 
vitamin D3. In contrast, CD28 signaling, favors Th2 (Tao et al., 1997a) and 
Treg differentiation (Gabryšová et al., 2011).  
 
An interesting feature of the direct effect of vitamin D3 on T cells during 
stimulation is a reported VDR-dependent upregulation of PLC-γ1 by naïve T 
cells (vonEssen et al., 2010). This at least partially underlies an enhancement 
of TCR-driven stimulation by primed T cells relative to naïve counterparts.  
However, this would suggest that vitamin D3 has both positive and negative 
effects on a TCR-driven response that appears paradoxical. Nevertheless it 
could be suggested that any inhibition of T cell proliferation by vitamin D3 in 
the absence of CD28-costimulation forms a negative feedback mechanism to 
confer control over ongoing T cell responses (Kongsbak et al., 2013). 
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In my assays, vitamin D3 significantly increases CD28 expression by 
proliferating T cells. These data are supported by other studies suggesting 
that vitamin D3 can increase the expression levels of CD28 during in vitro 
stimulation of CD4+ T cells derived from healthy controls or multiple sclerosis 
patients (Kickler et al., 2012). Additionally, vitamin D3 prevents the 
downregulation of CD28 by TNF-α among CD4+ T cells in patients with 
primary sclerosing cholangitis (Liaskou et al., 2014). An upregulation of CD28 
by vitamin D3 may facilitate T cell activation despite the corresponding 
inhibition of TCR-stimulation where CD80/CD86 are available. However, to 
some extent, this CD28-upregulation is paradoxical due to the increased 
expression of CTLA-4 that occurs in parallel and which serves to limit CD28-
costimulation by depletion of CD80/CD86 via trans-endocytosis (Qureshi et 
al., 2011). The timing of these events may allow a window in which CD28 is 
elevated prior to CTLA-4 upregulation in order to facilitate costimulation 
initially but to control its availability in the long term.  
 
Data presented here suggest that the induction of a pro-regulatory phenotype 
among activated T cells following 1,25(OH)2D3 could at least in part, be 
mediated by vitamin D3 tipping the T cell activation in favor of a CD28 driven 
response that is more pro regulatory in nature. T cell stimulation in the 
presence of 1,25(OH)2D3 promotes a regulatory phenotype characterized by 
increased expression of FoxP3 and CTLA-4; however this effect of vitamin D3 
is blocked by abatacept. In support of this, Gabryšová, et al. found that the 
generation of induced Treg populations from naïve T cells in vitro was 
associated with the balance of this integrative threshold between TCR and 
156 
 
CD28 signaling (Gabryšová et al., 2011). Their findings suggest that reducing 
anti-CD3 stimulation in the presence of strong CD28-costimulation provided 
the most effective conditions for FoxP3 expression, which is consistent with 
the impact of vitamin D3 upon T cell activation signals. Again, this highlights 
the inherent tension between inhibiting effector responses and at the same 
time influencing regulatory outcomes (Sansom and Walker, 2013).  
 
Any influence of costimulation-blockade upon T cell regulation may be offset 
by the fact that vitamin D3 and abatacept combine to more potently inhibit T 
cell proliferation. Thus greater inhibition of T cell proliferation as well as the 
reduction of inflammatory cytokines due to the presence of 1,25(OH)2D3 favor 
its combination with abatacept as a potential treatment of inflammatory 
diseases.  
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Chapter 5: Can in vitro T cell activation 
thresholds be utilized to predict disease 
outcome in early arthritis patients?  
 
5.1 Introduction 
The TCR repertoire is shaped by T cell development within the thymus so that 
mature T cells in the periphery display weak autoreactivity. As such, 
autoimmune thresholds are set at a high level to prevent autoimmune T cell 
responses and perturbations in negative selection are associated with 
systemic autoimmunity (Palmer, 2003). Additionally, due to the integrative 
relationship between TCR and CD28 signals in achieving T cell activation 
thresholds, the control of CD28 signaling is essential to maintaining tolerance. 
Based upon this notion, it is unsurprising that a loss of CD28-regulation 
associated with CTLA-4 deficiency or altered function is associated with 
CD28-driven autoimmunity (Tivol et al., 1995; Waterhouse et al., 1995; 
Mandelbrot et al., 1999).  
 
RA is an autoimmune disease where important genetic predisposing factors 
are MHCII and PTPN22 genotype (McInnes and Schett, 2011). By virtue of 
the MHCII variable affinity for antigen and the influence of PTPN22 on 
downstream TCR signal potency, both of these molecules may influence 
thymic selection and peripheral T cell activation thresholds. Several studies 
have identified reproducible intra-individual variations between various 
parameters of immune responses within standardized in vitro assays (Ye et 
al., 2014; Raj et al., 2014; Lee et al., 2014). The aims of this work presented 
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in this chapter are two-fold. Firstly, to determine whether differences between 
patterns of in vitro T cell activation within standardized in vitro assays could 
be identified between early arthritis patients who go on to develop RA relative 
to patients with transient joint inflammation. Secondly, to determine whether in 
vitro responsiveness to abatacept predicted subsequent clinical 
responsiveness.  
5.2 Results 
5.2.1. Ki67 as a marker of T cell activation 
In order to assess variations in patterns of in vitro T cell activation between 
early arthritis patients of different eventual outcomes, a simple in vitro assay 
was developed in which T cells, derived from patients from the Birmingham 
Early Arthritis Cohort, were stimulated by various concentrations of anti-CD3, 
with or without 20μg/mL abatacept. The inclusion criteria for this cohort was a 
patient presenting with either [i], inflammatory arthritis as indicated by 
clinically apparent synovial swelling affecting at least one joint, or [ii], a history 
considered by the assessing Rheumatologist to be indicative of new onset 
inflammatory arthritis in the absence of overt joint swelling. Patients already 
treated with DMARDs or with symptoms indicative of degenerative disease or 
other causes of joint pain were not included within this study.  
 
To circumvent difficulties associated with limited peripheral blood volumes, T 
cells were stimulated within whole PBMC samples. Previous experiments 
throughout this thesis have demonstrated T cell proliferation as indicated by 
CTV dilution to be a useful marker of T cell activation, however, CTV labeling 
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was not compatible with PBMC stimulation. As such, Ki67, which is 
upregulated as cells exit the G0 cell cycle phases and is subsequently 
expressed throughout the cell cycle (Scholzen and Gerdes, 2000), was 
utilized as a marker of T cell proliferation. A typical gating strategy for analysis 
of Ki67 expression by T cells stimulated by anti-CD3 is shown in fig. 5.1A. 
This demonstrates Ki67 expression exclusively within the CD25+ population 
when gating on CD3+CD4+ T cells. Time course analysis demonstrated Ki67 
expression levels to be more pronounced following 4 days stimulation and 
that this decreased following 5-6 days proliferation (fig. 5.1B). This seemed 
consistent with the idea of stalled proliferation at later time points, as such, 
samples were analysed following 4 days stimulation for this study. 
 
5.2.2. Differential in vitro TCR- and CD28-thresholds between individual 
early RA patients  
As part of the optimization of an assay by which to compare T cell activation 
between early arthritis patients, qualitative differences in patterns of T cell 
proliferation were observed between patients in response to a range of anti-
CD3 concentrations and abatacept treatment. For example, results from three 
patients  (SWB EAC 0014, SW EAC 0069 and SWB EAC 0052) are shown in 
fig. 5.2 and are representative of this inter-individual variability. For example, 
patient SW EAC 0014 displayed a fairly substantial Ki67+ T cell population 
following stimulation by 0.05ng/mL anti-CD3 which is relatively unaffected by 
abatacept (fig. 5.2A) whilst SW EAC 0069 displayed abatacept sensitive 
proliferation under these conditions (fig. 5.2B). In contrast, patient SWB EAC 
0052 showed limited T cell proliferation in response to stimulation by 
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0.05ng/mL anti-CD3 (fig. 5.2C). Together, these responses seem indicative of 
a degree of heterogeneity between in vitro T cell responses among early 
arthritis patients. 
 
In order to assess how these parameters of in vitro T cell activation related to 
disease outcome, PBMC samples were stimulated with varying 
concentrations of anti-CD3 with or without 20μg/mL abatacept and T cell 
proliferation was assessed at 4 days by Ki67 labeling. The results from a 
small early arthritis patient cohort are summarized in fig. 5.3A. The clinical 
details for these patients are presented in table 7.1 (Appendix). 
Unsurprisingly, these results demonstrate that the proportion of CD3+CD4+ T 
cells staining positive for Ki67 decreased as the anti-CD3 concentration 
driving proliferation was reduced.  However, abatacept had a consistent but 
modest effect upon T cell proliferation at all anti-CD3 concentrations tested, 
this may indicate that CD28 plays a relatively limited role within this 
stimulation system. T cell proliferation in response to anti-CD3 stimulation was 
stratified relative to patient outcome determined at 12-month follow-up. These 
outcomes were categorized as RA, Persistent Non-RA, Resolving Non-RA or 
inflammatory arthralgia. A comparison of the clinical details between these 
sub-groups is summarized in table 5.1. However, categorization of in vitro T 
cell proliferation according to these outcomes was not associated with 
convincing differences between patient sub-groups (fig. 5.3B/C). It is possible 
that this poor resolution between patient sub-groups reflects limitations 
associated with either a small overall sample size or an inherent variability 
associated with PBMC-based T cell stimulation. 
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Fig. 5.1. Ki67 is expressed by CD3+CD4+CD25+ activated T cells. PBMC samples 
were generated by density gradient centrifugation. T cells were stimulated with 0.5µg/
mL. A) Characteristic gating strategy for Ki67 analysis following anti-CD3 stimulation. 
Following initial discrimination based upon forward scatter (FS) vs. side scatter (SS) 
cells were gated on a low pulse width in order to exclude doublets. Ki67 expression 
was determined within the CD3+CD4+ population.  B) Flow cytometry data for time 
course analysis showing Ki67 vs. CD25 expression (by CD3+CD4+ T cells) following 
stimulation for indicated time periods.  
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gradient centrifugation. T cells were stimulated with indicated anti-CD3 concentrations 
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3 different early arthritis patients (A) SWB EAC 0014 (B) SWB EAC 0014  (C) SWB 
EAC 0052. 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
13 75.5
5.416.08
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
17.2 66.9
6.159.69
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10.3 74.2
11.54.08
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
21.9 60.2
9.028.84
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
23.7 34.7
10.830.9
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
31.7 24
3.7640.5
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
40.6 0.47
0.4358.5
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
36.1 0.5
0.5362.9
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
13.5 46
6.0234.6
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
16 37
8.138.9
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10.3 68
5.815.9
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
16.7 54.9
3.4825
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
30.4 27.6
6.0635.9
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
38.2 4.36
3.6853.7
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
37.3 3.09
2.6157
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
36.7 2.7
2.1658.5
C
o
n
tro
l 
A
b
a
ta
c
e
p
t 
S
W
 E
A
C
 0
0
6
9
 
A 
B 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
9.89 82.5
5.242.34
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
7.28 79
10.63.2
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
33 7.7
3.356
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
33 1.23
1.1264.6
C
o
n
tro
l 
A
b
a
ta
c
e
p
t 
S
W
B
 E
A
C
 0
0
5
2
 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
9.92 73.3
11.75.07
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
9.12 74.9
10.65.4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
34.1 1.67
1.4662.8
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
27.7 0.71
1.0270.6
C 
163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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C 
Fig. 5.3. Differential patterns of in vitro T cell proliferation in response to anti-
CD3 among early arthritis patients do not correlate with outcome of disease. 
PBMC samples were isolated from whole blood derived early arthritis patients. 2 x 105 
PBMCs were stimulated with various anti-CD3 concentrations and -/+ (20µg/mL) 
abatacept. Following 4 days stimulation T cell proliferation was determined by Ki67 
staining. A) The %Ki67+ T cells (gated on CD3+CD4+ cells) following 4 days stimulation 
from a cohort of 23 early arthritis patients. B) The %Ki67+ T cells from A are stratified 
by outcome of early arthritis as RA (n = 8), Persistent non-RA (n = 8), resolving arthritis 
(n = 3) or inflammatory arthritis (n = 4). C) A comparison of the %Ki67+ T cells under 
control conditions only. All data points represent mean values ±S.E. 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
 
5.2.3. In vitro T cell activation thresholds as an indicator of clinical 
responses to abatacept 
An additional aim for this study was to identify the capacity for patterns of in 
vitro T cell stimulation to predict likely patient responses to abatacept 
treatment. To address this, PBMC samples were obtained from patients who 
were about to commence abatacept treatment. For logistical reasons, 
samples were only obtained from 2 established RA patients whose clinical 
details are outlined in table 5.2. Responses to abatacept treatment were 
defined at 12 month follow up according to the European League against 
Rheumatism (EULAR) response criteria (van Gestel et al., 1999) whereby 
patient SW BSF 0042 showed a moderate response and patient SW BSF 
0042 displayed a good response. Analysis of in vitro T cell proliferation to 
graded anti-CD3 stimulation and abatacept treatment in relation to these 
clinical responses were considered in fig. 5.4A/B. Significant conclusions 
cannot be drawn from this due to the limited sample size. However, the data 
do reveal an impact of abatacept upon T cell proliferation in these two 
patients. A larger sample size including patients showing a poor response to 
abatacept would be needed to address was in vitro abatacept responsiveness 
correlated with eventual clinical outcomes. An additional drawback associated 
with the method of T cell stimulation in the context of whole PBMC samples is 
the limited abatacept sensitivity across the anti-CD3 titration range.   
 
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 
5
.2
. 
C
li
n
ic
a
l 
d
a
ta
 
fo
r 
p
a
ti
e
n
ts
 
c
o
m
m
e
n
c
in
g
 
a
b
a
ta
c
e
p
t 
tr
e
a
tm
e
n
t.
 
(A
b
b
re
v
ia
ti
o
n
s
: 
2
8
-t
e
n
d
e
r 
jo
in
t 
c
o
u
n
t 
(T
J
C
-2
8
),
 2
8
-s
w
o
lle
n
 j
o
in
t 
c
o
u
n
t 
(S
J
C
-2
8
),
 D
is
e
a
s
e
 a
c
ti
v
it
y
 s
c
o
re
 2
8
 (
D
A
S
2
8
),
 C
 R
e
a
c
ti
v
e
 P
ro
te
in
 (
C
R
P
),
 E
ry
th
ro
c
y
te
 
s
e
d
im
e
n
ta
ti
o
n
 r
a
te
 (
E
S
R
),
 r
h
e
u
m
a
to
id
 f
a
c
to
r 
(R
F
),
 C
y
c
lic
 C
it
ru
lli
n
a
te
d
 P
e
p
ti
d
e
 A
n
ti
b
o
d
y
 (
C
C
P
).
  
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
30.3 51.6
6.0812
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
35.6 45.7
4.7714
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
23.6 53.7
13.39.44
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
28.6 48.4
8.9614
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
28.9 46.7
11.313.2
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
38.8 33.6
5.6122
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
54.1 6.56
1.6237.7
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
56.1 3.7
0.7639.5
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
52.8 2.98
0.9743.3
0 10
1
10
2
10
3
10
4
0
10
1
10
2
10
3
55.2 2.77
0.7541.3
0 10
2
10
3
10
4
0
10
2
10
3
10
4
20.3 63.8
11.93.99
0 10
2
10
3
10
4
0
10
2
10
3
10
4
36.8 44.9
10.97.37
0 10
2
10
3
10
4
0
10
2
10
3
10
4
18 58.3
18.55.23
0 10
2
10
3
10
4
0
10
2
10
3
10
4
27.3 46.9
17.48.39
0 10
2
10
3
10
4
0
10
2
10
3
10
4
28.2 25.5
23.323
0 10
2
10
3
10
4
0
10
2
10
3
10
4
38.6 3.71
4.0253.7
0 10
2
10
3
10
4
0
10
2
10
3
10
4
34 24.9
19.921.2
0 10
2
10
3
10
4
0
10
2
10
3
10
4
41.3 2.92
2.3353.4
0 10
2
10
3
10
4
0
10
2
10
3
10
4
45.6 1.79
0.9851.6
0 10
2
10
3
10
4
0
10
2
10
3
10
4
42.5 1.38
0.6155.5
[a
n
ti-C
D
3
] (n
g
/m
L
) 
5
0
 
5
 
0
.5
 
0
.0
5
 
0
 
C
D
4
5
R
O
 
Ki67 
Control Abatacept Untreated Abatacept 
SW BSF 0042 SW BSF 0050 
C
D
4
5
R
O
 
Ki67 
A B 
Fig. 5.4. In vitro T cell stimulation as a predictive test for likely responses to 
abatacept-treatment. PBMC samples were isolated from 2 patients, SW BSF 0042 
with established arthritis who were commencing abatacept treatment. 2 x 105 PBMCs 
were stimulated with various anti-CD3 concentrations and -/+ (20µg/mL) abatacept. 
Following 4 days stimulation T cell proliferation was determined by Ki67 staining.  
(Good response) (Moderate response) 
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5.2.4. Monocyte:T cell ratios within PBMC samples determine the extent 
of T cell activation and abatacept sensitivity 
Data presented in chapter 3 of this thesis demonstrates that relative APC 
numbers affect the quality of T cell stimulation such that abatacept resistant T 
cell proliferation is observed at high APC:T cell ratios. As such, it seemed that 
the proportion of monocytes within the PBMC sample relative to CD3+CD4+ T 
cells could impact upon parameters of T cell activation. Ki67 expression and 
abatacept sensitivity were therefore expressed relative to the 
CD14+:CD3+CD4+ ratio determined by an ex vivo staining panel used to 
characterize the PBMC samples prior to stimulation. These data suggest that 
high CD14+ monocytes relative to CD3+CD4+ T cells within the PBMC sample 
at the time of stimulation increases the proportion of CD3+CD4+ T cells that 
express Ki67 following 4 days stimulation when stimulation was driven by 
higher anti-CD3 concentrations between (fig. 5.5A; 50-0.5ng/mL anti-CD3).  
Additionally, the influence of the monocyte:T cell ratios at initial stimulation on 
the abatacept sensitivity of the T cell response was assessed. Abatacept 
sensitivity was determined as the proportion of CD3+CD4+ T cells expressing 
Ki67 at day 4 under abatacept treated conditions relative to untreated 
controls. These data demonstrated a statistically significant (although 
relatively weak) correlation whereby abatacept resistance increased in 
association with elevated monocyte:T cell ratios when stimulation was driven 
by higher anti-CD3 concentrations (fig. 5.5B; 50-0.5ng/mL anti CD3). This 
correlation was not seen when stimulation was driven by the lowest anti-CD3 
concentration tested of 0.05ng/mL perhaps because any proliferation that 
occurs under these conditions is more dependent upon CD28-costimulation 
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as shown in fig. 5.5B. This supports the concept that CD28-independent 
proliferation occurs more effectively at higher APC:T cell ratios due to the 
summation of cross-linked anti-CD3 signaling between successive APC 
interactions. These monocyte:T cell ratios within the periphery did not 
however appear to significantly correlate with either disease outcome (fig. 
5.6A) or disease activity (fig. 5.6B) as defined by DAS28 score. As such, in 
the context of these assays the monocyte:T cell ratio can be considered an 
extraneous factor that determines variability between patterns of T cell 
proliferation in response to anti-CD3 stimulation. 
 
Patterns of T cell activation were also expressed relative to the proportion of 
CD45RO+ memory T cells within the CD3+CD4+ population at initial 
stimulation. This revealed no overall correlation at any of the anti-CD3 
concentrations tested with the proportion of T cells that expressed Ki67 
following 4 days stimulation (fig. 5.7A). Similarly, the impact of abatacept 
upon Ki67 expression following 4 days stimulation did not strongly correlate 
with the proportion of CD4+CD45RO+ T cells within the original PBMC 
population was stimulation was mediated by higher anti-CD3 concentrations 
(fig. 5.7B 50-0.5ng/mL anti-CD3). When stimulating T cells with 0.05ng/mL 
anti-CD3, a statistically significant correlation was observed whereby an 
increased proportion of CD45RO+ of memory T cells promoted increasingly 
abatacept-sensitive T cell proliferation (fig. 5.7B). This result was unexpected 
but may reflect the CD28-dependent proliferation of memory T cells at low 
anti-CD3 concentrations along with an absence of naïve T cell proliferation, 
even in the presence of abatacept, at low anti-CD3 concentrations. Another 
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potential source of variation in in vitro T cell responses under these conditions 
between patients was the relative abundance of Treg within the CD3
+CD4+ 
population. The proportion of CD3+CD4+ T cells that displayed a Treg 
phenotype was determined by an ex vivo staining panel where 
CD25highCD127low staining was considered to be indicative of the Treg 
population (Liu et al., 2006). However, these experiments revealed no 
significant correlation between the proportion of CD25highCD127low within the 
initial CD3+CD4+ population and either Ki67 expression (fig. 5.8A) or the 
impact of abatacept upon Ki67 expression (fig. 5.8B). This may be predicted 
based upon the observation that abatacept had a limited impact upon T cell 
proliferation under these conditions in association with the idea that CTLA-4 
expression is essential to the activity of Treg (Wing et al., 2008). 
 
 
5.2.5. PBMC stimulation by anti-CD3 is associated with limited CD25 
upregulation by activated T cells 
Fig. 3A demonstrated a modest impact of abatacept upon T cell proliferation 
even at low anti-CD3 concentrations. In contrast, purified CD4+CD25- T cells 
stimulated with allogeneic DCs and anti-CD3 demonstrated a consistent 
degree of proliferation at low anti-CD3 concentrations although this was 
CD28-dependent and therefore abatacept sensitive (see fig. 3.11).  One 
possibility was that stimulation occurred in a CD28-independent manner in 
association with high monocyte:T cell ratios (across the 23 early arthritis 
patients that were tested in this study the mean monocyte:T cell ratio within 
PBMC samples was 1:3.2). 
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Fig. 5.5. CD14+ Monocyte to CD3+CD4+ ratio within PBMC samples determines the 
extent of T cell proliferation and efficacy of abatacept blockade following anti-CD3 
stimulation. PBMC samples were isolated from whole blood derived from 23 early arthritis 
patients. Monocyte:T cell ratios were determined ex vivo and expressed as decimals i.e. 
CD14+ divided by CD3+CD4+. 2 x 105 cells were stimulated with various anti-CD3 
concentrations and -/+ (20µg/mL) abatacept. Following 4 days stimulation T cell 
proliferation was determined by Ki67 staining. A) The relationship between ex vivo 
monocyte:T cell ratios and the % Ki67+ T cells (gating on CD3+CD4+). B) The relationship 
between the outcome of abatacept-blockade and ex vivo monocyte:T cell ratios. The 
impact of abatacept upon T cell proliferation following was determined as the % Ki67+ T 
cells following abatacept treatment normalized to untreated controls. p values are derived 
from linear regression analysis and dotted lines represent the 95% confidence band. 
A B 
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Fig. 5.6. Monocyte:T cell ratios within the peripheral blood of RA patients does 
not reflect disease outcome or activity. Ex vivo monocyte:T cell ratios were 
determined by flow cytometry and expressed relative to various disease outcomes 
(A) or disease activity as indicated by DAS28 scores (B). p value is derived from 
linear regression analysis and dotted lines represent the 95% confidence band. 
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Fig. 5.7. The proportion of CD3+CD4+CD45RO+ memory T cells within PBMC samples 
does not strongly influence T cell proliferation or the efficacy of abatacept following 
anti-CD3 stimulation. PBMC samples were isolated from whole blood derived from 23 
early arthritis patients. % CD45RO T cells (gating on CD3+CD4+ cells) were determined 
prior to stimulation. 2 x 105 cells were stimulated with various anti-CD3 concentrations and 
-/+ (20µg/mL) abatacept. Following 4 days stimulation T cell proliferation was determined 
by Ki67 staining. A) The relationship between % CD45RO+ T cells at stimulation and the % 
Ki67+ T cells following activation (gating on CD3+CD4+). B) The relationship between the 
outcome of abatacept-blockade and ex vivo CD45RO+ T cells. The impact of abatacept 
upon T cell proliferation following was determined as the % Ki67+ T cells following 
abatacept treatment normalized to untreated controls. p values are derived from linear 
regression analysis and dotted lines represent the 95% confidence band. 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Fig. 5.8. The proportion of CD25highCD127low T cells within PBMC samples does not 
affect the extent of T cell proliferation or the efficacy of abatacept blockade 
following anti-CD3 stimulation. PBMC samples were isolated from whole blood derived 
from 23 early arthritis patients. The proportion of CD3+CD4+ T cells staining CD25high 
CD127low was determined ex vivo. 2 x 105 cells were stimulated with various anti-CD3 
concentrations and -/+ (20µg/mL) abatacept. Following 4 days stimulation T cell 
proliferation was determined by Ki67 staining. A) The relationship between the % 
CD25highCD127low prior to stimulation and the % Ki67+ T cells (gating on CD3+CD4+) 
following 4 days stimulation. B) The relationship between the % CD25highCD127low prior to 
stimulation and the outcome of abatacept-blockade. The impact of abatacept upon T cell 
proliferation following was determined as the % Ki67+ T cells following abatacept treatment 
normalized to untreated controls. p values are derived from linear regression analysis and 
dotted lines represent the 95% confidence band. 
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Fig. 5.9. CD28 blockade fails to significantly inhibit CD25 expression following 
anti-CD3 driven T cell proliferation in the context of whole PBMC samples. A) 
PBMC samples were isolated from whole blood derived from 23 early arthritis 
patients. 2 x 105 cells were stimulated with various anti-CD3 concentrations and -/+ 
(20µg/mL) abatacept. Following 4 days stimulation T cell proliferation was determined 
by Ki67 staining. A) CD25 MFI is shown for CD3+CD4+Ki67+ T cells. B) Flow 
cytometry data showing the impact of indicated abatacept concentrations upon the 
proportion of CD3+CD4+ T cells that express Ki67 and the expression of CD25 by 
CD3+CD4+Ki67+ T cells following stimulation with 500ng/mL anti-CD3. Data shows 1 
representative experiment of 3 performed. C) IL-2 production was determined by 
ELISA from supernatants taken at indicated time points following PBMC stimulation 
by 500ng/mL anti-CD3 -/+ (20µg/mL) abatacept. Data points represent mean values 
of 3 technical replicates for 2 early arthritis patients (SW EAC 0070 and SW EAC 
0072). 
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Additionally, it seemed plausible that T cell proliferation driven by anti-CD3 
within the context of whole PBMC samples did not facilitate robust CD28-
signaling, perhaps due to the provision of costimulation predominantly by 
monocytes. To explore this, the impact of abatacept upon CD25, which is a 
CD28-dependent activation marker (see fig. 3.8), was determined within the 
CD3+CD4+KI67+ population (i.e. activated T cells). In contrast to DC driven 
assays, abatacept displayed a very modest effect upon CD25 expression 
levels (fig. 5.9A). Addition of a higher abatacept concentration of 40μg/mL 
abatacept did not affect either the proportion of CD3+CD4+ T cells that 
expressed Ki67 or CD25 expression by CD3+CD4+Ki67+ T cells (fig. 5.9B), 
therefore the failure to inhibit CD25 was not due to incomplete CD80/CD86 
blockade. IL-2 ELISAs were performed on two separate donors. These data 
demonstrated IL-2 production by T cells at early time-points (24-48h) following 
anti-CD3 stimulation (fig. 5.9C). Although abatacept was observed to 
suppress IL-2 (particularly for patient SW EAC 0070) following 24hrs 
stimulation, IL-2 production was transient and appeared more comparable to 
the pattern of IL-2 production induced by anti-CD3 than anti-CD28 driven T 
cell activation presented in fig. 4.17. Together, these observations may 
suggest that monocytes within PBMC samples do not support robust CD28-
dependent T cell proliferation. As such, the upregulation of CD28-dependent 
activation markers e.g. CD25/IL-2 under control conditions is limited and 
therefore not strongly affected by abatacept. Therefore, T cell proliferation 
under these conditions is strongly dependent upon anti-CD3 stimulation. 
Therefore, T cell stimulation within the context of whole PBMC samples does 
177 
 
not appear to represent an optimal system by which to assess inter-individual 
differences between CD28-requirements and abatacept sensitivity.    
 
5.3 Discussion 
Considerable data now support the concept that early clinical intervention 
dramatically enhances outcomes in patients with RA, in particular, reducing 
the rate of long term joint damage (Raza and Filer, 2015). The optimal 
strategy for the effective management of patients with early arthritis would be 
to aggressively treat patients at a very early stage who are at risk of 
developing aggressive forms of the disease based upon prognostic 
biomarkers that indicate adverse disease outcomes. Current approaches 
focus on treating patients at the earliest stages of clinically apparent synovitis 
(for example, early undifferentiated arthritis and early RA) but ongoing trials 
are assessing the effects of therapy in patients at even earlier at risk stages 
(van Steenbergen et al., 2013), for example in the presence of RA related 
autoantibodies (Rantapää-Dahlqvist et al., 2003) but before joint swelling has 
actually occurred. 
 
The factors that dictate progression from early-undifferentiated arthritis to 
persistent RA are not entirely clear. One possibility is that patients who are 
eventually going to develop RA display reduced T cell activation thresholds. 
This may in part be due to the presence of variants in genes of relevance to T 
cell activation and regulation, providing an inherent bias towards 
autoimmunity and chronic inflammatory responses. Consistent with this idea, 
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previous work has demonstrated that RA patients display more effective ERK 
activation upon stimulation relative to healthy controls which predisposes 
patients to effective TCR-driven T cell activation in response to suboptimal 
stimulation (Singh et al., 2009).  
 
In this study, the aim was to utilize in vitro assays as a basis to assess inter-
individual T cell thresholds between patient subgroups. Peripheral T cells 
were stimulated by various anti-CD3 concentrations and abatacept in the 
context of whole PBMC samples. However, the variability associated with 
PBMC samples created a potential problem in this context. In particular, the 
monocyte:T cell ratio strongly affected the outcome of stimulation. This is 
consistent with data presented in chapter 3 of this thesis whereby the APC:T 
cell ratio affects stimulus strength as T cells integrate signals from multiple 
APC interactions. A more suitable approach may be to purify distinct T cell 
populations from the periphery and stimulate under more standardized 
conditions such as with varying anti-CD3 and anti-CD28 concentrations 
although this has a significant drawback of requiring larger whole blood 
volumes from which to isolate T cells. 
 
 
Another factor that complicates the management of patients with early arthritis 
is the heterogeneity within and between various forms of inflammatory 
arthritis, for example, the different responses to therapies seen in patients 
with early and established RA. In cancer, treatment strategies are frequently 
guided by an assessment of biomarkers predictive of treatment response 
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(Chan and Behrens, 2013). However, such biomarkers are generally less 
clearly defined within the context of RA (Miossec et al., 2011).  
 
With regards to predicting the efficacy of abatacept treatment, one possibility 
would be to utilize in vitro T cell stimulation in a comparable manner to this 
study to determine abatacept sensitivity perhaps dictated by an innate bias 
towards TCR driven responses. However, T cell stimulation in the context of 
mixed PBMC samples results in relatively limited CD28-driven responses as 
indicated by a general lack of abatacept-mediated suppression. Within the 
context of PBMC samples the primary source of costimulation are monocytes 
although a small population of DCs does exist within the peripheral blood.  
CD14+ monocytes did express CD86 in these experiments (data not shown). 
However, monocytes and T cells display different patterns of adhesion 
molecule expression (Brown et al., 1997). These differences may promote 
different T cell interaction dynamics with monocytes vs. DCs that could inhibit 
optimal CD28-costimulation. Together, the inherent variability along with the 
limited contribution of CD28 towards T cell proliferation in these PBMC-based 
assays makes observations with regards to abatacept efficacy difficult to 
interpret.  
 
The optimal approach towards utilizing in vitro assays to predict patient 
responses would be to develop a more standardized assay with less inherent 
variability. One possibility would be to use transfected cell lines (i.e. CHO-
CD80 or CD86 transfectants as utilized in chapters 3 and 4 of this thesis) to 
drive activation of purified T cell populations derived from patients. The main 
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drawback to this approach in this instance was the instability of CD80 or 
CD86 expression on an experiment-to-experiment basis. The generation of 
more stably transfected cell lines may therefore be a useful future generation 
in relation to this work. Another approach to this assay would be test CD28-
costimulation requirements independently of abatacept-blockade. For 
example, the ability for purified T cell populations to respond to different 
relative concentrations of plate-bound anti-CD3 or anti-CD28 could be used 
as an indicator of the capacity for TCR-driven T cell activation independent of 
CD28-costimulation thereby implying the propensity for abatacept-resistant 
proliferation to occur.   
 
Another approach to predicting patient responses to abatacept treatment 
would be to focus directly upon the T cells that are driving pathology within the 
synovium within early arthritis patients and to identify markers that are 
consistent with a CD28-dependent phenotype. The feasibility of this idea is 
demonstrated by the observation of a “costimulation signature” revealed by 
transcriptome analysis within T cells that is predictive of an aggressive course 
of disease in several forms of autoimmunity (McKinney et al., 2015). By 
determining the stimulation history of T cells in this way in the context of RA, it 
may provide an indicator as to how much CD28 is actively contributing to 
pathology and therefore be predictive of likely outcomes of abatacept-
treatment. A similar approach has been proposed to predict treatment 
responses to other biological DMARDs. For example, high soluble ICAM-1 
and low serum CXCL13 levels correlates with myeloid cell driven RA and 
robust responses to TNFα inhibition. In contrast, low soluble ICAM-1 and high 
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serum CXCL13 represents a more lymphoid pattern of RA and is associated 
with increased responses to tocilizumab (Dennis et al., 2014). The 
implementation of a range of these predictive tests for RA prognosis and 
treatment efficacy, especially in relation to early arthritis patients would 
represent a step towards more personalized and effective treatment.  
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Chapter 6: General discussion and future work 
 
6.1 General discussion 
T cell activation thresholds are achieved by the integration of signals initiated 
by TCR ligation and additional costimulatory signals that are predominantly 
delivered via the CD28:CD80/CD86 system (Viola and Lanzavecchia, 1996). 
This has been proposed to result in a system whereby strong TCR signaling 
overcomes a relative absence of costimulation and vice versa (Acuto and 
Michel, 2003). Nevertheless, CD28-costimulation blockade has been utilized 
as a strategy for the treatment of T cell mediated pathologies such as RA. 
However, the impact of TCR stimulation has not been widely considered in 
relation to this.  
 
In this study, factors affecting the efficacy of CD28-costimulation blockade by 
abatacept during in vitro T cell stimulation have been investigated. Overall, 
the data suggest that the intensity of TCR-stimulation determines 
costimulation requirements. Indeed, the outcome of clinical trials investigating 
the efficacy of abatacept in the treatment of RA frequently suggest a 
substantial proportion of patients with either negligible or limited clinical 
responses (Moreland et al., 2002; Kremer et al., 2003; Genovese et al., 2005; 
Kremer et al., 2006b; Schiff et al., 2008). As such, it may be suggested that in 
some cases, that the efficacy of abatacept in the treatment of RA would be 
determined in part by the strength of the TCR stimulus that drives the 
pathological T cell response.  
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Several factors determine the potency of stimulation that is generated 
following TCR ligation. A combination of these factors may contribute towards 
the generation of TCR signals that are potent enough to mediate CD28-
independent (and therefore abatacept-resistant) T cell proliferation. In addition 
to more intuitive parameters of TCR stimulus strength such as antigen affinity 
or concentration, evidence from this study suggest that relative APC numbers 
influence the strength of TCR stimulation. The result of this was that high DC 
numbers relative to responder T cells promoted abatacept-resistant T cell 
proliferation during in vitro T cell stimulation. This finding is in contrast to the 
idea that T cell priming occurs as a product of a single productive APC:T cell 
interaction and suggests that T cells integrate activation signals from multiple 
DC interactions. In many ways the translation of this observation to in vivo T 
cell stimulation is challenging. However, it is known that DC numbers are 
increased during chronic inflammation (Banchereau and Steinman, 1998), 
therefore, this is a factor that may contribute towards the outcome of 
abatacept treatment. 
 
A more intuitive factor that determines TCR–stimulus strength is antigen 
affinity. It could be suggested that the majority of autoreactive TCRs within the 
periphery display relatively low affinity towards autoantigen due to the impact 
of negative selection upon the TCR repertoire. This would suggest a scenario 
whereby autoimmune T cell responses are largely CD28-dependent in 
association with suboptimal TCR stimulation. As such, autoimmune 
responses could conceivably be biased towards abatacept-sensitivity. 
However, it is thought that a substantial proportion of autoreactive T cells 
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escape negative selection and enter the periphery (Bouneaud et al., 2000). 
Furthermore, the greatest potential for involvement in autoimmune responses 
is among TCRs that are close to the affinity threshold for negative selection 
which represent those T cell clones that are most likely to escape deletion and 
enter the periphery (Koehli et al., 2014). These observations would suggest 
the potential for autoreactive T cells to arise within the periphery that display 
sufficient affinity for autoantigen that facilitates abatacept resistant T cell 
activation. 
 
Understanding the affinity of TCR:antigen interactions that underlie T cell 
activation is more complex than was implied a historical dogma asserting that 
an individual TCR was strictly specific to a single antigen. For instance, the 
analysis of the memory T cell compartment of unexposed adults 
demonstrates the presence of virus specific T cells that have undergone the 
naïve to memory transition (Su et al., 2013).  This arises due to TCR cross-
reactivity between environmental and viral antigens. In relation to this, it is 
clear that specific T cell responses towards a specific peptide are significantly 
polyclonal in nature due to TCR binding degeneracy (Sewell, 2012). This 
cross-reactivity is essential for comprehensive immune coverage since the 
size of the TCR repertoire is significantly outnumbered by the amount of 
potential foreign antigens (Mason, 1998; Sewell, 2012). As such, TCR binding 
degeneracy exists to the extent that a single CD8+ T cell clone responds to >1 
million distinct peptides although many of these interactions are characterized 
by a relatively low affinity (Wooldridge et al., 2012). The structural homology 
between various peptides that interact with a cross-reactive TCR is variable 
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(Wilson et al., 2004). At one extreme, peptides can show no obvious 
homology whereby TCRs interact with structurally unrelated peptides in a 
promiscuous manner. In other cases there is considerable structural 
correspondence between peptides that and interact with a TCR due to 
molecular mimicry. Alternatively, structural similarity can be observed at 
specific residues within an epitope that form points of contact with the TCR. 
This was found to underlie low affinity interactions between autoreactive 
TCRs and microbial peptides which contribute towards pathogenesis within a 
humanized mouse model of multiple sclerosis (Harkiolaki et al., 2009). 
 
TCR cross-reactivity creates a basis whereby many T cell clones respond to a 
specific antigen but that the TCR binding affinity differs between individual T 
cells that contribute to the response. This opens the possibility for differential 
contributions of TCR- and CD28-signals towards the activation of various T 
cell clones that contribute towards a particular response. Consistent with this 
idea, results in this thesis suggested that during in vitro T cell responses to 
TSST-1, that low affinity vβ2- T cells respond in an abatacept-sensitive 
manner. In contrast, the proliferation of high affinity vβ2+ T cells was more 
resistant to abatacept.  These observations suggest that in the context of 
autoimmunity that abatacept may serve to tune an immune response by 
inhibiting T cells that display weaker affinities for autoantigen whilst those that 
display higher affinities are more likely to be abatacept-resistant.  
 
It could be suggested that those T cells that are activated by a predominantly 
TCR-driven response are those T cells that represent the most potent drivers 
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of pathology. For example, TCR-driven stimulation has been found to bias T 
cell differentiation towards Th1 (Tao et al., 1997a) or Th17 (Bouguermouh et 
al., 2009) differentiation. The activities of these proinflammatory T cell subsets 
are frequently associated with chronic inflammatory disorders and 
autoimmune disease (Damsker et al., 2010). In contrast, a predominant 
contribution of CD28-costimulation towards T cell priming has been thought to 
skew T cell differentiation of Th2 responses (Tao et al., 1997a). Based upon 
this, it may be speculated that the identification of Th2 driven responses may 
be more sensitive to abatacept blockade. In relation to this, a transient Th2 
polarized response is observed in early arthritis patients (Raza et al., 2005), 
this may highlight the necessity to utilize abatacept treatment at earlier stages 
of RA. Another hypothesis based upon these ideas would be that RA patient 
who are positive for autoantibodies, might demonstrate more substantial Th2 
responses and have the potential to respond more robustly to abatacept 
treatment. In support of this idea, it has been suggested that greater clinical 
responses to abatacept-treatment are observed in patients who display 
ACPA-seropositivity (Gottenberg et al., 2012; Pieper et al., 2013). However, 
this does not appear to be the case in terms of rheumatoid factor (RF)-
seropositivity which predicts better responses for rituximab (anti-CD20) but 
not abatacept (Maneiro et al., 2013).  
 
An additional factor that can influence TCR signal strength and potentially 
therefore the outcome of CD28-blockade is individual genetic polymorphisms 
associated with TCR signaling. Several studies have identified significant 
inter-individual variations between various parameters of immune responses 
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(Ye et al., 2014; Raj et al., 2014; Lee et al., 2014). This suggests the capacity 
for differences between T cell responses of individuals and therefore an 
innate propensity towards abatacept resistance or sensitivity. Interestingly, an 
increased responsiveness to TCR-stimulation has been shown among RA 
patients relative to healthy controls (Singh et al., 2009). This occurred in 
association with enhanced ERK activation among RA patients that acts to 
prevent negative regulation of Lck by the tyrosine phosphatase SHP-1 
(Stefanová et al., 2002). It is possible that this elevated TCR-signaling may be 
associated with an innate tendency towards CD28-independent T cell 
activation in RA and therefore abatacept-resistance.  
 
In addition to the impact of genetic polymorphisms upon TCR-driven 
activation in the periphery, it is also important to consider the impact of 
changes in TCR-signaling thresholds caused by genetic polymorphisms upon 
thymic T cell selection. For example, the tyrosine phosphatase PTPN22 
negatively regulates signals delivered via the TCR (Wu et al., 2006). The 
620W PTPN22 allelic variant has been implicated as a risk factor in several 
autoimmune diseases including RA (Gregersen et al., 2006). Given this 
association with autoimmunity it would be expected that the 620W allelic 
variant would be associated with a loss of function resulting in elevated TCR 
stimulation. However, it has been suggested that the allelic variant is 
associated with gain-of-function that promotes T cell hypo-responsiveness to 
TCR stimulation. As such, it has been postulated that the 620W PTPN22 
variant may drive autoimmunity by altering T cells thresholds during central 
tolerance (Gregersen et al., 2006). Similarly, a mutation within the ZAP-70 
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gene, another TCR-signaling mediator, promotes autoimmune arthritis in mice 
occurring due to defects in negative selection leading to increased prevalence 
of autoreactive T cells within the periphery (Sakaguchi et al., 2003). These 
studies highlight significant complexity in understanding inter-individual 
differences between responses to TCR-stimulation due to the interaction 
between numerous genetic factors.  
 
 
An additional factor that is involved in the generation of TCR signals is the 
nature of interactions between APCs and T cells. It is interesting to note that 
several adhesion molecules have been found to display costimulatory 
function. For example, it is suggested that costimulation is delivered via T cell 
surface LFA-1 (Dubey et al., 1995) and ICAM-1 (Chirathaworn et al., 2002). 
Similarly, ICAM-3 expressed at the T cell surface has been suggested to act 
as a costimulatory molecule (Hernandez-Caselles et al., 1993; Berney et al., 
1999; Martinez, 2005). The generation of “outside-in” signaling pathways 
delivered via LFA-1 that lead to IL-2 production has been partially elucidated, 
this is suggestive of some degree of costimulatory function (Ni et al., 1999; 
Wang et al., 2009). However, in other cases adhesion molecules may simply 
act as accessory molecules that facilitate the acquisition or duration of TCR 
signals (Bachmann et al., 1997; Graf et al., 2007; Balkow et al., 2010). It is 
possible that the capacity for a costimulatory pathway to drive T cell activation 
in the absence of TCR-stimulation may serve as a point of differentiation 
between molecules that fulfill a true costimulatory vs. an accessory function. 
In relation to this, stimulation by cross-linked CD28 in the absence of TCR-
189 
 
stimulation can promote T cell proliferation due to the generation of a strong 
(and likely supra-physiological) stimulus that is reminiscent of the activity of 
CD28 superagonists (Hünig, 2012).  
 
Where a robust TCR signal is delivered, abatacept fails to completely 
suppress T cell activation and may in fact heighten inflammatory processes by 
favoring Th17 differentiation (Bouguermouh et al., 2009; Riella et al., 2012a). 
It may therefore be concluded that abatacept treatment would be most 
effective for patients in whom pathology is associated with weak TCR-
stimulation. To enhance clinical responses to abatacept in those in whom 
pathology is associated with a strong TCR-stimulus, the combination of 
abatacept with other immunomodulatory therapies that target TCR signaling 
may prove beneficial. For instance, in this study, an interaction between CsA 
and abatacept led to robust suppression of T cell proliferation. This finding 
has also been suggested by several other studies (Bolling et al., 1994; Van 
Gool et al., 1994; Perico et al., 1995; Ossevoort et al., 1999). Unsurprisingly, 
the combination of CsA with abatacept was less beneficial under stimulation 
conditions where CD28-requirements were lower. For example, abatacept 
and CsA alone robustly inhibited the proliferation of T cells when stimulation 
was mediated at a low DC:T cell ratio, therefore, the combination of both 
agents under these conditions was unnecessary for potent suppression.  In 
contrast, at a high DC:T cell ratio, CsA inhibited CD28-independent T cell 
proliferation that was driven by an increased potency of anti-CD3 stimulation. 
Therefore, an ability to identify instances where strong TCR stimulation is 
present may allow the use of CsA to be appropriately targeted. This is an 
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important consideration because a significant drawback to the combination of 
CsA with abatacept for the treatment of RA is the inherent toxicity that is 
associated with calcineurin-inhibition (van den Borne et al., 1999; Gremese 
and Ferraccioli, 2004; Liu et al., 2007). It is possible that an increased efficacy 
of treatment associated with the combination of CsA in combination with 
abatacept may allow CsA treatment at reduced doses compared to with CsA 
monotherapy. Nevertheless, this does not however circumvent the need to 
understand the antigen specificity of T cells underlying RA. Additionally, the 
identification of novel strategies to inhibit TCR-driven activation could serve to 
enhance the efficacy of abatacept-treatment.  
 
An important consideration in relation to the safety profile that is associated 
with abatacept treatment. A direct comparison of the efficacy of abatacept 
against infliximab therapy for RA in the ATTEST trial demonstrated a reduced 
incidence of serious infections associated with abatacept treatment relative to 
infliximab (Schiff et al., 2008). It is possible to conceive a scenario where high 
intensity TCR-driven T cell activation occurring in conjunction with infection 
drives protective T cell responses, even in the presence of CD28-blockade by 
abatacept. As such, the incidence of severe infections in association with 
simultaneous blockade of TCR and CD28 signals deserves further 
consideration. 
 
The redistribution between TCR and CD28 signals that results from abatacept 
treatment and the altered T cell differentiation that occurs as a product of this 
also deserves further consideration, in particular, the apparent trade off 
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between effects upon Treg populations and effector T cells. For example, it has 
been suggested that abatacept therapy in the treatment of RA leads to a 
decrease in regulatory T cell subsets (Pieper et al., 2013). Similarly, CTLA-4-
ig has a deleterious effect upon CD4+CD25+ Treg in mouse models (Salomon 
et al., 2000; Tang et al., 2003). Interestingly, in an MHC II-mismatched 
cardiac transplantation model, CTLA-4-ig promoted allograft rejection in a 
manner that was associated with a loss of nTreg and subsequent increased 
Teff: Treg ratio. In contrast, the dominant impact of CTLA-4-ig was the 
suppression of Teff responses in a fully allogeneic cardiac transplant model in 
which CTLA-4-ig significantly enhanced allograft survival (Riella et al., 2012a). 
Thus, the outcome of any negative impact upon T cell regulation following 
CD28-blockade depends upon the relative contribution of Treg to disease 
processes.  
 
Any impact upon T cell regulation represents a potential unwanted effect 
associated with CD28-blockade but would be predicted given the role of CD28 
in Treg biology. For example, the generation, function and maintenance of 
nTreg in the periphery appear to be highly CD28-dependent processes 
(Gogishvili et al., 2013; Zhang et al., 2013). The impact of CD28-signals upon 
iTreg is less clear. For example, strong CD28-costimulation is actually found to 
supress iTreg induction in vitro (Semple et al., 2011). In other cases, it is 
reported that the generation of iTreg is dependent upon CD28-signals (Guo et 
al., 2008), although this may depend upon the context of accompanying TCR 
stimulation intensity (Gabryšová et al., 2011). As such, optimal conditions for 
iTreg induction may be tied to the overall strength of stimulation. The role for 
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CD28 in Treg biology is likely to be associated with the upregulation of IL-2 
signaling since IL-2 is essential for Treg maintenance and function (Nelson, 
2004; DeLaRosa et al., 2004; Maloy and Powrie, 2005). Therefore, IL-2 
blockade in therapy is also associated with a defect in T cell regulation (Pilat 
and Wekerle, 2012). CsA is also known to induce and propagate 
autoimmunity under certain conditions (Prud'homme et al., 1991). Again, the 
immunological basis underlying this is thought to be associated with effects 
upon Treg arising from the inhibition of IL-2 production (Mantel et al., 2006; 
Malek, 2008; Presser et al., 2009). 
 
Several experiments in this study show a loss of markers of T cell regulation 
such as FoxP3 and CTLA-4 by proliferating T cells following abatacept 
treatment. Furthermore, abatacept inhibited the upregulation of FoxP3 and 
CTLA-4 occurring in the presence of 1,25(OH)2D3 supplementation 
suggesting that 1,25(OH)2D3 acts in association with CD28 to promote a 
regulatory phenotype. However, it could be predicted that any loss of 
regulation would be offset by the extent to which abatacept, or indeed, the 
combination of 1,25(OH)2D3 and abatacept, supress T cell responses.  
 
It is interesting that despite a proposed negative impact of CD28-costimulation 
blockade upon T cell regulation, reports do not suggest instances of RA 
severity increasing following abatacept-treatment. Nevertheless, the induction 
of other autoimmune diseases following abatacept treatment in RA has been 
reported (Buch et al., 2008). However, the factors underlying this have not 
been widely considered. It has been suggested that a detrimental impact upon 
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Treg underlies higher acute rejection rates associated with belatacept-based 
immunosuppression compared to CsA (Riella and Sayegh, 2013). However, 
in opposition to this view, a study evaluating the impact of belatacept upon 
Treg following renal transplantation actually found an increased prevalence of 
CD3+FoxP3+ relative CD3+FoxP3- following belatacept treatment compared to 
CsA within graft biopsies during acute rejection belatacept therapy (Bluestone 
et al., 2008). This suggests that the trend towards acute rejection associated 
with belatacept therapy is not associated with deleterious effects upon Treg. In 
the case of RA, it is possible that any deleterious impact upon Treg is 
inconsequential due to the fact that Treg in RA display defective function 
(Byng-Maddick and Ehrenstein, 2015). 
 
Interestingly, belatacept dosing has been found to confer only 80% saturation 
of CD86 expression levels at the time of basal levels (Bluestone et al., 2008). 
Indeed, it may be speculated that the affinity of CTLA-4 has specifically 
evolved in order to allow CD28 access to CD86 even in the presence of 
CTLA-4 expressed constitutively by Treg. Therefore, abatacept which confers 
less potent blockade of CD80 and CD86, may inhibit T cell responses whilst 
sparing Treg and thereby represent a balanced blocker of costimulation 
(Gardner et al., 2014).  
 
6.2 Future directions 
A consistent theme throughout this work has been that strong TCR stimulation 
can overcome CD28-requirements thereby promoting abatacept-resistant T 
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cell proliferation. A useful future direction in relation to this would be to learn 
how to discriminate between predominantly TCR- vs. CD28-driven T cell 
responses. This may facilitate the identification of biomarkers upon which to 
predict responses to abatacept-treatment. In relation to this, T cell stimulation 
by cross-linked anti-CD3 or anti-CD28 independently generates T cell 
responses and is associated with distinct expression profiles of surface 
activation markers. An interesting future study may be to determine the 
expression of these markers by activated T cells isolated from sites of 
inflammation and to utilize these differences to determine the relative 
contribution made by TCR vs. CD28 towards activation. This information 
could be utilized in order to predict clinical responses to abatacept 
downstream. 
 
Another future direction may be to classify patient clinical responses to 
abatacept according to genetic risk factors that determine the strength of the 
TCR signal, for example, to determine PTPN22 status in the context of the 
outcome of abatacept treatment. In relation to this, it may also be relevant to 
determine the impact of CTLA-4 polymorphisms upon abatacept treatment. 
This is because CTLA-4 mediated transendocytosis of CD80 and CD86 
serves to inhibit CD28-ligation (Qureshi et al., 2011) and therefore acts in a 
manner that is comparable to the mechanism of action of abatacept. As such, 
a defect in CTLA-4 function may imply that disease is CD28-driven and 
therefore inherently abatacept-sensitive.  
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Data presented in this study support a novel function for the active form of 
vitamin D3, 1,25(OH)2D3, as an inhibitor of TCR-driven T cell proliferation. 
Thus, in cases where abatacept-resistant T cell activation occurs due to 
strong TCR stimulus strength, vitamin D3 supplementation can enhance the 
efficacy of treatment in a similar manner to CsA. Identifying the outcomes of 
abatacept treatment retrospectively from previous clinical trials relative to 
vitamin D3 status (where this information is available) could further 
substantiate these data from in vitro assays. 
 
Further studies are required to determine how the observations of a negative 
effect of CD28-blockade upon T cell regulation during in vitro studies and 
mouse models translate to clinical outcomes of abatacept and belatacept 
therapy. An interesting future direction may be to compare the impact of 
abatacept to belatacept upon Treg populations. 
 
6.3 Final summary 
The efficacy of abatacept in the inhibition of in vitro T cell stimulation is 
strongly associated with the potency of TCR-stimulation. As such, T cell 
stimulation by low anti-CD3 or TSST-1 concentrations is abatacept sensitive. 
Results also suggested that relative DC numbers affected TCR-stimulus 
strength such that stimulation at high DC:T cell ratios facilitated CD28-
independent T cell proliferation. This has implications for the use of abatacept 
in an inflammatory environment in which DC maturation and numbers in 
inflamed lymph nodes are increased. Together, these data suggest that 
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suboptimal RA patient responses to abatacept could be partly determined by 
various parameters that determine the strength of the TCR stimulus and 
highlight the importance of inhibiting TCR- and CD28-driven activation signals 
simultaneously. One way to achieve this is through combining abatacept with 
the calcineurin inhibitor CsA. Alternatively, data presented here suggests that 
the active vitamin D3 metabolite, 1,25(OH)2D3 specifically inhibits TCR-driven 
activation in the absence of CD28-costimulation. In addition to this effect, 
1,25(OH)2D3 enhances CD28-expression and therefore may facilitate 
costimulation during the earlier phases of T cell stimulation. The result of 
these effects is the induction of a CD28-dependent T cell response that is 
characterised by the expression of a CD28-driven T cell phenotype including 
high CTLA-4 expression. By increasing CD28 requirements, vitamin D3 
supplementation may serve to enhance clinical responses to abatacept in the 
treatment of T cell mediated inflammatory diseases. 
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